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ABSTRACT
Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin)
superfamily of proteins, circulates in blood in a complex with vitronectin (VN). These two
proteins are also found localized together in the extracellular matrix in many different
pathophysiological conditions. Both of these proteins are involved with a number of
physiologically important processes. Though PAI-1 is a well-known inhibitor of serine proteases,
more emphasis is now geared towards its protease independent functions. VN, on the other hand,
is a binding protein that exists in the circulation in a preferred monomeric conformation.
However, in the extracellular matrix, VN exists as multimer with altered conformation. Though
the exact reason for such conformational alterations and compartmentalization is unknown, there
are a number of biomolecules, including PAI-1 that are proposed to cause such alterations. In last
few years, sufficient experimental evidence has been gathered to confirm this proteaseindependent effect of PAI-1 by which it induces multimerization of VN in a concentrationdependent fashion. It has been observed also that PAI-1 remains associated with this multimeric
complex for several hours. A major focus of this dissertation work was to extend our
understanding of the mechanism of the interaction between these proteins and to explore the
physiological relevance of the multimeric complexes formed by their interaction on cellular
adhesion and migration. In our study, emphasis has been given to the presence of an appropriate
microenvironment so that the role of the multimeric complexes could be investigated in a
relevant biological setting. Our findings indicate the importance of the surrounding
microenvironment in establishing the specific role of the VN/PAI-1 complex in cell-matrix
interactions. In a previous study from our lab, it was found that vitronectin knock-out mice were
vii

more resistant to Candida infection compared to wild type C57Bl/6 mice. One of the goals of
this dissertation work was to provide a mechanistic explanation for their increased survival of the
vitronectin knock-out mice upon Candida infection. Another important aspect of this work was
to establish biophysical methods for understanding the structural changes that happen in PAI-1
naturally or due to ligand binding.
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CHAPTER-1
General Background

1.1. Vitronectin
1.1. a. Localization & Biosynthesis
Vitronectin (VN) is a glycoprotein that was initially termed as „serum spreading factor‟
because of its presence in human serum and involvement in cellular attachment [1]. Originally it
was purified from serum using glass bead chromatography columns [1]. This protein, when
isolated from human serum, could support cell growth and spreading of fibroblast and epithelial
cells under serum-free conditions [2-3]. Podack et al. first reported a method of purification of
this protein from plasma [4]. The concentration of VN in the circulation is about 0.2-0.4 mg/ml
(0.3-0.6µM) [5-6]. The presence of VN in the extracellular matrix and tissue was first reported
by Ruoslahti and his group [7]. With specific monoclonal antibody staining, this group clearly
showed the presence of vitronectin in fetal membrane tissue and in the extracellular matrix
associated with the surface of fibroblast cells [7]. They were the first to denote „serum spreading
factor‟ as „vitronectin‟ because of its glass-binding and cell-adhesive properties. S-protein is
another circulatory protein that was identified as part of a soluble complement complex, known
as the SC5b-9 complex [8]. Later, cDNA sequence analysis and immunological/functional
studies confirmed that VN and S-protein were identical proteins [9-12]. In blood, VN circulates
mainly as a monomer [13-14], but in the extracellular matrix it exists as a multimer. The source
of extracellular matrix-associated VN has been thought to be mainly from the plasma. While the
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exact mechanism for its compartmentalization is unknown, it is accepted that vitronectin has
specific and distinct functions in the blood and extracellular matrix.
The primary site of VN synthesis is the liver, and a severe reduction in the plasma level
of VN has been observed in patients with cirrhosis of liver and liver failure [5, 15-16]. The
presence of VN has been observed in the medium of cultured hepatoma cell lines, e.g. HepG2
and Hep3B [13, 17]. VN is expressed at a high level in tumors also [13-14]. Endodermal sinus
tumor cells (yolk sac carcinoma cells resembling parietal endoderm) derived from human
testicular teratoma have also been found to secrete VN, and they do not require serum for
attachment and growth [18]. Hetland et al. reported that monocytes and macrophages could also
synthesize and secrete VN in the culture medium [19]. The other major site of VN synthesis is
the platelet. Parker et al. first reported the intracellular storage of VN in platelets [20]. Later in
the same year, Preissner et al. quantified the amount of VN present in platelets (8.1 +/4.6µg/10platelets) [21].

1.1. b. Structural Organization and Post-translational Modification
While VN is an important protein involved in several physiological processes, it is
unfortunate that no high-resolution structure for full-length vitronectin has yet been solved. The
protein appears to be organized into distinct domains: the N-terminal SMB (somatomedin-B)
domain, the central domain and the C-terminal domain as shown in Figure-1.1. A crystal
structure of the recombinant SMB domain in complex with recombinant PAI-1 has been
determined [22]. The structure of this SMB domain has been included in Figure-1.1. There are
three other NMR solution structures available for the SMB domain (a recombinant SMB domain,
SMB domain isolated from purified monomeric VN from blood and recombinant SMB domain
2

Figure 1. 1: Domain organization of VN

Figure-1.1: The structural model of VN includes several domains. Cyan: crystal
structure of SMB domain (1-44 aa) [22], Amber: Intrinsically disordered domain (48130 aa) predicted by PONDR, Green: Central domain predicted to be four bladed βpropellers (131-323 aa), Red: C-terminal domain, predicted to have half of four bladed
β-propellers (354-456 aa), yellow: region in SMB that contacts with PAI-1 [26-27]. ‘S’
indicates sulfations, ‘P’ indicates phosphorylation and ‘Y’ indicates glycosylation.
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expressed in Pichia) [23-25]. Though certain differences exist among all of these solved
structures in terms of disulfide bond arrangements, folding and secondary structure, the main
similarity that they share is the presence of a surface exposed patch of hydrophobic residues
(encompassing Phe13, Val15, Leu24, Tyr27 and Tyr28) responsible for ligand binding (PAI-1,
urokinase Plasminogen Activator Receptors). For all the other domains in VN, only
computationally predicted models are available [26]. These models indicate that the central
domain adopts a full four-bladed β-propeller fold like that described in hemopexin and gelatinase
[26]. The C-terminal domain is predicted to contain half of that four-bladed β-propeller fold. We
also know from bioinformatic analysis with PONDR that the region between the SMB domain
and central domain (residues 54-130) is intrinsically disordered [27] asdepicted in Figure-1.1. A
lower resolution structure of full length monomeric VN was proposed by the Peterson laboratory
using small angle X-ray scattering data [27]. This model indicates that the entire molecule
possesses a peanut-shaped bi-lobed structure that remains extended in solution (maximum length
of about 110 ).
VN contains a total of 14 cysteine residues. Out of these, eight are present within the
SMB domain and form four disulfide linkages. Though there were controversies related to the
arrangement of these four disulfide bonds, a recent publication from Li et al. claimed that the
correct arrangements of the disulfide linkages in the SMB domain of native VN are: Cys5–
Cys21, Cys9–Cys39, Cys19–Cys32, andCys25–Cys31 [28]. Such extensive disulfide bridging
makes this SMB domain strongly resistant to proteolysis [29]. Six other cysteine residues (Cys137, 161, 196, 274, 411, 453) are located within the central and C-terminal domains. Cys-274
and Cys-453 are known to be disulfide linked [5]. This disulfide linkage has an important role in
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the formation of the two-chain form of VN. VN in circulation exists in two different forms: a
single chain and a two-chain form [7, 30-32]. This results from the genetic polymorphism that
exists at residue 381 of VN. Tollefsen et al. found that the presence of Thr instead of Met at
position 381 makes the protein more susceptible to proteolytic cleavage at R379 [33] and results
in the formation of the two-chain form of VN connected by a disulfide linkage between Cys274
and Cys453. Cys137 and Cys161 within the central domain form the intra-domain disulfide
linkage. Cys196 and Cys411 are free but remain buried within the folded structure [26, 34].
VN also contains several other post-translational modifications, including glycosylation,
sulfation and phosphorylation. There are three N-linked glycosylations at residues N67, N150
and N223 [5, 35]. Recently Sano et al. reported that reducing the extent of glycosylation on VN
increased multimerization and also collagen binding [36]. Tyrosine residues at position 56 and
59 have been found to be sulfated by the action of a membrane enzyme in the Golgi which is a
tyrosylprotein sulfotransferase [37]. The presence of these sulfated-tyrosines within the relatively
acidic region (residue 53-64) of VN has been proposed to be important for interaction with the
thrombin-antithrombin complex. VN is phosphorylated at many different sites, which include
Thr60, Thr67, Ser362 and Ser378. There are several different kinases implicated in the
phosphorylation of these residues. Korc-Grodzicki et al. reported that a cyclic-AMP dependent
kinase (PKA) released from platelets upon thrombin activation could specifically phosphorylate
VN at Ser378 [38]. Though phosphorylation by PKA was mainly limited to the single chain
form, the presence of heparin apparently caused phosphorylation of the two-chain form also [39].
Phosphorylation at this residue appears to lower the binding affinity of vitronectin for PAI-1 and
plasminogen and thus has been implicated in fibrinolysis [40]. Seger et al. reported
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phosphorylation of Thr50 and Thr57 by casein kinase II (CK2), which is found in blood and on
the surface of blood cells like neutrophils, platelets etc. Phosphorylation at these residues has
been implicated in cell adhesion/spreading and also in induction of αvβ3-mediated cell signaling
[41-42]. Phosphorylation at Ser262 is thought to be mediated by protein kinase-C (PKC) and is
implicated in providing resistance to plasmin cleavage [43].

1.1. c. Physiological Function of Vitronectin
VN is an important protein involved in several physiological processes; the multifunctional
nature of this protein results from its ability to recognize various ligands including the thrombinantithrombin complex (T-AT) [44-45], heparin [46-48], PAI-1 [49-51], complement proteins
[52], and several cell surface receptors, including integrins and the urokinase plasminogen
activator receptor (uPAR) [53-59]. VN exhibits functions that are specific to its localization. For
example, in blood it has a role in the regulation of thrombus formation, coagulation and
fibrinolysis, whereas in the tissue or extracellular matrix, it has an important role in regulating
pericellular proteolysis, wound healing, inhibition of the membrane attack complex, and cellular
adhesion/migration.
The regulation of thrombus formation, coagulation, fibrinolysis, wound healing and
pericellular proteolysis by VN is mediated by its interaction with heparin, the T-AT complex and
PAI-1 [60-66]. Coagulation is mediated by thrombin, which transforms fibrinogen into fibrin.
There are a number of serine protease inhibitors (serpins) that control the amount of active
thrombin in the circulation. Among those, the most important is antithrombin-III [5]. This
inhibitor by itself causes slow inactivation of thrombin (T), whereas in the presence of heparin,
the inactivation rate is significantly accelerated [67-69]. Heparin binding to antithrombin-III
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(AT) causes a conformational change in the inhibitor, which stabilizes the complex by
decreasing the dissociation constant [70-71]. Bound heparin on antithrombin-III acts as a bridge
to bring the inhibitor and the protease spatially close to each other which increases the rate of the
reaction [70]. After the formation of the T-AT complex, heparin is released; the formation of the
protease-inhibitor complex results in a further conformational change in the inhibitor that
reduces its affinity for heparin [72-73]. Released heparin can then cause further rounds of
thrombin inactivation. VN acts a heparin scavenger and thus regulates the rate of antithrombin
inactivation of thrombin [74-75]. Furthermore, VN has been found to bind to the T-AT complex.
Binding to the TAT complex occurs through thrombin and appears to be stabilized by disulfide
linkage [45, 75-76]. Binding induces a conformational change in VN that can be probed by a
conformationally specific antibody [44, 77]; this change results in an increase in the affinity for
heparin. Thus, it has been proposed that the pro-coagulant nature of VN requires the presence of
the T-AT complex in the blood [31, 74]. It has been also proposed that VN plays a role in the
clearance of the T-AT complex when it binds and forms the ternary complex. It appears that the
VN-T-AT complex interacts with the surface of HepG2 cells and then can be internalized and
degraded. This clearance is inhibited by heparin, indicating the involvement of heparin binding
domain of VN [78].
Plasminogen activator inhibitor-1 (PAI-1) is a biomolecule that plays an important role in
the regulation of plasminogen activation to form its active counterpart plasmin. Regulation is
achieved by the ability of PAI-1 to inhibit tissue-Plasminogen Activator (tPA) and urokinasePlasminogen Activator (uPA), the two common serine proteases that are involved in the
activation of plasmin [79-80]. By regulating activation of plasmin, PAI-1 participates in the
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regulation of fibrinolysis, pericellular proteolysis and wound healing. VN has been found to
contribute to such regulation in two ways. First of all, VN increases the half-life of PAI-1 and
thus keeps it stable for a longer time [81-82]. As a result, PAI-1 remains active in its inhibitory
form for a longer period of time. VN is also known to localize PAI-1 to its specific site(s) of
action. For example, VN was found to localize PAI-1 in the fibrin clot and thus influence the role
of PAI-1 in fibrinolysis. The presence of VN in the fibrin clot increased the affinity of PAI-1
binding to the clot site and also kept PAI-1 stable for longer period of time [61].
VN acts as an inhibitor of the membrane attack complex (MAC) formed by the assembly of
complement proteins. MAC forms a pore by inserting into the membrane of target cells and
causes their lysis. MAC is built by the sequential assembly of various complement proteins,
including C5b, C6, C7, C8 and C9 [83-85]. Each of these individual units is hydrophilic, but
their assembly results in the formation of an amphiphilic complex. Once the complex between
C5b, C6 and C7 is formed, the initial hydrophilic-to-amphiphilic transition happens [86-87] and
this complex is targeted to the membrane. Membrane-inserted C5b-7 complex binds to C8, and
the resulting complex catalyzes polymerization of C9; the entire C5b-9 complex adopts an
amphiphilic, membrane pore forming, tubule-like structure that causes cytolysis [88-90]. VN can
regulate the formation of this active membrane attack complex. It binds to the C5b-7 complex
and inhibits the hydrophilic-amphiphilic transition and renders the complex soluble (SC5b-7).
Though the subsequent binding of this complex to C8 and C9 can occur, polymerization of C9
does not happen and thus the entire complex becomes inactive [8, 91].
Regulation of cellular adhesion/migration comes from the ability of VN to act as a matrix
protein that can bind to different cell surface receptors like uPAR (urokinase plasminogen
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activator receptor) and certain subclasses of integrins [92].VN has been found to regulate
adhesion and migration properties of different cell types, e.g. fibroblasts, endothelial cells,
megrakaryocytes, platelets, tumor cells, etc [92]. VN modulation of cellular adhesion and
migration has been implicated in various physiological processes, including angiogenesis [66].
Integrins are heterodimeric cell surface receptors that are known to establish a link between the
extracellular matrix and cytoskeleton. There are approximately 24 different types of integrins
that can recognize a variety of extracellular matrix components [93]. Many of them can interact
with VN, including αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and αIIbβ3 [13, 94]. Recently Mac1 (αMβ2)
has been added to the growing list of vitronectin partners [95]. Out of all these, αvβ3 and αvβ5
are thought to be the two most common cell surface receptors for VN and have been found to be
overexpressed in activated endothelial cells undergoing angiogenesis [96-97]. Several
antagonists of these two integrins are currently being studied for the inhibition of angiogenesis as
a possible treatment strategy for cancer [98-99]. Most of these integrins recognize VN via an
RGD sequence (residues 45-47) that is located immediately after the SMB domain. uPAR is
another cell surface receptor that is anchored to the membrane via a GPI
(glycosylphosphatydylinositol) link. The primary function of uPAR is to bind and localize uPA
at the cell surface and regulate pericellular proteolysis [100]. uPAR has three distinct domains
(DI, DII and DIII), which together form a central cavity that contains the uPA binding site [101102]. The VN binding site is located on the outside of this cavity along the outer surface of the
protein [103]. Thus, uPA binding does not block VN binding; rather binding of uPA causes an
increase in the affinity of uPAR binding to VN. The uPAR-binding site on VN is located within
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the SMB domain. Figure-1.2 summarizes the variety of interactions of cell surface receptors
with matrix-associated VN. A major focus of this study is to understand the role of VN in
regulating cellular adhesion and migration in relation to its interaction with Plasminogen
Activator Inhibitor-1 (PAI-1).
As mentioned above, VN exists as monomer in the circulation, but the preferred
conformation of its matrix-associated form is multimeric. Multimeric and monomeric VN exhibit
distinct functional properties. Multimeric VN was found to bind more to collagen compared to
monomeric VN [104]. Multimeric VN also appears be endocytosed through an αvβ5-dependent
process in skin fibroblast cells; this was not observed with monomeric VN [105-106]. Another
example is that only multimeric VN was found to induce tyrosine phosphorylation by binding to
αvβ3 on the endothelial cells [107].
In the last few years, researchers have begun to understand the importance of VN in
pathogenic infections. For example, Candida albicans was found to possess αvβ3-like or αvβ5like receptors for VN binding, and it was also shown that binding of Candida to endothelial cells
was VN mediated [108]. One of the major aims of this research is also to compare Candia
infection and pathogenesis between vitronectin knock-out mice and wt C57BL/6 mice.
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Figure 1. 2: Vitronectin as a part of the ECM interacting with cell surface receptors

Figure-1.2: A simplistic representation of the extracellular matrix comprised of a few
major components, including collagen, laminin, proteoglycan, vitronectin and
fibronectin is shown. Cell surface receptors (uPAR & integrins) interacting with VN
associated with the extracellular matrix are shown. The domain organization of
vitronectin with proposed binding sites for both uPAR and integrins is also shown.
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1.2. Plasminogen Activator Inhibitor-1 (PAI-1)
1.2. a. Expression and Regulation
PAI-1 is another member of the serpin family of proteins. Like VN, it is found to be present in
the circulation and extracellular matrix. In the circulation, PAI-1 concentration varies between 520ng/ml. Under normal physiological conditions PAI-1 is released into the circulation by a
number of cells, including platelets, smooth muscle cells (SMCs), hepatocytes and adipocytes
[109]. In addition, under many pathological conditions, high expression of PAI-1 is observed in
other cell types, e.g. vascular endothelial cells and tumor cells. Plasma concentrations of PAI-1
can be dramatically increased in several inflammatory disease conditions, including
atherosclerosis, severe sepsis etc [109-110]. An elevated plasma concentration of PAI-1 has been
also observed in various thrombotic disorders, including myocardial infarction and deep vein
thrombosis [111-113]. High levels of PAI-1 are positively correlated with the invasiveness of
several different types of cancers [114]. In an immunohystochemical study of more than a
hundred breast cancer patients, Dublin et al. showed that high levels of PAI-were positively
correlated with both the grade and invasiveness of the various breast tumors. They also found
that PAI-1 expression was elevated in the stromal fibroblasts associated with the tumors [115]. It
appears that visceral abdominal adipocytes express high level of plasma PAI-1 in patients with
central obesity [116-117]. Both obesity and insulin resistance are now known to be associated
with high levels of PAI-1 in plasma [118-119].
The expression of PAI-1 can be regulated by inflammatory mediators like
lipopolysaccharide (LPS). Cultured endothelial cells showed increased expression of PAI-1 in
the presence of LPS [120]. Various inflammatory cytokines also cause induction of PAI-1
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expression. TGF-β1 is one of the most potent inducers. Vascular injury causes release of TGF-β1
from the α-granules of platelets, and then the local expression of PAI-1 becomes elevated. TGFβ1 and PAI-1 mutually control expression of each other via a feed-back mechanism [109, 121123]. Interleukin-1 (IL-1) and TNF-α are also implicated in transcriptional activation of PAI-1 in
endothelial cells and fibrosarcoma [109]. Plasma levels of PAI-1 are elevated in type-II diabetes
patients with hyperglycemia [124]. In vitro studies showed that addition of glucose and insulin to
the culture medium increased PAI-1 expression by vascular endothelial cell and SMCs [125126]. Besides insulin, its precursor molecules, such as proinsulin and split-insulin, have also
been found to cause induction of PAI-1 expression in cultured endothelial cells [127]. Cultured
hepatocytes showed increased expression of PAI-1 by free fatty acid (FFA, elevated in diabetes
mellitus) and very-low-density lipoprotein (VLDL, elevated in hypertriglyceridemia) [109, 128].
Another important factor that has been found to be involved in the up-regulation of PAI-1 is
angiotensin-II [129]. Activation of the renin-angiotensin system is associated with increased risk
of ischemia, which appears to be mediated by elevation of PAI-1 expression in plasma [130131].

1.2. b. PAI-1 as a Member of the Serpin Family of Proteins
The primary function of PAI-1 is to regulate the cleavage of plasminogen to yield its active
counterpart, plasmin. Regulation is achieved by PAI-1 inhibiting the proteases, tPA & uPA.
Studies with bovine PAI-1 indicate that it can also inhibit plasmin directly [132]. Indeed, PAI-1
can act on other proteases, but with low efficiency [133]. Serpin molecules contain a reactive
center loop (RCL) that acts as bait for the serine proteases. RCLs of all serpins contain a scissile
bond (termed the P1-P1/ peptide bond) recognized by specific target proteases. For PAI-1, R34613

M347 forms this P1-P1/ scissile bond [134]. The residues located at the N-terminal side of the
scissile bond are denoted as Px (where, x=1, 2, 3.etc). In other words the residues at the Nterminal side of the scissile bond are termed as P1/, P2/, P3/, P4/ etc. The residues that are located
at the C-terminal side are termed as Px/ (where, x=1, 2, 3….etc.). In other words the residues at
the N-terminal side of the scissile bond are termed as P1, P2, P3, P4 etc. The general reaction
mechanism for serpin-mediated inhibition involves these steps (see Figure-1.3, [135]): a.
formation of a non-covalent Michaelis complex between the serine protease and the P1-P1/
scissile bond, b. cleavage of the P1-P1/ scissile bond and formation of a covalent acyl
intermediate between the serine residue of the protease and the P1 residue of the serpin. This is
shown as the loop-bound acyl enzyme in Figure-1.3, c. pre-insertion of the RCL bound protease
indicated as loop-displaced acyl-enzyme complex, d. insertion of the N-terminal portion of the
RCL (from P1 residue) into the central β-sheet A region of the serpin body. During this insertion,
the covalently linked protease is translocated via a major conformational change so that it moves
~70Å to the opposite face of PAI-1. With this translocation, the structure of the protease is also
perturbed, leading to disruption of the active site conformation of the protease [136-140]. For a
usual serine protease reaction, formation of the acyl enzyme intermediate is followed by the
substrate release step and regeneration of the active site. In contrast, when the active site
conformation of the serine protease is disrupted due to this dramatic translocation, the substrate
release step of the serine protease reaction is hindered. As a result, the serpin involved in this
reaction is permanently consumed and the protease is also permanently inhibited. Because of
this, serpins are called suicide inhibitors.

14

Figure 1. 3: Basic scheme of the serpin reaction mechanism

Figure-1.3: The basic scheme of serpin reaction mechanism includes formation of
noncovalent michaelis complex (step-a), cleavage of the RCL with covalent attachment of
the protease with the serpin (step-b), pre-insertion of the RCL with the bound protease
(step-c). At this point the serpin reaction may take two pathways. It can act as a
substrate which results in the release of active protease with permanent cleavage of the
serpin or the serpin may act as an inhibitor. In the inhibitor pathway,y the protease
undergoes a 70Å translocation to the opposite face of the serpin followed by the
permanent destruction of the protease active site (step-d) [134].
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Figure-1.4 shows the structure of the Michaelis (non-covalent) complex formed between α1proteinase inhibitor (PI)-Pittsburg (a natural variant of antithrombin, containing a Met to Arg
mutation at P1) and trypsin [141]. Since the formation of the Michaelis complex between the
serpin and the target protease is typically transient and not amenable to crystallization, seven
stabilizing mutations (to prevent polymerization) were introduced in α1-PI-Pittsburg. Also, the
C232S mutation was introduced in order to prevent formation of an intermolecular disulfide
linkage. The active site serine of trypsin has also been changed to alanine (S195A), to yield
catalytically inactive trypsin). With all of these changes, Demetiev et al. could solve the only
crystal structure of the non-covalent complex between a serpin and its target protease [141]. This
structure shows minimum contact between the serpin and the protease. The P1 Arg side chain
was inserted into the S1 specificity pocket of the protease and thus made extensive contacts.
Other than that, there were hydrogen bonds formed between the backbone residues P2/-P2 of the
serpin and the backbone residues of the trypsin. Figure-1.5 on the other hand, shows the
structure of a covalent complex between α1-antitrypsin and trypsin [142]. This structure shows
that the protease portion of the complex experiences a major translocation of ~ 71A0 towards the
opposite pole of the serpin after forming the covalent bond. In this study, Huntington et al. also
found that the formation of this covalent linkage and the subsequent translocation caused
significant loss in the structural integrity of the protease molecule (including distortion of the
active site), rendering it more sensitive towards destruction by protease. Although we do not
have the structure of PAI-1 in its active conformation or in its protease bound form, it is believed
that PAI-1 follows the same inhibitory mechanism of the serpin family of proteins represented by
the 1-antitrypsin-trypsin pair. With an environmentally sensitive fluorescent probe (NBD)
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Figure 1. 4: Non-covalent
complex between trypsin and
serpin

Figure 1. 5: Covalent complex
between trypsin and serpin

Figure-1.4: A noncovalent complex (Michaelis complex) between S195A trypsin (shown
in gold) and α1-proteinase inhibitor Pittsburgh (containing seven stabilizing mutation
and C232S mutation, shown in brown) [141]. Figure-1.5: A covalent complex between
active trypsin (shown in turquoise) and α1-antitrypsisn (shown in gray color). Dotted
region within covalently linked trypsin indicates disordered structure from
conformational transition [142]. This structure also shows a 71A0 translocation of P1
Met of α1-antitrypsisn (covalently linked with trypsin) and insertion of the cleaved
reactive center loop as 4th β-strand (shown in yellow) of the central β-sheet (shown in
red).
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placed at P9 position, Lawrence et al. showed that the inhibition of protease by PAI-1 involves
the formation of an initial covalent complex and a subsequent movement of the RCL loop
towards the central β-sheet region along with the protease [137]. Egelund et al. later showed that
the linkage formed between PAI-1 and uPA is an ester linkage, as found with other serpinprotease partners [143].

1.2. c. PAI-1 and its Inherent Structural Flexibility
The presence of the reactive center loop (RCL) makes the serpins special. The RCL acts as
substrate bait for the protease attack. The RCL is a highly mobile structure with a great deal of
conformational flexibility. Several different conformations of the RCL have been found to exist
in nature [144-145]. Ovalbumin is a noninhibitory serpin characterized by an RCL that contains
a 3-turn α-helix. The RCL in this protein is completely exposed [146-147] and acts simply as
substrate, and the reaction with protease is not followed by an insertion of the RCL to the central
beta sheet region for ovalbumin. Many groups have proposed that the RCL needs to be at least
partially inserted in order for serpins to be effective inhibitors. This requires flexibility in the
region spanning the base of the RCL [144, 148-149]. Mutation in the base region residues,
especially at the conserved P12 residue (Ala for all inhibitors), causes severe impairment to the
inhibitory activity. For example, mutation of the P12 (Ala) residue by glutamate completely
disrupted the inhibitory activity of C1-inhibitor [150]. The conclusion was that the flexibility in
the base region is required for the partial insertion of the RCL loop in order to maintain
inhibitory properties. Lawrence et al. reported that mutation of the P14 residue (Thr333) of PAI1 to a charged residue caused a total loss of the inhibitor activity towards uPA & tPA but
maintained the protease binding activity [138]. It has been proposed that the presence of a
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charged residue at this position retarded the insertion of the RCL and thus impaired the inhibitor
function by precluding the large conformational change upon inhibition of the protease. At times,
cleavage of the RCL at, or outside of, the P1-P1/ sequence by some non-target proteases may
leave the serpin in a proteolytically cleaved inactive form. Such cleaved serpins also exhibit
insertion of the newly generated C-terminal end of the RCL loop (corresponding to the P1
position) into the central β-sheet region [149, 151-152]. Translocation of the RCL in these
cleaved forms also causes a separation of the P1 and P1/ residue by 70A0. Structural flexibility of
the RCL is thus closely connected with the inhibitory function of serpins. Furthermore, insertion
of the RCL requires a conformational change in other parts of the serpin. A prerequisite for
successful insertion is a sliding movement of the β1-3A of the central β-sheet and helix-F away
from the structure so that the groove region between strand 3A and 5A is opened for the RCL
insertion [153]. Egelund et al. performed a thorough study on different forms of PAI-1 (active,
latent, cleaved and complex with protease) and showed that with each separate form there were
specific conformational changes associated in different region of the protein other than in the
RCL and central β-sheet [154].
With some serpins the conformational lability can be so pronounced that the RCL can
undergo self-insertion into the central β-sheet region without the involvement of any protease.
Such a conformation in serpins is called a latent form, reflecting the absence of anti-protease
activity in this structure. For example, there is a natural variant of antithrombin that can be found
in patients exhibiting premature thrombosis, where mutation of Thr85 (situated at the main
opening of the central β-sheet) to Lys has made the RCL extremely labile so that spontaneous
self insertion is observed. As a result, the serpin converts to a latent form and permanently loses
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its protease inhibition function. This variant is called antithrombin Wobble [155]. Patients
carrying this variant of antithrombin show onset of thrombosis near the age of 10. Another
variant of antithrombin is antithrombin Wibble, which contains the Thr85Met mutation. The
phenotype of this variant is normal overall, but the presence of this mutation makes the RCL
highly susceptible to spontaneous insertion under the influence of stress conditions such as a
mild increase in temperature. There are other examples of serpins that exhibit susceptibility to
loop insertion upon exposure to denaturants or high temperature. α1-antitrypsin was found to be
converted in to its loop-inserted latent form upon treatment with 0.5M citrate at 600C [156].
Wild-type antithrombin was also found to be converted in to its latent form upon similar
treatment [157]. Among all the serpins, PAI-1 is special, as it exhibits the highest susceptibility
towards this large conformational transition in its native form. The half-life of this latency
transition for PAI-1 ranges between 1-2hrs at 370C [158-159]. No mutation or denaturant is
required for initiating the self-insertion of the RCL for PAI-1.
Mottonen et al. were the first to report the crystal structure of latent PAI-1 [160]. Later
Stout et al. reported a high resolution crystal structure [161] of this form. Figure-1.6 shows the
high-resolution crystal structure of latent PAI-1 from Stout et al. Both of these structures clearly
indicate that in latent PAI-1, the RCL is inserted to form the fourth strand of the central β-sheetA, and the conformation of the inserted RCL closely resembles what was found with other
cleaved serpins. This latent form is thermostable and protected from the target protease attack as
the P1/-P1 bond is buried inside the core body of the protein. Denaturation/renaturation or
treatment with negatively charged phospholipids has been found to cause partial conversion of
the latent PAI-1 into its active form [162-163].
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Figure 1. 6: Crystal structure of latent PAI-1

Figure-1.6: High resolution structure of latent PAI-1 [161].
Structure shows RCL (in red), β-strand-3A (in blue), β-strand-5A
(in turquoise), helix-F (in gray), P1 residue (in yellow), P1/ residue
(in magenta), Q123 residue (in green).
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1.2. d. Factors Affecting Stability of PAI-1
Inherent conformational instability is presumably the reason why there is not yet
available any crystal structure of active wt-PAI-1. Different groups have attempted to
strategically introduce different sets of mutations to stabilize the structure [159, 164]. So far the
highest stabilization obtained is a half-life of about 145hrs. This stabilization is exhibited by a
mutant of PAI-1 that is thus constitutively active and referred to as the 14-1-B form; it contains
four different mutations: N150H, K154T, Q319L and M354I [164]. The crystal structure of this
mutant [165] along with all the mutated residues is depicted in Figure-1.7. As demonstrated in
this example, stabilization of PAI-1 by altering the conformational flexibility has remained a
subject of great interest. It seems that the slightest change in the structure can cause a difference
in the half-life of PAI-1 stability. It is well known that stabilization of the structure is obtained
with lowering of temperature. It has also been found that lowering of pH or an increase in
concentration of salt in the buffer has a dramatic stabilizing effect on the structure [166-167].
Sensitivity to pH and salt indicates that it is not just the RCL or portion of the β-sheet-A that are
flexible, but rather the entire body of the protein possesses inherent flexibility; a slight
conformational change in one region may cause a subsequent change in the conformation or
dynamics of another portion of the molecule. Such change, in turn, may affect the stability of the
molecule.
His364 has been implicated in the pH dependent stability of the molecule [167]. This
residue is located at the distal C-terminal end of the molecule. A change in pH alters the
ionization status of this residue, which in turn causes structural changes in the molecule
responsible for lowering the insertion rate of RCL. Blouse et al. showed that mutation of the
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Figure 1. 7: Crystal structure of stable mutant (14-1-B) of PAI-1

Figure-1.7: Crystal structure of stable mutant of PAI-1 with all
the stabilizing mutations [165]. Structure shows RCL (in red), βstrand-3A (in blue), β-strand-5A (in turquoise), helix-F (in gold),
P1 residue (in yellow), P1/ residue (in magenta), four stabilizing
mutations (in green) and Q123 residue (in green with color of
elements) [165].
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conserved Tryptophan residue (Trp175) with a replacement by Phe increased the inherent
stability of the structure from a half-life of about 2hrs to 22hrs [135]. Trp175 is located in the
hydrophobic pocket of the breach region of the molecule. The location of this breach region
close to the base region of the RCL is critical for the initial insertion of the loop. Thus, the
conservative change from Trp to Phe interfered significantly with the rate of RCL insertion and
increased the half-life. All these studies point toward how much conformational lability exists in
the whole structure of PAI-1.
Ligand binding to PAI-1 has also been found to affect the stability of this molecule. VN
is one of the major binding partners of PAI-1 and is known to cause a moderate stabilization of
the structure. We have shown that the stability with VN in a buffer of 100mM Tris, 1mM EDTA,
1% BSA (pH-7.4) increases by 33%, with a change in half-life of PAI-1 from 1.14hr to 1.5hr.
VN binding to PAI-1 has been proposed to interfere with the RCL insertion by blocking the
sliding movement of s1A and s2A toward the gap between helix-E & F. A crystal structure
(Figure-1.8) of the complex containing recombinant SMB domain of VN and the 14-1-B stable
form of PAI-1 provided convincing evidence for this mechanism for structural stabilization [22].
Once again, it is noted that a conformational change at one region of the structure may perturb
another part of the molecule. Although this study was done with SMB domain, full-length VN
interacts with PAI-1 with an even larger surface [168], and thus the interaction between PAI-1
and VN extends beyond SMB domain of VN. This conformational flexibility and the
corresponding change in the stability of PAI-1 resulting from ligand binding are fascinating and
require more careful investigation. One of the areas of focus in this dissertation study has been to
probe the conformational change in PAI-1 that occurs due to ligand binding. This has been
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Figure 1. 8: Crystal structure of 14-1-B & SMB domain

Figure-1.8: Crystal structure of stable mutant of PAI-1 in complex with
recombinant SMB domain [22]. Structure shows RCL (in red), central
β-sheet (in turquoise), helix-E & F and β-strand-1A (in green).
Somatomedin domain is shown in gray with pink disulfide bridges.
Dotted regions indicate disordered structure in the RCL and residues
leading the RGD sequence of SMB domain [22] which could not be
resolved by X-ray crystallography.
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approached by strategically placing a nitroxide spin label and following changes in electron
paramagnetic resonance that occur with structural changes in PAI-1.
Recently our lab has found that different metals can significantly affect the stability of
PAI-1. Type-II metal ions (Co, Cu, Ni) were found to largely destabilize the active conformation
of PAI-1, whereas type-I (Mg, Ca) metal ions conferred instead a slight stabilization. When the
effect of these metal ions was tested in the presence of VN, it was found that type-I metals did
not show much difference in the absence or presence of VN, but type-II metals had completely
opposite effects. In presence of VN, type-II metals dramatically stabilized PAI-1. Figure-1.9
shows the effect of different metals on the stability of PAI-1 in the absence/presence of VN
(Thompson et al., submitted). Significant progress has been made in terms of unraveling
mechanistic aspects of these differential metal effects by studying binding and ensuing structural
changes. My goal in this study has been to characterize the binding interaction between PAI-1
and different metals using biophysical techniques.

1.2. e. Physiological Role of PAI-1
PAI-1 is an essential biomolecule. The importance of PAI-1 is evident from its involvement in
several important biological processes, including fibrinolysis, extracellular proteolysis, cellmatrix interaction etc. The physiological function of PAI-1 can be broadly classified into two
main categories- protease dependent and protease independent activities. Under proteasedependent functions, PAI-1 is mainly involved in the inactivation of tissue-plasminogen activator
(tPA) and urokinase-plasminogen activator (uPA) and thus regulates activation of plasmin [7980]. The primary function of uPA and tPA is to cause formation of plasmin from inactive
plasminogen as shown in Figure-1.10. While uPA is involved in the activation of plasmin
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Figure 1. 9: Metal effect on the stability of PAI-1

Figure-1.9: Half life of wild type active PAI-1 with (purple) or
without VN (blue) in the presence of different type-I (Mg, Ca)
and type-II (Mn, Co & Ni) metals. It also includes the half life
of PAI-1, measured in the absence of metal but in the presence
of equivalent amount of chloride.
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Figure 1. 10: Activation of the fibrinolytic pathway

Figure-1.10: Activation of the fibrinolytic pathway adapted from the
journal published by Kohler et al., New Eng J Med, 2000 [112].
Activation of plasmin occurs by tPA when plasminogen is bound to
the fibrin clot. PAI-1 bound to the fibrin clot maintains tPA
inactivation activity. Factor-XIII causes formation of insoluble fibrin
by crosslinking [112].
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mainly on the cell surface, tPA on the other hand causes activation of plasmin in the extracellular
matrix [169]. In the terminal steps of the coagulation cascade, activated thrombin causes
formation of soluble fibrin from fibrinogen. Soluble fibrin then polymerizes to form the fibrin
clot, which can be further stabilized by activated factor-XIII-mediated crosslinking [112].
Fibrinolysis is a process in which degradation of the fibrin clot happens by the tPA/uPA
mediated activation of plasmin. tPA and inactive plasminogen are known to bind to the fibrin
polymer. Fibrin-bound tPA causes activation of plasmin on the clot surface, and activated
plasmin causes lysis of the clot [170-171]. PAI-1 is also known to associate with the fibrin clot
and causes inactivation of tPA on the clot surface and thus inhibits fibrinolysis [172]. As a result,
PAI-1 plays an important role in the regulation of coagulation and fibrinolysis which is depicted
in Figure-1.10 [112].
Activated thrombin has been found to cause activation of platelets [112]. Thrombosis is
characterized by the aggregation of the activated platelets on fibrin mesh. The presence of PAI-1
is connected with the regulation of thrombolysis by virtue of its ability to inhibit the plasminogen
activation system. Activation of the thrombolytic system remains a major strategy for the
treatment of myocardial infarction. However, the major problem with such treatment is the
thrombotic reocclusion of the initially treated blood vessel [173-174]. Platelet aggregation has
been found to play a major role in such thrombotic reocclusion. It has been found that each
activated platelet contains 4000-8000 PAI-1 molecules [175-176]. Activated platelets release
PAI-1 from α-granules, and as a result, the local concentration of PAI-1 is elevated to around 50100µg/ml [175, 177]. Thrombin can induce the release of PAI-1 from endothelial cells [178].
Such locally elevated PAI-1 concentrations protect the platelet-rich thrombi from thrombolysis.
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Platelet-rich thrombi have been found to be more readily degraded by the application of tPA in
mice deficient in PAI-1 [178]. Levi et al. reported that inhibition of PAI-1 activity by a
monoclonal antibody blocked extension of thrombus formation in an experimental model of
thrombosis [177]. The ability to influence the process of fibrinolysis and thrombolysis by virtue
of its protease dependent function has put PAI-1 at the centerpiece of various coronary artery
diseases. A strong positive correlation has been found between high levels of plasma PAI-1 and
the risk of development of coronary sclerosis, restenosis, myocardial infarction, and deep vein
thrombosis [109, 113, 179]. The ability to interfere with the plasminogen activation system also
has implicated PAI-1 in other diseases that involve fibrosis resulting from increased fibrin
deposition. Such inflammatory lung diseases that involve pulmonary fibrosis include adult
respiratory distress syndrome, bronchopulmonary dysplasia; elevated PAI-1 concentrations have
been found in bronchoalveolar lavage fluid from disease tissue [109]. A high concentration of
PAI-1 has also been associated with renal diseases such as nephritic syndrome and hemolytic
uremic syndrome [109].
Protease-independent functions of PAI-1 have recently grown in prominence. These
functions refer to the activities of PAI-1 that are not directly related to its ability to inhibit
proteases. Instead, these functions depend on the ability of PAI-1 to interact with other binding
partners. For example, binding of PAI-1 to receptor-bound uPA on the cell surface causes
internalization of the ternary complex of PAI-1/uPA/uPAR [180-181]. This internalization
requires the interaction of PAI-1 within the ternary complex with the α2-macroglobulin
receptor/low density lipoprotein receptor-related protein (α2-MR-LRP) or epithelial
glycoprotein-330 or very low density lipoprotein (VLDL) receptor on the cell surface [182-185].
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Formation of the complex with uPA opens up a cryptic high affinity LRP binding site on PAI-1
[186]. While the internalized uPA-PAI-1 complex undergoes lysosomal degradation, uPAR is
recycled back to the cell surface [187]. PAI-1 also appears to be involved in the internalization of
the tPA/PAI-1 complex via the α2-MR-LRP endocytic receptor [188]. Thus, such proteaseindependent activities of PAI-1 play important roles in the turnover of its target proteases.
Another important protease-independent function of PAI-1 is the regulation of cell matrix
interactions. Involvement of PAI-1 in such processes is largely mediated by its ability to interact
with VN. (A detailed discussion of this protease independent effect of PAI-1 on cell-matrix
interaction is given in the following section.) In fact, understanding the interaction between PAI1 and VN and how such interaction affects their ability to regulate cell-matrix interaction is a
major focus of this dissertation work. High PAI-1 expression has been found to be positively
correlated with the increased invasiveness and metastatic spreading of different types of cancer.
Tumor extracts from several types of cancers showed high expression of PAI-1 [189-190]. PAI1-deficient mice appear to be inefficient in supporting invasion of cancer cells [191]. This creates
a paradox, as cancer cell invasion requires proteolysis at the pericellular region and high
expression of PAI-1 at the tumor site is expected to work against invasion by virtue of its antiproteolytic property. Such apparent contradictions may be explained, at least in part, by the
protease-independent functions of PAI-1.

1.3. Interaction between VN and PAI-1
1.3. a. Structural Aspects of the Interaction
PAI-1 is one of the major interacting partners of VN. In blood, PAI-1 circulates in a
complex with VN [81, 192]. VN also serves as the primary binding protein for PAI-1 in the
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ECM [193]. Interaction between vitronectin and PAI-1 has remained an interesting subject in the
area of protein-protein interactions. A primary interaction site involves the SMB domain of VN
[194], as first demonstrated by Seiffert et al. using a recombinantly expressed version of the
SMB domain. Deng et al. used alanine scanning mutagenesis and reported that each of the
cysteine residues within the SMB domain is important for proper folding, maintaining the threedimensional topology required for binding to PAI-1 [195]. Alanine scanning mutagenesis and
antibody binding studies also reported that residues G12, D22, L24, Y27 and Y28 at the SMB
domain are important for maintaining the PAI-1-binding property of vitronectin [195-196].
Several groups have used site-specific mutagenesis studies to localize the complementary VNbinding site on PAI-1. Lawrence et al. reported five point mutants in PAI-1 that had low affinity
for VN. Out of these, three (Q55P, L116P and Q123K) had ten times lower affinity for VN
binding compared to wild type [197]. Magdolen and his group used site directed mutagenesis to
demonstrate the importance of residues in the helix-E and F region of PAI-1 for VN binding
[51]. Several other groups have performed domain-swapping experiments between PAI-1 and
PAI-2 (another serpin molecule) to localize the VN binding site on PAI-1. These studies
indicated that a broad region between amino acids 91 to 167, encompassing helices-E and F and
part of the central β-sheet is responsible for VN binding [198-199]. Zhou et al. reported a crystal
structure of the recombinant SMB domain bound with 14-1-B, the stable mutant of PAI-1
(Figure-1.8). This structure shows a single-turn 3-10 α-helix of SMB interacting with helices-E
and F and part of the central β-sheet (strand 1A) of the 14-1-B mutant form of PAI-1 [22]. Most
of the residues on the SMB domain that were previously considered important for PAI-1 binding
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from mutagenesis studies were found to be involved in the interaction with PAI-1 in the crystal
structure.
Binding of the two proteins has been conventionally considered to follow a 1:1
stoichiometry, mediated thorough the SMB domain of vitronectin. However the possibility of
the presence of a lower affinity binding site outside the SMB domain of VN has been proposed
by a number of groups. Mimuro et al. reported such a site in the intrinsically disordered domain
(residues G115 to E131) [200]. Other groups have suggested the presence of another PAI-1binding site in the C-terminal region of vitronectin (residue K348-K370) [201-202]. In the last
few years, our lab has devoted considerable effort toward understanding the details of this
interaction, and these efforts have shown that the vitronectin-PAI-1 interaction is more complex
than it was previously perceived. Our research has produced evidence that indicates that,
although the primary high affinity (Kd~1nM) binding site of PAI-1 lies within the SMB domain
of vitronectin, there is an additional binding site (of comparatively lower affinity, Kd~100nM)
that lies outside of the SMB domain [203]. Direct evidence for this second binding site was
obtained after a recombinant VN lacking the SMB domain was generated. This deletion mutant
was found to maintain its PAI-1 binding property with a relatively lower affinity of 100nM
[204].

1.3. b. Interactions Leading to Formation of Higher-Order Complexes and
Multimerization of Vitronectin
There are a number of biomolecules that may initiate the process by which VN transitions
to the multimeric conformation, e.g. the thrombin-antithrombin-III (TAT) complex and the
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terminal complement complex (C5b-C7) [44, 205]. PAI-1 binding to VN is the molecule which
has been most extensively evaluated for causing conformational changes and multimerization of
monomeric plasma VN [206]. Seiffert et al. showed that PAI-1, while mixed with monomeric
plasma VN, caused multimerization [206]. This interaction also exposed the conformationally
sensitive epitope (for 8E6 monoclonal antibody), usually only found in multimeric VN. The
exact cause of the multimerization of VN in biological systems remains one of the unresolved
issues to the present day.
VN released from platelets is multimeric in nature [77, 207]. Though PAI-1 concentration
in plasma is about 600-1000 fold lower than that of VN (4nM vs. 2.5-4µM), their \concentration
within platelets is similar [176, 207-208]. This locally elevated concentration of PAI-1 has been
contemplated as a cause for the transformation into a conformationally altered, multimeric form
of VN within platelets. In last few years our lab has made significant progress towards
understanding this process of PAI-1 mediated multimerization of VN. By size exclusion HPLC
and analytical ultracentrifugation studies, we have confirmed that PAI-1 can induce
multimerization of VN in a concentration-dependent fashion [203, 209-210]. We have observed
that initiation of this multimeric complex starts with the formation of a heterotrimer containing
two molecules of PAI-1 and one molecule of VN, confirmed by FRET and a multi-signal
sedimentation velocity study [204, 211]. We are also confident that PAI-1 remains associated
with this multimeric complex for several hours [209, 211]. With these data in support, we
hypothesize that PAI-1 acts a biological partner for the transformation of VN into the matrixassociated form. Furthermore, we propose that the multimeric complexes formed by the
interaction between these two proteins significantly influence their matrix-associated roles. In
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this study, we have emphasized a more complete understanding of the mechanism of complex
formation between VN and PAI-1.

1.3. c. Functional Aspects of the Interaction Between VN and PAI-1
The interaction between these two proteins is a subject of great interest in the field. These
two proteins are co-localized in a number of pathological conditions, such as atherosclerosis,
hepatic fibrosis, and membranous nephropathy [212-214]. While PAI-1 is mainly known as an
inhibitor of uPA and tPA, the interaction with VN expands its inhibitory properties to target
other proteases, e.g.thrombin and activated protein-C (APC) [215-216]. APC has been proposed
to act as a profibrinolytic substance by virtue of its ability to neutralize PAI-1 in circulation.
Rezaie et al. showed that while the direct inactivation of APC by PAI-1 proceeds very slowly,
interaction of VN with PAI-1 increases the rate of such inactivation by 300-fold. Furthermore,
in the presence of VN, PAI-1 becomes the most effective inhibitor of APC [216]. Interaction
between PAI-1 and VN has been implicated in the profibrinolytic property of thrombin also.
Ehrlich et al. showed that endothelial cell matrix-associated PAI-1, while bound to VN, can
inhibit thrombin [215, 217]. This alternative targeting toward proteases may also deplete active
PAI-1 from the circulation and ECM, and thus protect plasminogen activators and promote
activity of the plasminogen activation system. Stefansson et al. later reported that PAI-1
mediated inactivation of matrix-associated thrombin, which occurs in the presence of VN, has an
important role in the cellular clearance of the protease in an LRP-dependent process [218]. The
presence of VN and PAI-1 in the atherosclerotic vessel wall has been shown by many groups
[110, 219]. There are studies that indicate that active thrombin is also present in the
atherosclerotic lesion [220]. Stoop et al. showed that VN, PAI-1 and active thrombin are co35

localized in the atherosclerotic lesion and they have proposed that interaction of VN and PAI-1
in the vessel wall is important for the regulation of thrombin activity, since the natural regulator
of thrombin (antithrombin-III) is not present in the deeper region of atherosclerotic lesion [212].
PAI-1 has been found to be associated with VN in the subcellular matrix of endothelial
cells and platelets [21, 192-193]. Owensby et al. showed that binding of PAI-1 to the
extracellular matrix of HepG2 cells is exclusively mediated by matrix-associated VN [49]. Such
VN-mediated localization of PAI-1 to the extracellular matrix appears to be required for the
effect of PAI-1 in fibrotic renal diseases. These diseases are characterized by increased fibrin
deposition and accumulation of matrix [133, 221]. The plasminogen activation system has a
major role in maintaining the proper balance of matrix turnover [222], and this balance is
compromised in renal fibrotic diseases. PAI-1 expression is highly elevated in renal fibrotic
conditions and thus is thought to be one of the major causes for loss of such balance [223-224].
In these disease conditions, VN plays an important role in localizing PAI-1 within the fibrotic
matrix [225].
PAI-1 also plays a role in regulating cellular adhesion and migration. In fact, a significant
portion of the protease-independent functions of PAI-1 is mediated through its interaction with
VN. PAI-1 interferes with the interaction of cell surface receptors with VN. The PAI-1-binding
site on the SMB domain of VN overlaps with the uPAR binding site, and thus PAI-1 competes
for uPAR binding to the SMB domain of VN [226-227]. A recent crystal structure of uPAR in
complex with the SMB domain and uPA shows that many residues of the SMB domain that were
found to be involved in PAI-1 binding are also involved in uPAR binding [103]. Waltz et al.
showed that uPAR mediated binding of TGFβ1/Vitamin-D3 stimulated U937 cells and uPAR
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transfected 293 cells to VN could be blocked by PAI-1 [226]. In a similar approach, Kanse et al.
showed that PAI-1 could block uPAR-mediated binding of VN to endothelial cells [53]. PAI-1
mediated blocking of the uPAR-VN interaction was found to promote migration of U937 and
melanoma cells [226, 228]. Such a promigratory effect of PAI-1 has been ascribed to the lack of
cell adhesion.
PAI-1 interferes with integrin binding to VN also. Stefansson et al. showed that αvβ3
binding to immobilized VN was blocked by PAI-1 in a dose-dependent manner [229]. The
integrin binding site on VN lies beyond the SMB domain (within the RGD motif, residues 4547), as seen in the crystal structure of 14-1-B and the SMB domain (Figure-1.8) [22]. So
structural overlap is not the direct cause of PAI-1 interference of αvβ3 binding to VN.
Nevertheless, exogenously added PAI-1 inhibited αvβ3 mediated smooth muscle cell (SMC)
binding to VN [229]. In the same study PAI-1 was found to block migration of SMC through
VN. In another study Kjøller et al. showed that PAI-1 could block migration of WISH and Hep2
cell lines through VN, and this inhibition was due to PAI-1 mediated blockage of αvβ3 binding
to VN [230]. Though in all these studies PAI-1 blocked cell binding to VN, the effect on
migration is contradictory.
There are studies that show that PAI-1 is proangiogenic and protumorigenic. Mice
deficient in PAI-1 showed reduced angiogenesis, tumor invasion and tumor formation [191,
231]. On the other hand in a separate study Stefansson et al. reported that addition of PAI-1
inhibited basic-fibroblast growth factor (bFGF) induced angiogenesis [232]. They also found that
such inhibition of angiogenesis was mediated through interaction of PAI-1 with VN. In an effort
to explain such apparent contradiction, McMahon et al. reported a study where they showed that
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the PAI-1 mediated effect on tumor formation and angiogenesis is dose-dependent. While at low
concentrations PAI-1 acted in a pro-angiogenic manner, at high concentrations it was antiangiogenic [233]. Thus PAI-1 appears to play a regulatory role in the processes like,
angiogenesis, tumorigenesis. A major focus of this study is to understand the role of PAI-1/VN
interactions in the regulation of cell binding and migration.

1.4. Research Goals
Vitronectin and Plasminogen Activator Inhibitor-1 (PAI-1) are two important circulatory
proteins, that are also found in the extracellular matrix (ECM). As discussed above, each of these
proteins is involved in a variety of physiological and pathophysiological processes by virtue of
their ability to interact with a wide variety of ligands. For PAI-1, conformational flexibility is
closely connected with its function, and conformational flexibility can be influenced by ligand
binding. In addition, interactions between these two proteins have been implicated in several
biologically important processes such as cell binding and migration. We have seen that the
interaction between vitronectin PAI-1 is much more complicated than a simple 1:1 binding.
While we have made considerable progress towards understanding the mechanism of this
interaction, more work is needed. The major goals of this research are:
I.

To understand how the interaction between VN and PAI-1 influences their functional
roles in the extracellular matrix

II.

To understand the structure and dynamics of PAI-1 in the presence of binding
partners like VN and various metals.
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III.

To understand the role of vitronectin in mediating infection by comparing the
pathogenesis of Candida albicans infection between C57BL/6 mice and vitronectin
knock-out mice.
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CHAPTER-2
Developing Methods to Investigate the Structure and Dynamics of
PAI-1 and Effects of Cofactors

2.1. Introduction
Conformational flexibility is an important property for serpins. Mobility of the reactive
center loop is directly connected to the inhibitory property of serpins. Insertion of the RCL
requires a conformational change in other parts of the protein also. A prerequisite for successful
insertion of the RCL is a sliding movement of the β1-3A strand of the central β-sheet and helix-F
away from the structure so that the groove region between strand 3A and 5A is opened [153].
Egelund et al. performed a thorough study on different forms of PAI-1 (active, latent, cleaved
and the complex with protease) and showed with each form that there were specific
conformational changes associated in different regions of the protein other than RCL and central
β-sheet [154]. PAI-1 is probably the most conformationally sensitive among all the serpins, with
an inherent tendency of the RCL of PAI-1 to insert into the central β-sheet region of the
molecule. This conformational change transforms active PAI-1 into latent PAI-1. The half-life of
this latency transition for PAI-1 ranges between 1-2hrs at 370C [158-159]. Binding of ligands has
been found to influence the latency transition. VN is one of the major binding partners of PAI-1
and is known to cause moderate stabilization of PAI-1 to slow down this conversion to the latent
form. Our lab has showed that VN can cause an increase in half-life of PAI-1 from1.14 hr to 1.51
hr (Thompson et al., submitted to Biochemistry). This VN binding to PAI-1 is proposed to
interfere with the RCL insertion by causing blockage to the sliding movement of the s1A and
40

s2A towards the gap between helix-E and F. A crystal structure of the recombinant SMB domain
of VN and the 14-1-B stable mutant form of PAI-1 supports this mechanism of structural
stabilization [22].
Though binding of VN to PAI-1 is primarily mediated through the SMB domain, there
are a number of important questions regarding this interaction that are still unanswered. For
example, are the functional effects of the SMB domain binding to PAI-1 equivalent to the
binding of full-length vitronectin? In other words, is the interaction of PAI-1 and vitronectin
solely mediated by the SMB domain? Recently, pre-steady state kinetic analyses have revealed
some unique features of the vitronectin/PAI-1 interaction. Stopped-flow experiments done under
conditions where only 1:1 binding is possible between strategically labeled (fluorescent) PAI-1
and vitronectin, show a concentration dependent biphasic binding of a single PAI-1 molecule to
VN followed by a conformational change step [168]. Binding between PAI-1 and the isolated
SMB domain, on the other hand, was monophasic. These data indicate that interaction with fulllength VN is more complex and involves multiple interactions. Addressing this conformational
flexibility and the corresponding change in the stability of PAI-1 is an aim of this study. One of
the goals is to probe the conformational change that occurs in PAI-1 due to ligand binding by
strategically by placing nitroxide spin labels within the RCL of VN. Also, there is evidence that
suggests that the interaction between VN and PAI-1 causes formation of higher order of
multimeric complexes [206, 209-211]. We believe that the interaction between PAI-1 and VN
that extends beyond the SMB domain is critical for this multimeric complex formation. In this
study we have also focused on understanding mechanistic aspects of this multimerization process
using sedimentation velocity experiments in the analytical ultracentrifuge.
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In addition, our lab has recently observed that different metals can significantly affect the
stability of PAI-1. Type-II metal ions (Co, Cu, Ni) were found to largely destabilize the active
conformation of PAI-1, whereas type-I (Mg, Mn, Ca) metal ions slightly stabilized it. Progress
has been made in the mechanistic aspects of these differential effects by studying binding and
ensuing structural changes. The goal in this study is to characterize the binding interaction
between PAI-1 and different metals using biophysical techniques.

2.2. Materials and methods
2.2. a. Materials
PAI-1 cloned into the pET 24d expression vector was obtained from Dr. Grant Blouse
(Henry Ford Health Sciences Center Detroit, MI) as a gift. Anti-PAI-1 polyclonal antibody
(ASHPAI) and octa-peptide (PEP-1-M1660s Inc) (TVASSSTA) were bought from Molecular
Innovations Inc, Southfield, MI. Pentapeptide (TVASS) was gift from Dr. Peter Andreasen‟s lab
at Aarhus University, Denmark. Rosetta2(DE3)pLysS was purchased from EMD Biosciences
Gibbstown, NJ. The QuikChange XL II kit for mutagenesis was purchased from Stratagene Inc
Cedar Creek, TX. Primers for the PCR-mutagenesis reaction was purchased from Invitrogen.
Protease inhibitor cocktail P8465 was purchased from Sigma Aldrich Corp. St. Louis, MO. SP
Sepharose FF, chelating Sepharose FF and high-resolution Sephacryl S100 were purchased from
GE Healthcare Piscataway, NJ. The MTSL spin label was purchased from Toronto Research
Chemical Inc. The C18 reverse-phase HPLC column (250*4.6mm, 300 A0 pore size), Proteo RPHPLC column (4µm bead diameter, 250 A0 pore size) and their companion guard columns were
purchased from Phenomenex, Torrance, CA. Trypsin Gold mass spectrometry grade was
purchased from Promega, Madison, WI. The NTA chip, CM5 chip, amine-coupling kit and HBS42

EP buffer were purchased from GE Healthcare Piscataway, NJ. The Biomax-10 column for
concentrating protein solutions was purchased from Millipore. All other chemical reagents
(buffer & salt) were purchased from Fisher Scientific (unless otherwise specified).

2.2. b. PCR mutagenesis, expression and purification of P9 mutant of PAI-1
In order to mutate Ser338 (P9 residue) to Cys, a PCR mutagenesis reaction was carried
out on the cDNA encoding PAI-1 cloned into the pET 24d expression vector. The primer used
for this mutagenesis reaction is shown below:
Forward: 5/- gtggcctcctcatgcacagctgtcatagtc -3/
Reverse: 3/- caccggaggagtacgtgtcgacagtatcag -5/
Pfu Ultra HF DNA-polymerase was used for the PCR reaction. PCR reaction conditions are
shown below:
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Template DNA was digested using DPN-I, and the final product was transformed into XL10GOLD competent cells (Stratagene Inc) following manufacturer‟s instructions. Transformed
cells were plated on Kanamycin containing TB-agar plates and incubated overnight at 370C for
colony formation. On the next day, an isolated single colony was used for subculturing.
Subculturing was performed in 50ml Falcon tubes, each containing 10ml of Terrific Broth (TB)
with kanamycin. Tubes were shaken overnight at 250rpm at 370C. Cell pellets were then
collected from each tube by centrifugation, and plasmid purification was carried out using the
Promega Wizard Plus miniprep DNA purification system. The presence of the desired mutation
was confirmed by DNA sequencing.
For expression purposes, the plasmid containing the mutation was transformed into
Rosetta2(DE3)pLysS cells following manufacturer‟s instructions. Transformed cells were plated
on TB-agar plates containing kanamycin (34µg/ml) and chloramphenicol (50µg/ml) and grown
overnight at 370C. An isolated single colony was used for subculturing into a conical flask
containing 200ml TB with kanamycin (34µg/ml) and chloramphenicol (50µg/ml). This
subculture was grown overnight at 280C with shaking at 250rpm. The 280C temperature was
used to maintain growth within the 0.5-1 OD range at 600nm within the overnight time frame.
After the overnight incubation, the subculture was transferred into flasks containing 1L TB with
kanamycin (34µg/ml) and chloramphenicol (50µg/ml) using an inoculum volume to give an OD
at 600 nm for the 1L culture of ~ 0.01. The 1L cultures were grown at 370C with 300rpm shaking
until the OD became 0.1. At 370C the Rosetta strain has a doubling time of about 25min. The
temperature of the incubator was reduced to 150C and growth continued until the temperature
was stabilized (about 1-2hr). Expression of PAI-1 was induced by adding 1ml IPTG (1M stock
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concentration) to each of the 1L cultures and subsequent growth overnight at 150C. The cells
were harvested by centrifugation and stored at -800C.
For purification of the P9 mutant, the cell pellet was resuspended in lysis buffer (50 mM
NaH2PO4, 1 mM EDTA, 1mM DTT, pH 6.5) with stirring at room temperature for ~ 1hr. 10ml of
lysis buffer was used for each gram of pellet. During stirring, 10 mg of Protease cocktail
Inhibitor P8465 was added per gram of pellet. Resuspended cells were lysed by sonication (each
cycle had 30sec pulse and 1min pause, 20 total cycles) in an ice bath with stirring. Cell debris
was removed by centrifugation (15000g for 15min). In order to maintain PAI-1 in an active
form, the entire purification was performed at 4 0C. The cell lysate was loaded onto an SP
Sepharose FF column (2.5 x 25 cm). Prior to loading of the cell lysate, the column was
equilibrated with lysis buffer containing 80mM (NH4)2SO4. Following loading, the column was
washed with the same lysis buffer containing 80mM (NH4)2SO4. Elution was carried out with a
linear gradient of 80-500 mM (NH4)2SO4 in the same lysis buffer (total elution volume was
800ml, 13ml fraction size). SDS-PAGE and Western blotting were performed on the elution
fractions to confirm the presence of PAI-1. Selected fractions were pooled and dialyzed
overnight against imidazole buffer (50 mM NaH2PO4, 500 mM NaCl, 20 mM imidazole, 1mM
DTT, pH 7.0). A chelating Sepharose FF column (1.0 x 12 cm) was loaded with Ni according to
manufacturer‟s protocol and equilibrated with imidazole buffer without DTT. (DTT causes
reduction of Ni with a color change from bluish green to blackish brown.) Just before PAI-1 was
loaded on to the column, DTT was added to the imidazole buffer and equilibration was continued
for about one column volume and then PAI-1 was loaded. Then the chelating Sepharose FF
column was washed with the imidazole buffer containing DTT. PAI-1 was eluted with a 20-
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200mM imidazole gradient (total volume of 400 ml) in the same buffer containing 1mM DTT.
The appropriate fractions were chosen to be pooled according to the SDS-PAGE and Western
blot analysis. Pooled fractions were concentrated to 3 ml, and then loaded onto a highresolution Sephacryl S-100 column (2.5 x 115 cm) equilibrated with gel-filtration buffer (50 mM
NaH2PO4, 300 mM NaCl, 1 mM EDTA, 1mM DTT, pH 6.25). Elution was carried out at
0.5ml/min with the same buffer (fraction size- 3ml). PAI-1 eluted as a single peak. The presence
of PAI-1 was once again confirmed by SDS-PAGE and Western blotting. Fractions were pooled,
concentrated, and stored at -80 0C. Protein identity was confirmed by MALDI-MS. PAI-1
concentration was determined by absorbance at 280 nm using

280

= 0.93 mlmg-1cm-1 [234]

and a molecular weight = 43760 g/mol (calculated from the amino acid sequence).

2.2. c. Spin labeling of the P9 mutant
A nitroxide spin label, MTSL [(1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl)methanethiosulfonate], was chosen for labeling the P9 mutant. This methanethiosulfonate type of
spin label requires a free sulfahydryl group for labeling. The scheme of the labeling reaction is
shown in Figure-2.1. The labeling reaction was performed at 40C. Before labeling, DTT was
removed from the mutant protein in storage buffer (50 mM NaH2PO4, 300 mM NaCl, 1 mM
EDTA, 1mM DTT, pH 6.25) using a PD-10 column. Initially, the PD-10 column was
equilibrated with storage buffer without DTT. The mutant PAI-1 was diluted to 2.5ml in this
equilibration buffer and loaded on to the PD-10 column. After loading of PAI-1, 3ml
equilibration buffer was utilized for elution by gravity flow. MTSL was added to the mutant
PAI-1 at a 10-fold molar excess, and the reaction was conducted on ice for 4hrs.
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Figure 2. 1: Reaction mechanism for MTSL labeling

Figure-2.1: The reaction mechanism for MTSL labeling involves oxidation that
happens between the thiosulfonate group of MTSL with the free sulfahydryl
group of the cysteine side chain on the protein. This reaction results in the net
loss of 184Da mass.

The MTSL/PAI-1 mixture was loaded on to another fresh PD-10 column pre-equilibrated with
equilibration buffer in order to remove unbound MTSL. MTSL-labeled PAI-1 was eluted using
3ml equilibration buffer. Labeled PAI-1 was concentrated using a Biomax-10 spin column
(10Kd cut off) centrifuged at 12000rpm for 18min. Analysis of the labeled-PAI-1 sample on a
RP-HPLC (C4) column showed a single peak that analyzed by MALDI in order to confirm the
presence of the label.

2.2. d. Isolation of the SMB domain by trypsin digestion and RP-HPLC
purification
The recombinant SMB-IDD domain was used for isolating the SMB domain. The SMBIDD was dialyzed against 100mM NH4HC03 buffer (pH-7.8). For trypsin digestion, the required
pH is in between 7-9. Trypsin-Gold was dissolved in HPLC-grade water to a final concentration
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of 1mg/ml and mixed with the SMB-IDD sample at a ratio of 1:50 (w/w). As a control, the same
amount of trypsin was mixed with 0.1M NH4HC03. The reaction was performed at 370C and
stopped by adding 1%TFA in water, so that the final concentration of TFA is 0.1%. Trypsin
digestion time, which was standardized to maximize production of the SMB domain, was 140
min. The reaction mixture was separated on a Proteo RP-HPLC column with 24-28%
Acetonitrile (ACN) gradient over a 30min time period at 0.5ml/min flow rate. The gradient was
standardized in order to maximize the separation of peptides after digestion. HPLC peaks were
collected for mass analysis by MALDI. Multiple injections were made (each 50µl) on the Proteo
column, and the peak that corresponds to SMB domain was collected. The mass of this collected
peak was again confirmed by MALDI. Collected fractions were combined, lyophilized in a
Speed-Vac and frozen at -800C. The lyophilized sample was resuspended in 1XPBS, and the
concentration was measured by absorbance at 276nm wavelength. using

276

= 4,500 M-1cm-1

[235] and a molecular weight of 5678.26Kd (calculated from the amino acid sequence including
4 disulfide bonds).

2.2. e. Electron paramagnetic resonance measurements
EPR-spectroscopy was performed on this Labeled P9-mutant in a Bruker-EMX machine.
For titration with VN or the SMB domain, 3µM of the labeled PAI-1 mutant was mixed with
varying concentrations of vitronectin or the SMB domain. Each mixture was incubated at room
temperature for 15minutes, and then 60µl of the reaction mixture was loaded in a quartz capillary
for data collection. Spectra were collected at room temperature using incident microwave power
at 2.158mW and a 100 kHz field modulation of 4Gauss. A total of 8 scans were accumulated for
each sample; for each scan, a 100gauss scan-width centered at 3514.31Gauss was used. The
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recorded spectra were analyzed using WIN-EPR software from Bruker. The intensity of the
middle peak was measured, and the normalized intensity was plotted against the ratio of ligand to
PAI-1 concentration.
For half-life measurements, the temperature of the instrument was maintained at 370C by
using the nitrogen gas driven temperature control device. 7µM of the labeled PAI-1 mutant was
loaded into the quartz capillary tube, and the tube was capped using a Teflon plug on both sides
to avoid leakage. Spectra were collected at 370C, using incident microwave power at 2.16mW
and a 100 kHz field modulation of 4Gauss. Two scans were added for each time point; for each
scan, a 100gauss scan-width centered at 3365.31Gauss was used. Spectra were collected starting
from the zero-time point and continued for a period of 22hr. A multiple-field-sweep (MFS)
strategy was used for collecting spectra at different time intervals. Proper tuning of the
instrument was maintained between scans. The absolute area of the middle peak at each time
point was measured by WIN-EPR software from Bruker. Area was plotted against time and fit
to a single exponential decay equation using GraphPad Prism software.

2.2. f. Surface plasmon resonance measurement
In order to confirm the proper function of the isolated SMB domain, SPR experiments
were performed on a Biacore-3000 instrument. About 4000 response unit (RU) of monomeric
Vitronectin (25µg/ml) was covalently immobilized (acetate buffer with pH-4.5) on a CM5 chip
following 1-ethyl-3-(dimethylaminopropyl)carbodimide hydrochloride/Nhydroxysulfosuccinimide coupling chemistry (EDC/NHS coupling). 25nM of wtPAI-1 in HBSEP buffer (10 mM HEPES, 150mM NaCl, 3 mM EDTA, 0.005% surfactant P20, pH 7.4) was
flowed over the VN-chip in the presence and absence of equimolar concentration of isolated
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SMB domain. The conditions for this experiment were a10µl/min flow rate with protein, with a
3min association followed by 3min dissociation phase with a flow of buffer alone. The chip was
regenerated with 50mM HCl at 10µl/min flow rate for 1min.
For metal binding experiments with PAI-1, the NTA chip was used. The structure of
NTA is shown in Figure-2.2. Freshly prepared (filtered and degassed) Tris buffer (50mM Tris,
200mM NaCl, pH-7.4) was used as running buffer. For each metal a highly concentrated stock
solution was made in water and stored at 40C under low pH. Before each experiment a solution
of 0.5mM (unless otherwise specified) was made from the stock solution using the running
buffer. For regeneration, a 350mM EDTA solution was made in running buffer. For washing the
loosely bound metal from the microfluidic channel and the chip, a 50µM EDTA solution was
made in running buffer. All the reagents were filtered and degassed before the experiment. No
reagent was used for more than two days. PAI-1 was dissolved in running buffer (filtered,
degassed) at the desired concentration, and the final mixture was filtered before loading on the
chip. The basic scheme of the experiment is shown in Figure-2.3. Metal was loaded on FC2 (or
FC4) at a 10µl/min flow rate for 0.7min. Loosely bound metal was flushed out of the system by a
brief injection of (1.5min) 50µM EDTA on both the metal loaded and reference flow cells at a
10µl/min flow rate. PAI-1 was loaded on to the chip (on both flow cells) at 10µl/min flow rate
for 2 min and the dissociation was monitored for 3 min. Specific binding of PAI-1 to metal was
obtained by subtracting the background binding on the reference flow-cell. Steady state response
units were determined using the BIA-evaluation software, plotted against PAI-1 concentration
and fit to a single-site specific binding model in Graphpad-Prism to obtain the affinity constant.
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Figure 2. 2: Nitrilotriacetic acid
Figure-2.2: The structure of nitrilotriacetic acid shows
three carboxy-methylene groups are attached with the
central nitrogen atom

Figure 2. 3: Basic scheme for the Biacore experiments of PAI-1 binding to metal

Figure-2.3: The basic scheme for PAI-1 binding experiment to the
immobilized metal on NTA chip. The change in response unit (RU) for
each injection over both the test flow cell (in green) and the reference
flow cell (in red) is represented schematically.
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For competition experiments, a fixed concentration of PAI-1 was mixed with varying
concentrations of MgCl2. The mixture of PAI-1 and MgCl2 was then injected at a 20 µl/ml flow
rate over both nickel-bound and reference flow cells for 2 min. Competition of magnesium with
NTA-bound nickel for binding to PAI-1 was measured by the decrease in steady-state response
units. For this competition experiment, response curves obtained at each concentration of MgCl2
were plotted with that of PAI-1 by itself. Free metal ion concentration was calculated according
to the following equation: Mf = Mt – [(Mt + Bt + Kd) – ((Mt + Bt + Kd)2 – 4•Bt•Mt)1/2]/2 where Mf
= free metal concentration, Mt = total metal concentration, Bt = total buffer concentration, and Kd
= buffer/metal dissociation constant. The specific affinity information between a metal ion and
the buffer was obtained from the previous work done by other groups [236-238]. By using the
known buffer/metal affinity values ( β1) as described in these articles, the dissociation constants
of the metals in the Tris buffer were calculated following the equation: β1= Ka = 1/Kd.

2.2. g. Sedimentation velocity experiments
Sedimentation velocity experiments were carried out in an Optima XL-I analytical
ultracentrifugation instrument. Both interference and absorbance optics were utilized. When
interference optics was used, proteins were dialyzed against a common buffer overnight at 40C.
For example, when experiments were performed to characterize the multimerization between VN
and PAI (wild type and its variants- 14-1-B & W175F), each of these proteins were loaded into
Slide-A-lyzer dialysis cassettes (10Kd cut off). Each of these cassettes was then dialyzed
overnight against 1XPBS in the same dialysis chamber in order to match the buffer composition
between the various samples. VN and PAI-1 (or its variants) were mixed at the required
concentrations and the mixture was incubated at 370C for 1hr. A volume of 390µl of the mixture
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was loaded into the sample sector of a double-sector charcoal-filled epon (12mm path length)
centerpiece inside the centrifugation cell. For interference optics, buffer from the dialysis
chamber was used in the reference sector of the centrifuge cell in order to match the buffer
composition between reference sector and sample sector. For absorbance optics buffer matching
was not as critical. For experiments with RCL peptide mimics, only absorbance optics was used.
Peptides at required concentrations were mixed with PAI-1 and incubated at 370C for 1hr.
Following this incubation, VN was added, and incubation was continued for an additional hour at
370C. Samples were loaded on to centrifugation cell as described above.
Centrifugation cells were properly aligned inside an 8-hole An50 Ti rotor and the rotor
was subject to temperature equilibration inside the centrifuge under vacuum. Temperature
equilibration was continued for at least 1hr at 250C. For interference data collection, proper
temperature equilibration is very critical. For interference scans, radial calibration was carried
out before starting the data collection. Sedimentation velocity experiments were performed at
50,000 rpm at 25°C. Analysis of the sedimentation velocity data was carried out using the
continuous c(s) distribution model described by the Lamm equation with the freely available
software, SEDFIT [239-240]. The built-in integration tool of SEDFIT was used to calculate the
amount of loading signal present within a specific sedimentation coefficient range.
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2.3. Results
2.3.I. Characterizing the Interaction between Vitronectin and PAI-1 by
Strategic Placement of a Spin Label in PAI-1
2.3.I.a. Isolation of the Correctly Folded SMB Domain
Expression of the SMB domain (first 44aa of vitronectin) in a recombinant system is
challenging because of the likelihood of producing misfolded protein due to improper disulfide
bridge formation. The SMB domain has 8 cysteine residues that form 4 disulfide bonds. The
correct formation of these four disulfide bonds yields a structure that is resistant to protease
digestion. However, expression in a bacterial system results in the formation of several different
disulfide bonded species. In a separate study, a segment from vitronectin containing both the
SMB and IDD domains (i.e., the first 130aa of VN) of VN was expressed in our lab. Following is
the sequence of the piece that was expressed as SMB-IDD. The first four amino acids of the
GSAMDQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAECKPQVTRGDVFTMPED
EYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPVLKPEEEAPAPEVGASKP
EGIDSRPETLHPGRPQP

sequence (GSAM) are an extra portion that resulted from the cloning strategy. The portion
highlighted in green is the SMB domain, and the portion highlighted in yellow is the IDD
domain with a RGD sequence in between them. A method was developed to use a trypsin
digestion method to isolate and purify the correctly folded SMB domain from the expressed
recombinant SMB-IDD pool (which presumably contains a mixture of species due to various
disulfide arrangements). The working hypothesis was that the correctly folded form will be
resistant to such digestion. Following trypsin digestion for ~ 140 min at 370C, reverse phase
HPLC purification was pursued on the digested proteins, using a C18 Proteo column.
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Figure-2.4 represents the elution profile of the digested SMB-IDD by HPLC. Various peaks
were collected, and their mass was checked by MALDI. If the SMB domain remains resistant to
trypsin digestion then a digestion after R49 residue will result in the release of the isolated SMB
domain with a calculated mass of 5506Da including GSAM at the N-terminus. The peak that
eluted at 10.11min showed a mass of 5505.339Da, close to the expected mass. Large scale
trypsin digestion was carried out, and the peak corresponding to the undigested and intact SMB
domain was collected upon multiple injections of the digested sample. Again, several collected
fractions were selected and were tested along with the target fraction by MALDI to confirm the
mass. Figure-2.5 represents the mass chromatogram obtained from the target fraction, and the
observed mass was once again very close to calculated mass for the isolated SMB domain. All of
the collected peaks were combined, freeze-dried and reconstituted in 1XPBS and stored at 40C.
Confirmation of the correct folding of the purified SMB was performed by carrying out a
SPR-based competition assay in the BIACORE instrument. A CM5 chip was covalently coupled
with monomeric vitronectin. Mixtures of PAI-1 and the isolated SMB domain were passed over
the VN-chip. The SMB domain, at equimolar concentrations with PAI-1, (25nM:25nM) was
observed to completely block PAI-1 binding to VN chip. Figure-2.6 shows the sensogram data
with PAI-1 run over the chip alone or in combination with the SMB sample. While PAI-1 by
itself showed a steady state response unit (RU) of about 500, the addition of the SMB domain
reduced the binding close to baseline. These data clearly confirm the proper function of this
SMB preparation.

55

Figure 2. 4: HPLC elution profile of trypsin digested SMB-IDD

Figure-2.4: Digestion of SMB-IDD was carried out for 140min at 370C in
NH4HCO3 buffer at pH-8. 50µl of the digested sample was loaded on a Proteo-RP
column and separated using a 24-28% gradient run for 30min at 0.5ml/min flow
rate. The peak that eluted at 10.118min represented undigested SMB domain. The
numbers indicated in the elution profile are the time points (in minutes) of the
appearance of each peak.
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Figure 2. 5: Confirmation of the mass of the isolated SMB domainby MALDI

Figure-2.5: The SMB-IDD domain was digested with trypsin at 370C in
NH4HCO3 buffer at pH-8. Samples were injected on to RP-HPLC. The peak
eluted at 10.11min for each injection was collected. This peak represented
undigested SMB. Some of the fractions were randomly selected and checked by
MALDI. This figure shows the mass information obtained from one of those
samples. The observed mass (5505.893) nicely matches up with the calculated
mass.
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Figure 2. 6: Confirmation of the PAI-1 binding activity of the SMB by SPR

Figure-2.6: A competition experiment of SMB domain with full length VN for PAI-1
binding was designed. Monomeric VN was immobilized on a CM5 chip. Injection was
carried out for 5min at 30µl/min followed by a 5min dissociation phase. PAI-1 (25nM)
alone showed a response unit change of around 500. However, addition of equimolar
SMB decreased the change in response units to nearly baseline, demonstrating effective
competition of the SMB domain with full length VN for PAI-1 binding. This figure
shows results from duplicate injections of each sample.
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2.3.I.b. MTSL-labeled PAI-1 Accurately Reports the Transition to the Latent Form
Use of spin labels has been found to be quite useful in the understanding of structural
changes upon protein-protein interaction. Spin labels are extremely sensitive to changes in the
local environment and can provide valuable information on conformational changes. PAI-1 has
an inherent advantage in that it does not have any cysteine residues in its primary structure. This
allows us incorporating a single cysteine at any location within PAI-1 by site-specific
mutagenesis, and thus in turn permits us to put a spin label at our position of choice. In this
study, the Serine-338 residue in the RCL (known as the P9-residue), was chosen to be spin
labeled. The S338C mutant of PAI-1 was successfully expressed and purified, and the purified
mutant was successfully labeled with MTSL spin-label following the reaction mechanism shown
in Figure-2.1. Incorporation of a single label was confirmed by MALDI (Figure-2.7). This
result confirms that the observed mass (42784.043Da) of the purified mutant (S338C) agrees
with the calculated mass which is 42785.45Da. If the reaction with MTSL at a single position has
been achieved then the increase in mass should be 184Da. Our result shows an increase in
184.7Da.
Once the labeling was confirmed, we aimed to verify our idea that strategically placed
spin-labels in PAI-1 would be sensitive to changes in the local environment. Placement of the
fluorescent probe at the P9 position has been successfully utilized to probe the insertion of the
RCL during the transition of PAI-1 to the latent conformation [241]. Likewise, it was predicted
that this spin-label at P9 position could successfully report the insertion of the RCL. 8µM
MTSL-labeled PAI-1 was loaded into the EPR tube, and scans were collected at different time
intervals. Temperature inside the EPR cavity was maintained at 370C throughout the experiment.
At each time point, two scans were collected, and the absolute area of the middle peak of the
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Figure 2. 7: Conformation of MTSL labeling of S338C PAI-1 by MALDI

Figure-2.7: MALDI analyses for comparing the mass of S338C-PAI-1 and MTSLlabeled S338C-PAI-1. The top panel shows the mass of purified S3368-PAI-1, and
the bottom panel shows the mass of S3368-PAI-1 with the spin label attached. The
major peak in the spectrum represents the average molecular weight of each
species. The observed increase in mass (184.7Da) nicely corresponds to the presence
of a single label on PAI-1
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EPR-spectrum was calculated. Peak area was plotted against time and fitted to a single
exponential decay equation. With increasing time, the peak area decreased until it reached a
plateau. Figures-2.8 and 2.9 show the spectrum collected at time zero and at 22hr respectively.
Figure-2.10 shows the area vs. time curve. The half-life of the signal change was ~ 85 min,
which is similar to the half-life of the latency transition found in the literature (1-2hrs) [158-159].
This indicates that the method can effectively sense the change occurring at a structural level.
2.3.I.c. The Effect of VN or the SMB Domain Binding on MTSL-Labeled PAI-1
An experiment was designed to check the effect of the binding of the isolated SMB
domain or full length VN on MTSL-labeled PAI-1. A titration experiment was carried out in the
Bruker-EMX EPR instrument, using varying concentrations of vitronectin or the SMB domain
mixed with a fixed concentration of MTSL-S338C PAI-1 (3µM). Figure-2.11 shows the data
from this experiment. Four scans from each sample were collected, and the peak height of the
second (middle) peak of the MTSL-labeled PAI-1 was calculated using WINEPR software (from
Bruker-EMX). The peak height of each sample was normalized with respect to the peak height
obtained from MTSL-PAI-1 alone. The normalized data were plotted against the concentration
of the ligand. This titration analysis shows an interesting difference in the interaction comparing
the isolated SMB domain and full-length, intact vitronectin with PAI-1. While the addition of
increased concentrations of SMB to PAI-1 did not cause much change in the spin label, addition
of VN to PAI-1 caused a decrease in the signal intensity. These results provide another indication
that the interaction of full length VN with PAI-1 is more extensive than that exhibited by the
SMB domain by itself.
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Figure 2. 8: Spectrum of MTSL labeled PAI-1: at time zero

Figure 2. 9: Spectrum of MTSL labeled PAI-1: at 22hr

Figure-2.8-2.9: EPR spectra of MTSL-S338C PAI-1 at time zero (Figure2.8) and at 22hr (Figure-2.9). MTSL-labeled PAI-1 was tested at an 8µM
concentration, and each spectrum at the respective time points represents
the addition of two scans.
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t1/2 ~ 85min

Figure 2. 10: Exponential decay of EPR signal of labeled PAI-1with time at 370C

Figure-2.10: The absolute area of the middle peak from the EPR spectra at each time
point was calculated and plotted against time interval. Data have been fit to a single
exponential decay equation. The half-life obtained from this study was 85min.
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Figure 2. 11: Comparison of VN and SMB binding to S338C-PAI-1by EPR

Figure-2.11: Titration of MTSL-S338C PAI-1 (3µM) with varying
concentrations of SMB and VN. Four scans for each sample were collected. The
peak height of the middle peak of each sample was calculated and normalized
with respect to the peak height obtained from MTSL-labeled S338C-PAI-1
alone. Normalized data have been plotted against ligand concentration. Solid
circles (red) show the titration with SMB and open squares indicate the
titration with VN.
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2.3. II. Characterizing the Mechanism of Formation of Complexes Between
VN and PAI-1
2.3.II.a. Comparison of Formation of Higher-order PAI-1/VN Complexes with Wild-type
and Stable Mutant Forms of PAI-1
Sedimentation velocity experiments are routinely done in our lab to understand the
association process for VN and wtPAI-1. Figure-2.12 shows the formation of the multimeric
complexes between VN and PAI-1 (mixed at equimolar concentration, 6µM) from a
sedimentation velocity experiment. Absorbance data were collected and analyzed using the c(S)
continuous size distribution model described by the Lamm equation using SEDFIT [240]. A
distribution plot is generated relating the concentration of various species (y-axis) and their
sedimentation coefficient ((s) plotted on the y-axis). Monomeric VN and PAI-1 have a
characteristic sedimentation coefficient of ~ 4.5S and 3.5S respectively [210]. The appearance of
higher-order multimeric species becomes evident when these two proteins are mixed together.
Figure-2.12 shows the multimeric species (with S-values greater than 6); integrating the area
between specific sedimentation coefficient values allows us to quantify the relative amount of
protein mass present within that range. When PAI-1 and VN are mixed together (6µM:6µM)
about 65% of the total loading signal is present within the range of 6S to 60S as higher-order
multimeric complexes.
We next evaluated association of vitronectin with two mutants of PAI-1 (14-1-B and
W175F) that are known to have much higher stability than wild type active PAI-1 [135, 164].
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Figure 2. 12: Sedimentation velocity study of oligomeric complex formation between VN and wtPAI-1
Figure-2.12: Proteins (VN and PAI-1) were mixed at an equimolar concentration (6µM) at 370C for 1hr and loaded into the
centrifuge cells. Absorbance data were collected at 50000rpm at 250C and fitted to a c(S) distribution model using SEDFIT.
The top-panel indicates the RI noise and TI noise subtracted data fitted to the c(S) distribution model. The numbers indicate
the fitted parameters referring to the model. The middle-panel indicates the residual of the fit. The bottom-panel is the
distribution plot of different sedimenting species (c(S) vs. S). Integration of the distribution between 6S and 60S indicates
that 65% of the loading concentration was present as higher order complexes.
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Mutations at these different positions apparently cause structural changes that oppose the
spontaneous insertion of the RCL. In a previous study done by our lab, it was found that the
W175F mutant had a greatly decreased affinity (Kd>10µM) for binding to VN at the site situated
outside of the SMB domain [242]. Therefore, a significant functional difference exists between
wild type PAI-1 and theses mutants. Our goal was to further compare the functional properties of
these two mutants with wild type active PAI-1. Although these two mutants are showing
stabilizing effect on PAI-1 by bringing structural alteration, important question remains
regarding their ability to form multimeric complexes with VN. Sedimentation velocity
experiments were performed to compare the amount of higher-order multimeric complexes
generated with VN. Figure-2.13 shows the comparison of the distribution of higher order
multimeric species formed by the interaction of VN with equimolar amounts of wild type active
PAI-1 or either of the mutants. Integration of the distribution range between sedimentation
coefficients of 7S to 45S demonstrates that about 50% of the loading signal from all the variants
was present within this range. Thus, the total amount of higher order multimers formed between
active PAI-1 and the mutants was not much different. If we carefully observe the size
distribution profile it appears that with the 14-1-B mutant, formation of higher order multimers
was largely limited to sedimentation values of <20S. The relative amount of higher order species
present beyond that range was much lower compared to the other mutant and wild-type protein.
2.3.II.b. Studies to Address the Way in which VN and PAI-1 Interact within Multimeric
Complexes
We have generated evidence in our lab that indicates that the multimerization between
VN and PAI-1 is initiated by the formation of a heterotrimeric complex (1:2 stoichiometry) that
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Figure 2. 13: Sedimentation velocity study: comparison of oligomerization between
wtPAI-1 and its stable mutants with VN

Figure-2.13: Comparison of multimeric complex formation between wtPAI-1
(red) and mutant forms of PAI-1, W175F (green) and 14-1-B (black).
Interference data were collected at 50000rpm and fitted to a c(S) distribution
model using SEDFIT. Each variant of PAI-1 was mixed at an equimolar
concentration with VN (6µM) and incubated for 1hr at 370C before loading
into the centrifuge cells for the analysis.
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contains one VN molecule and two PAI-1 molecules. Although our idea was that two PAI-1
molecules bind to one VN directly within the 2:1 complex, we did not have direct evidence to
validate this hypothesis. Several approaches have been pursued to address this idea. For one, we
have an ongoing collaboration with scientists at the Oak Ridge National Lab (ORNL) to study
the mechanism of complex formation between VN and PAI-1 by performing small angle neutron
scattering (SANS). These studies have been performed with a complex of monomeric VN and
perdeuterated W175F. A model of full-length VN previously generated from a small angle x-ray
scattering (SAXS) study [27] and the crystal structure of 14-1-B have been used to fit the data
obtained from these SANS studies. This has resulted in the generation of an intriguing model of
how VN and PAI-1 interact within 1:2 complexes as shown in Figure-2.14. This model indicates
that within the 2:1 complex, only one PAI-1 molecule is in direct contact with the VN molecule.
The second PAI-1 molecule has no connection with VN; instead, it forms direct contacts with the
first PAI-1 molecule that directly interacts with VN. This model points us in new directions
regarding the interaction between VN and PAI-1. Obviously, a direct interaction between VN
and PAI-1 is important for initiating the process; this means that use of a PAI-1 variant that
completely lacks the ability to interact with VN will be expected to fail in forming multimeric
complexes. Another interesting aspect of this model is the interaction between the PAI-1
molecules within the complex. It appears that PAI-1/PAI-1 interactions make a significant
contribution in the multimerization process. Indeed, PAI-1/PAI-1 interactions in a
polymerization process have been observed previously. For example, serpins are known to
exhibit intermolecular interactions via their reactive center loop; polymerization of serpins (α1antitrypsin, antithrombin, C1-inhibitor etc.) has been implicated in several diseases like, cirrhosis
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Figure 2. 14: Model of interaction between VN and W175F-PAI-1: result from
SANS study

Figure-2.14: SANS (Small Angle Neutron Scattering) study for understanding
the interaction between VN and W175F-PAI-1 (Peterson lab, unpublished).
Within this model, four PAI-1 molecules (blue) and two VN molecules (green)
are indicated by arrows. Within the 1:2 complex, PAI-1 is connected with VN
by another PAI-1 molecule. Connection between two 1:2 complexes is
mediated by VN.
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of liver, thromboembolism, angioedema [243-245]. There are a few potential ways in which the
RCL of one molecule can be inserted into the β-sheet of another serpin to initiate the process of
multimerization. Figure-2.15 indicates three possible mechanisms for loop insertion that have
been proposed [246]. Insertion can occur and form the 4th β-strand or 7th β-strand of the central
β-sheet A, or it may occur in a way that forms an additional strand of β-sheet C.
Replacing glutamate-123 in PAI-1 with arginine has been found to weaken the affinity
for the primary site interaction within the SMB domain of VN [197]. Figure-2.16 shows the
result of sedimentation velocity study done between monomeric VN and Q123K-PAI-1 mixed at
equimolar concentration (4µM). Only 10.3% of the total loading signal was present between
sedimentation coefficient ranges of 6S to 37S, whereas a control experiment done between VN
and native PAI-1 under similar condition had 37% of the total loading signal present within the
same distribution range. This result shows that disrupting the primary site interaction between
VN and PAI-1 significantly blocks the formation of higher order complexes. The lower quantity
of higher order complexes observed with Q123K are presumably due to the high concentration of
the protein (4µM) used during the experiment.
If the loop insertion is the cause of PAI-1/PAI-1 interaction in the complex, use of latent
PAI-1, which already has the RCL inserted as the 4th strand of β-sheetA, should presumably
block the formation of the complex. This will be valid only if the PAI-1/PAI-1 interaction is
„loop to strand 4A of central β-sheet‟-mediated. Figure-2.17 shows that sedimentation velocity
study done using equimolar concentrations of VN and latent-PAI-1 (4µM). While the amount of
higher order complexes formed with latent-PAI-1 was much lower than native PAI-1 (around
37%), it was significantly higher compared to the Q123K mutant. 18.3% of the total loading
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Figure 2. 15: Loop insertion mechanisms for different serpins

Figure-2.15: Multiple ways in which loop insertion may happen between serpin
molecules (obtained from Ref: 246). The left panel indicates loop insertion as the 4th
strand of β-sheet-A (observed with naturally occurring mutants of α1 antitrypsin). The
middle panel indicates loop insertion as a strand of β-sheet-C (observed with the
crystal structure of anti-thrombin). The right panel indicates insertion as the 7th stand
of β-sheet-A (observed with the crystal structure of PAI-1) [246].
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Figure 2. 16: Sedimentation velocity study of oligomeric complex formation between VN and Q123K-PAI-1
Figure-2.16: Proteins (VN and Q123K-PAI-1) were mixed at equimolar concentration (4µM) at 370C for 1hr and loaded into the
centrifuge cells. Absorbance data were collected at 50000rpm at 250C and fitted to c(S) distribution model using SEDFIT. The
top-panel indicates the RI noise and TI noise subtracted data fitted to the c(S) distribution model. The numbers indicate the
fitted parameters referring to the model. The middle-panel indicates the residual of the fit. The bottom-panel is the distribution
plot of different sedimenting species (c(S) vs. S).Integration of the distribution between 6S and 36S indicates that 10.3% of the
loading concentration was present as higher order complexes.
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Figure 2. 17: Sedimentation velocity study of oligomeric complex formation between VN and latent-PAI-1
Figure-2.17: Proteins (VN and lat-PAI-1) were mixed at equimolar concentration (4µM) at 370C for 1hr and loaded into the
centrifuge cells. Absorbance data were collected at 50000rpm at 250C and fitted to c(S) distribution model using SEDFIT.
The top-panel indicates the RI noise and TI noise subtracted data fitted to the c(S) distribution model. The numbers
indicate the fitted parameters referring to the model. The middle-panel indicates the residual of the fit. The bottom-panel is
the distribution plot of different sedimenting species (c(S) vs. S). Integration of the distribution between 6S and 44S
indicates that 18.3% of the loading concentration was present as higher order complexes.
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signal was present between sedimentation coefficient ranges of 6S to 44S. This indicates that it is
possible that the interaction between PAI-1 can occur through more than one mechanism.
2.3.II.c. Effect of RCL Peptide Mimics on the Interaction Between VN and PAI-1
In order to further evaluate the concept of RCL insertion as a mechanism for PAI-1/PAI1 interaction, an alternative approach was utilized. RCL-mimicking peptides have been utilized
in a number of cases to interfere with the loop insertion process and study ligand binding
interaction with PAI-1 [247-248]. There are two different RCL peptide mimics that are most
commonly used. They are: i. octapeptide: N- TVASSSTA –C (mimics P14-P7 residues) and ii.
pentapeptide: N- TVASS –C (mimics P14-P10 residues). A crystal structure exists for a cleaved
PAI-1 mutant (Ala335Pro) complexed with the pentapeptide [249]. Figure-2.18 and 3.19
represent the relative positions of the residues that correspond to octapeptide and pentapeptide in
the inserted RCL of latent PAI-1, respectively. Each of these RCL peptide mimics was incubated with native PAI-1 (at ~ 330 fold higher molar concentration) for 1hr at 370C and then
mixed with an equimolar concentration of monomeric VN (6µM) to test for complex formation.
Figure-2.20 and Figure-2.21 show the results of sedimentation velocity experiments on
mixtures of VN and native PAI-1 in the presence of octapeptide and pentapeptide respectively.
With each of these peptides, only about 7% of the loading signal was present as higher order
complexes between the sedimentation coefficient values of 6S to 60S. The control experiment
performed in the absence of peptides showed that 65% of the loading signal is present as higher
order complexes within the same sedimentation coefficient range. Another striking observation
was that, with the presence of each peptide, the interaction between VN and PAI-1 was almost
completely inhibited. Almost no 1:1 complex between VN and PAI-1 was observed.
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Figure 2. 18: Relative orientation of the
pentapeptide sequence in latent PAI-1

Figure 2. 19: Relative orientation of the
octapeptide sequence in latent PAI-1

Figure-2.18 & 2.19: Crystal structure of latent-PAI-1 with RCL inserted as
4th strand of β-sheet-A [161]. Figure-2.18 shows relative positions of the
residues (in red) that correspond to the octapeptide. Figure-2.19 shows the
positions of the pentapeptide (in red). In both structures R346 (P1) is shown
in yellow and Q123 residue is shown in green.
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Figure 2. 20: Effect of the octapeptide on the interaction between VN and wtPAI-1: sedimentation velocity study
Figure-2.20: Analysis of the effect of the binary complex between wtPAI-1 (6µM) and octapeptide (2mM) on the oligomerization
by AUC. The mixture was incubated at 370C for 1hr. This was mixed with 6µM VN and incubated for 1hr at 370C prior to
loading the centrifuge cells. Absorbance data were collected at 50000rpm at 250C and fitted to a c(S) distribution model using
SEDFIT. The top-panel indicates the RI noise and TI noise subtracted data fitted to the c(S) distribution model. The numbers
indicate the fitted parameters referring to the model. The middle-panel indicates the residual of the fit. The bottom-panel is the
distribution plot of different sedimenting species (c(S) vs. S).Integration of the distribution between 6S and 44S indicates that
6.7% of the loading concentration was present as higher order complexes.
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Figure 2. 21: Effect of the pentapeptide on the interaction between VN and wtPAI-1: sedimentation velocity study
Figure-2.21: Analysis of the binary complex between wtPAI-1 (6µM) and octapeptide (2mM) on the oligomerization by AUC. The
mixture was incubated at 370C for 1hr. This was mixed with 6µM VN and incubated for 1hr at 370C prior to loading the
centrifuge cells. Absorbance data were collected at 50000rpm at 250C and fitted to a c(S) distribution model using SEDFIT. The
top-panel indicates the RI noise and TI noise subtracted data fitted to the c(S) distribution model. The numbers indicate the fitted
parameters referring to the model. The middle-panel indicates the residual of the fit. The bottom-panel is the distribution plot of
different sedimenting species (c(S) vs. S).Integration of the distribution between 6S and 44S indicates that 7.4% of the loading
concentration was present as higher order complexes.
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2.3. III. Characterizing the Binding between PAI-1 and Different Metals
There are multiple factors that influence the stability of PAI-1, including temperature,
buffer, salt, pH and different ligands. Recently our lab has found that metal ions are also
important regulators of PAI-1 function and stability. This work has been performed in
conjunction with Dr. Larry Thompson, a postdoctoral associate of our lab. It was observed that
Type-I (Mg+2, Ca+2) and Type-II (Ni+2, Cu+2) metal ions exhibit different effects on the stability
of PAI-1. While the effect of type-II metals was strongly destabilizing, type-I metals caused
slight stabilization of PAI-1. The effect of these metals was even more interesting in the presence
of VN. While the type-I metals did not show much difference in the absence or presence of VN,
type-II metals had completely opposite effects. In presence of VN, type-II metals dramatically
stabilized PAI-1. Figure-1.9 (chapter-1) shows the effect of different metals on the stability of
PAI-1 in the absence/presence of VN (Thompson et al., submitted). The physiological relevance
of this interaction between metals and PAI-1 will be largely dictated by the affinity of their
interaction. The goal for these experiments was to establish a reproducible method for
characterizing the binding affinity between PAI-1 and different metals.
2.3. III.a. Comparing Ni Binding with wtPAI-1 and PAI-1 Variants Using SPR.
The availability of a NTA (nitrilotriacetic acid)-chip from Biacore offered a way to make use of
surface plasmon resonance for this study. NTA is a reagent that is commonly used for
immobilized metal affinity chromatography (IMAC). In this chip, NTA is covalently linked with
a carboxy-methyl chain and is available for metal binding. Since IMAC was used for purifying
recombinant PAI-1, the same principle was utilized here to characterize the metal binding
affinity. An assay was standardized as described in the method section. Briefly, metal was loaded
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on to the test flow cell, and PAI-1 passed through both test and reference flow cells in order to
establish specific metal binding in contrast to background (nonspecific) binding. This assay was
then utilized to obtain information on the affinity of the interaction between PAI-1 and Ni.
Figure-2.22 shows the representative sensograms obtained from the injections of varying
concentrations of active PAI-1 on immobilized Ni on the NTA chip. Each of these response
curves indicates that binding has reached steady state. Figure-2.23 shows the binding isotherm
of active PAI-1 binding to Ni using the steady-state binding response versus PAI-1
concentration. This isotherm was fitted to Langmuir‟s 1:1 binding equation. The affinity
obtained for PAI-1 binding to Ni from these experiments is 6.22

0.05 µM.

Since type-II metal severely destabilized active PAI-1, it was important for us to
determine the affinity of latent-PAI-1 for type-II metals. A titration experiment was carried out
for checking latent-PAI-1 binding to Ni. Figure-2.24 shows the binding isotherm of latent-PAI-1
binding to Ni. The affinity of latent-PAI-1 was found to be 21.8

3.5 µM. Thus, the latent-PAI-

1 has at least three times weaker affinity for Ni binding compared to active-PAI-1. This indicates
that the destabilization of active PAI-1 by Ni is not a direct consequence of preferable binding of
Ni to the latent form. Binding of Ni most likely causes a conformational change in active PAI-1
that favors the conversion to latent form.
The effect of type-I and type-II metals on PAI-1 stability was essentially the opposite. A
plausible explanation of this finding is the presence of different binding sites for type-I and typeII metals. In order to check the presence of multiple binding sites, a competition experiment was
designed. Varying concentrations of MgCl2 (type-I metal) was mixed with a fixed concentration
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Figure 2. 22: Representative sensogram of titration experiment of
PAI-1 binding to Ni-NTA

Figure 2. 23: Binding isotherm of wtPAI-1 binding to Ni

Figure-2.22: This figure shows representative sensograms of varying
concentrations (serial dilution from1600nM to 100nM) of PAI-1 injected on a
Ni-NTA chip (1.5min association and 5min dissociation). Figure-2.23: binding
isotherm of wtPAI-1 binding to Ni-NTA. Equilibrium binding responses were
plotted against PAI-1 concentration. Data were fitted to Langmuir 1:1binding
equation.
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Figure 2. 24: Binding isotherm of latent-PAI-1 binding to Ni: SPR study

Figure-2.24: Varying concentrations of PAI-1 (serial dilution from 56µM to 0.875µM)
were run on a Ni-loaded NTA chip. Equilibrium binding responses were plotted against
PAI-1 concentrations. Data were fitted to Langmuir 1:1binding equation.

82

(2µM) of active-PAI-1, and the mixtures were allowed to flow over Ni immobilized on the NTA
chip. Figure-2.25 shows the representative sensograms of PAI-1 binding to Ni in the presence of
different concentrations of MgCl2. At high concentrations (millimolar), binding of PAI-1 to Ni
(type-II) could be partially blocked by Mg (type-I). This indicates that type-I metal can bind to
the type-II metal site, but with much lower affinity.
14-1-B, the constitutively active form of PAI-1, exhibits a half-life of about 145 hrs
[164]. Because of this marked stability, this mutant PAI-1 has been used in different studies as an
alternative to wild type active PAI-1. Blouse et al. reported that the mutation of the conserved
Tryptophan residue (Trp175) by Phenylalanine increased the inherent stability of the structure
from a half-life of about 2 hrs to 22 hrs [135]. We aimed to compare the metal binding of these
two stable mutants with that of wild type active PAI-1. Figure-2.26 and 2.27 show the binding
isotherm of W175F and 14-1-B binding to Ni, respectively. The affinity of these two mutants for
Ni binding were 33.6

2.7 µM and 38.44

3.2 µM respectively. This study indicates that wt-

PAI-1 possesses an optimal conformation for type-II metal binding.
2.3. III.b. The SPR Based Assay was not Suitable for Measurements with Other Type-II
Metals.
We hoped to extend the application of this SPR method for studying other type-II metal
binding to PAI-1. Unfortunately, this method could not be applied to other type-II metals like
Cu, Co, or Zn. When Cu was used for immobilization, the initial binding to the chip was found to
occur normally, but with time it showed gradual leaching off the chip. Cu bound to NTA could
not even withstand the mild EDTA wash that was part of the original Ni-binding assay. Omitting
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Figure 2. 25: Competition experiment of Mg binding with Ni: SPR study

Figure-2.25: Sensograms showing a competition experiment of Mg binding to PAI-1
with Ni. PAI-1 was mixed with varying concentrations of MgCl2, and the mixtures
were run on a Ni-loaded NTA chip. The free concentration of MgCl2, after binding to
Tris buffer, is calculated and included in the graph.
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Figure 2. 26: Binding isotherm of W175F-PAI-1 binding to
Ni: SPR study

Figure 2. 27: Binding isotherm of 14-1-B binding to Ni: SPR
study
Figure-2.26 & 2.27: Binding isotherms of W175F-PAI-1 (Figure-2.26) and 14-1-B
(Figure-2.27) binding to Ni-NTA respectively. Varying concentrations of PAI-1 (serial
dilution from 128µM to 0.5µM) were run on a Ni-loaded NTA chip. Equilibrium
binding responses were plotted against PAI-1 concentrations. Data were fitted to
Langmuir 1:1 binding equation.
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the EDTA wash stabilized better Cu binding to the chip. However, when PAI-1 was loaded on to
the Cu-NTA surface, the initial protein binding followed normal association behavior but it
never reached steady state, as shown in Figure-2.28. It can be observed that when the PAI-1
injection was made, another interaction phase occurred in parallel that reduced the overall Cu
binding. Co and Zn could not be immobilized on the chip even when used at 2mM concentration.
On the other hand, when these two metals were separately premixed with PAI-1 and the mixture
was loaded directly on to NTA chip, binding could be observed. Figure-2.29 shows the loading
of a mixture of 1µM PAI-1 and 1mM CoCl2 on to NTA chip. It can be observed that binding
followed a single phase association pattern and reached steady state. A titration experiment was
conducted where different concentrations of CoCl2 were mixed with fixed concentration of PAI1 and the mixtures were allowed to flow over NTA chip one at a time. Steady state response
units were measured and plotted against free Co concentration (Figure-2.30). The binding
isotherm was fit to a Langmuir‟s 1:1 binding equation. The dissociation constant obtained from
this fitting was 170µM. However, the specificity of the interaction (PAI-1 binding to Co or PAI1/Co complex binding to NTA) was not clear from this experiment. When the mixture of PAI-1
and Zn was loaded on to NTA chip, the binding interaction was found to exhibit more than one
phase of interaction (Figure-2.31). It seems that the specific coordination geometry provided by
nitrilotriacetic acid is most suitable for studying Ni binding, but less appropriate for the other
metals in this situation.
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Figure 2. 28: SPR study on wtPAI-1 binding to Cu-NTA

Figure-2.28: 1mM CuCl2 was loaded on to flow cell-4 (test cell) of the
NTA chip. No EDTA wash was performed. 1µM PAI-1 was run on
both flow cell-3 (reference, shown in red) & flow cell-4 (test, shown in
blue). Injection was carried out for 1min, at a 20µl/min flow rate,
followed by a dissociation phase. Though PAI-1 binding to flow cell-4
showed rapid association, it never reached steady state.
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Figure 2. 29: Representative sensogram for Mixture of PAI-1 & CoCl2 to NTA

Figure 2. 30: Binding isotherm of mixture of CoCl2 & PAI-1 to NTA
Figure-2.29 & 2.30: 1mM of CoCl2 was mixed with 2µM PAI-1 and the mixture
was run on flow cell-2 (test) for 2min at 20µl/min flow rate (Figure-2.29). Binding
reached steady state. The bottom panel (Figure-2.30) indicates the result from a
titration study where 2µM PAI-1 was mixed with increasing concentrations of
CoCl2. The mixtures were run on a NTA chip (test flow cell only) and allowed to
reach steady state. Free Co concentration was calculated and used for plotting the
binding isotherm.
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Figure 2. 31: Representative sensogram of mixture of wtPAI-1 & ZnCl2 binding to
NTA

Figure-2.31: 1mM ZnCl2 was mixed with 2µM PAI-1 and the mixture
was run on both flow cells (FC1- red, FC2- blue) for about 2min at
20µl/min flow rate. Binding to flow cell-1 and flow cell-2 are shown in
red and purple, respectively. Binding was found to follow more than
one phase of interaction.

89

2.4. Discussion
2.4. a. Interaction Between VN and PAI-1, Binding Interface and
Stoichiometry
Understanding the interaction between VN & PAI-1 has been one of the main objectives
of this work. In fact, it has remained as one of the major research areas for our lab for the last
few years. We have always recognized the relevance of this interaction based on the vast
information in the literature that supports its physiological significance. Thus, we have carefully
addressed a number of issues regarding the interaction between these two proteins that have
remained controversial. PAI-1 binding to VN has typically been considered to be mediated by
the SMB domain of VN. Though there are other groups that suggested the presence of another
PAI-1 binding site outside SMB domain [200-202], no confirmatory evidence has been pursued
prior to our recent work [204]. The issue of one versus. two binding sites on VN appears of great
importance, as the simple 1:1 binding between VN and PAI-1 is not enough to explain the
reaction mechanism by which these two proteins form higher-order multimers. Our lab has
recently provided the most direct evidence in support of the presence of another PAI-1-binding
site outside the SMB domain [204]. A deletion mutant of VN lacking the N-terminal SMB
domain was found to retain PAI-1 binding activity with a relatively lower affinity (Kd~100nM)
than that of with SMB domain (Kd~1nM) of VN [204]. Furthermore, using stopped-flow
analysis our lab has provided evidence that indicates that the binding interaction between PAI-1
and full length VN involves residues that exist beyond the SMB domain [168]. These studies
suggested that the interaction between full length VN and PAI-1 is more complex and involves
an extended binding interface.
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This stopped-flow analyses in the published work [168] utilized fluorescently labeled
PAI-1 in order to probe the structural changes resulting from binding. In this present study we
have standardized a method that will allow us to perform strategic incorporation of a nitroxide
spin label in the PAI-1 structure. Nitroxide spin labels used in electron paramagnetic resonance
(EPR) study are extremely sensitive towards the change in local environment and no other group
before us has reported the use of a spin label on PAI-1. We have successfully incorporated the
MTSL spin label at the P9 residue of the RCL of PAI-1. Labeling of the P9 residue with the
environmentally sensitive fluorescent probe has been utilized before to probe the structural
change during latency transition. We have used our MTSL labeled PAI-1 for probing the RCL
insertion that happens during the latency transition. The half-life obtained from this study
allowed us to validate the idea of probing structural changes of PAI-1 with EPR. We have further
utilized the spin-labeled PAI-1 to probe the binding interaction with the isolated SMB domain
and full-length VN. We have found that, while the signal of labeled PAI-1 did not change with
increasing concentration of the SMB domain, there is a decrease in EPR signal upon the addition
of the full-length vitronectin. This preliminary EPR study with SMB and VN falls in line with
stopped-flow analyses and suggests once again that the binding interactions that involve these
two partners are different from each other. This EPR based method will also allow us to probe
the structural change that occurs in PAI-1 with response to metal binding.
In the last few years our lab has also made significant progress in the understanding of
the formation of the higher-order PAI-1/vitronectin complexes. By using a variety of techniques
(size exclusion chromatography, sedimentation velocity, FRET) we have obtained evidence that
leads us to the following conclusions: 1. PAI-1 can induce the multimerization process in dose
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dependent fashion. 2. Initiation of the multimeric complexes begins with the formation of a
heterotrimer containing two molecules of PAI-1 and one molecule of VN. 3. PAI-1 remains
associated with these multimeric complexes for several hours [203-204, 209-211]. Although
significant advances have been made, we are keen to know more about the mechanism by which
the multimerization occurs. There are many questions that are still in need of answers. What is
the relative contribution of the partner proteins (VN and PAI-1) in initiating the complex
formation? Are the two PAI-1 molecules in the heterotrimer directly connected to VN? How
does the heterotrimer further associate to form even larger multimeric complexes? Our initial
thought was that the heterotrimer formed between VN and PAI-1 (1:2 stoichiometry) contains
two PAI-1 directly occupying two different binding sites on VN. Though the model generated
from the SANS study (Figure-2.14) confirms the formation of a heterotrimer between two PAI-1
molecules and one VN molecule, the heterotrimer appears to involve only a single interaction
between VN and PAI-1. The second PAI-1 molecule, on the other hand connects to the first PAI1 that is in direct contact with VN. We must be cautious since this SANS study was done with
the W175F-PAI-1 mutant, which is a stable variant of wt-PAI-1[135]. Though sedimentation
velocity studies performed with this mutant and VN in PBS buffer showed a similar pattern of
multimerization as with wtPAI-1 (Figure-2.13), for the buffer conditions in which the SANS
experiment (50mM sodium-phosphate, 300mM NaCl, pH-7.4) was done, this mutant was found
to form less amount of multimeric complexes compared to wtPAI-1 (data not shown). Since the
SANS study is highly sensitive to the presence of high molecular weight species and our goal
was to capture the initial part of the multimerization reaction (1:2 and 2:4 complex), formation of
fewer multimeric complexes with W175F-PAI-1 was chosen as a favorable condition for the
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SANS experiment. Although our assumption was that the wtPAI-1 and the mutant W175F form
higher-order complexes with VN in similar fashion, we need to be careful about the fact that
some distinct structural differences exist between these two proteins.
We have addressed the importance of the initial VN/PAI-1 contact for the
multimerization reaction (as indicated by the model) by performing sedimentation velocity
analysis with the Q123K mutant of PAI-1. Q123K-PAI-1 exhibits low affinity for VN binding
and showed a dramatic decrease in the formation of multimeric complexes by comparison with
wtPAI-1. We have also devoted significant effort to address the PAI-1/PAI-1 interaction that
may occur within the heterotrimer. Serpin-serpin interaction is not uncommon and has been
found to happen with serpins like α1-antitrypsin, antithrombin etc [243-245]. Most of these
interactions have been found to be mediated by the insertion of RCL of one serpin molecule to
the β-sheet region of the other serpin molecule. Examples of loop-sheet interaction have been
included in Figure-2.15 [246]. Under normal condition PAI-1 does not form polymers by loopsheet interaction like other serpins, but Zhou et al. showed that at low pH both native and latent
PAI-1formed dimer via loop-sheet insertion mechanism [246]. Polymerization in native PAI-1
occurs by the insertion of the loop as the 4th β-strand A of the other molecule, whereas for latent
PAI-1 the insertion happens to form β-stand1C [246]. It is possible that the binding to VN
promotes conformational changes within PAI-1 that are conducive to PAI-1/PAI-1 interaction.
Important questions are yet to be answered. Is this interaction at all loop-sheet insertion
mediated? Are there other processes involved or it is the combination of more than one process?
If the interaction is loop-sheet insertion mediated, is there more than one possible way by which
loop-sheet insertion occurs within the higher-order complex of VN and PAI-1 (as indicated in
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Figure-2.15)? In order to check if the PAI-1/PAI-1 interaction within the heterotrimer is
exclusively mediated by the loop-sheet4A linkage, sedimentation velocity experiment was
performed with VN and latent-PAI-1. Latent-PAI-1 does not have an exposed RCL, as it is
involved in the formation of 4th β-strand of the central β-sheetA. The sedimentation velocity
experiment showed formation of a significant amount of multimeric complexes (Figure-2.17)
with latent-PAI-1. Zhou et al. proposed that dimerization of latent PAI-1 at low pH happened
through the loop-sheet insertion mechanism. They also proposed that the inserted RCL of one
latent PAI-1 molecule formed strand-1C of the other latent-PAI-1 molecule [246]. If this is true,
then it seems that there is more than one way in which loop-sheet insertion occurs within
multimeric complexes of VN and PAI-1. The presence of the inserted RCL in latent-PAI-1
disrupts loop-sheet4A linkage that may normally happen with active PAI-1. However, the loopsheet1C linkage remains unaffected, although the RCL is fully inserted. It is also possible that
latent-PAI-1 forms multimeric complexes through a mechanism totally independent of loopsheet insertion. In this case the decrease in the amount of multimeric complexes that we observe
with latent-PAI-1 compared to active PAI-1 could be due to its relatively lower affinity for VN.
The experiment with latent-PAI-1 indicated that the PAI-1/PAI-1 interaction within the
multimeric complexes was not exclusively loop-sheet4A mediated, but the experiments with the
RCL peptide mimics virtually completely disrupted the formation of the multimeric complexes
between VN and PAI-1. These results can be explained relatively simply. Since the RCL is
known to take part in loop-sheet insertion through more than one possible mechanism, these
RCL mimicking peptides may be binding to all the possible locations where insertion may
happen. As a result, no PAI-1/PAI-1 interaction is possible. Also interesting is the observation
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that the interaction between VN and PAI-1 was almost completely disrupted in the presence of
the peptides. Almost no 1:1 complex was found when VN and wtPAI-1 were mixed at equimolar
concentrations (6µM) in the presence of 2mM peptide. A simple binding of the peptides within
the groove between strand-3A and 5A may not be enough to explain this finding. While the exact
mechanism by which these peptides disrupt the VN/PAI-1 interaction requires further attention,
the finding itself has promise. Considering how important the interaction between VN and PAI-1
is and how many different pathophysiological conditions for which this interaction is involved,
use of these peptides may represent a new therapeutic prospect.

2.4. b. Immobilization of Metal and Coordination Chemistry
The function of a protein can be regulated in many ways, including post-translational
modification, the action of an activator or inhibitor etc. For PAI-1, functional regulation has
attained an extra level of sophistication due to its inherently low half-life (1-2hrs at 370C) [158159]. Such a low half-life of PAI-1 activity results because PAI-1 naturally favors the latent
conformation [133, 164]. This also provides a means for this delicate balance to be harnessed as
a means for regulating the functional activity of PAI-1.
Ligand binding to PAI-1 and the subsequent effect on the conformational flexibility is a
subject of keen interest among the serpin biologists. The stabilization of the half-life of PAI-1,
although modest under most conditions, has been considered as the major role for its interaction
with VN [82, 158, 250]. Though PAI-1 was known to bind to metals, as immobilized metal ion
chromatography (IMAC) was used for the purification of recombinant PAI-1 [251], no one has
investigated the implications of metal binding on regulating conformational flexibility of PAI-1.
Our group now has shown that metals may significantly impact this structural stability of PAI-1
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(Thompson et al., submitted). We have investigated the effects of different metals (both type-I
and type-II) and found that, while type-I metals (Ca, Mg) do not have much impact on the
stability of PAI-1, type-II metals (Ni, Cu, Co) cause substantial reduction in its half-life. In the
presence of VN, the effect of type-II metals is the exact opposite (a significant increase in halflife). Thus, metals appear to have a significant impact on the regulation of PAI-1 activity in our
body, as transition metals like Cu are naturally present in different tissues, like blood, liver, brain
etc [252-255].
The physiological relevance of this metal effect will be dictated by the affinity of such
interaction. In this present study, a surface plasmon resonance based assay has been developed
for the determination of the affinity of the interaction between PAI-1 and metals. We have
utilized an NTA (nitrilotriacetic acid) chip for the immobilization of Ni and successfully
obtained affinity information for the binding of wtPAI-1 and its variants with Ni. Currently we
are trying to locate the metal binding site on PAI-1 using multiple mutants of PAI-1. This SPR
based method will help us to perform rapid screening of PAI-1 mutants for metal binding.
We also hoped to extend this Ni binding study to other type-II metals such as, Cu, Co,
Zn. Unfortunately none of these metals could be successfully immobilized on the NTA chip. For
example, the initial loading of Cu to the NTA chip could be carried out nicely but the binding
was not as stable as for Ni. Running of Tris buffer through immobilized Cu caused slow but
continuous leaching of Cu from the chip. During the assay of PAI-1 binding to Ni-NTA, a short
pulse of low concentration of EDTA was used following metal immobilization in order to
remove unbound/loosely bound Ni in the microfluidic channel. Use of this low concentration of
EDTA during the assay with Cu caused even stronger leaching of the metal. When PAI-1 was
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run on to Cu loaded chip, the initial phase of that binding showed clear association event that
reached a maxima but a steady state was never established, as the protein showed continuous
release from the chip surface (as shown in Figure-2.28). With Co and Zn successful
immobilization could not be achieved even at higher metal concentration (about 2mM). On the
other hand, when Co or Zn was premixed with PAI-1 and ran on NTA chip binding of protein
could be observed. For Co, binding showed a clear association phase that reached steady state
(Figure-2.29). We attempted to plot the steady state binding response from Co/PAI-1 mixture
binding to NTA with a series of free Co concentration (Figure-2.30). This resulted in a saturable
binding isotherm that could be fit reasonably well to single-site specific binding equation. We
could not draw any conclusion on the affinity information of Co binding to PAI-1 because it was
not clear whether the calculated Kd was reporting the binding of Co to PAI-1 or the binding of
PAI/Co mixture to NTA. Moreover the goodness of the fit was only moderate. When Zn was
mixed with PAI-1 and ran on to NTA chip, protein binding could be observed but the binding
was even more complicated to explain as it was not found to follow a single phase interaction
(Figure-2.31).
Investigating these anomalies with metals in the SPR method was beyond the scope of
current study. It is clear that the coordination chemistry involved with each of these metals for
binding to NTA and specific amino acid residues that coordinate the metals in PAI-1 had a
significant role to play. NTA is commonly used in Ni-based IMAC for the purification of Histagged proteins. NTA can maintain a strong and stable binding with Ni. NTA is tetradentate and
provides four coordination sites for Ni binding. Thus, Ni bound to NTA can coordinate with two
additional His molecules of a His-tagged protein (see Figure-2.32) [256] to fulfill its six
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coordination sites. Co also has six coordination sites, but the stability constant for the binding of
Co to NTA has been found be much lower [257]. For Co-based IMAC, the TALON resin (from
BD biosciences) has been found to be more suitable. The TALON resin provides an optimal
geometry that allows for four coordination sites with Co and that result in much tighter binding
and much less leaching of the metal. This explains in part why Co immobilization was not
successful on the NTA chip. A similar explanation is reasonable for Zn immobilization on NTA
as well, but how the metal bound to PAI-1 complements the coordination with NTA chip is
unknown. It is possible that the local geometry within PAI-1 favors formation of four coordinate
bonds with Co or Zn. Once this stable coordinating conformation was achieved, the bound metal
could then bind to two carboxylate groups of NTA. Though the use of Cu in IMAC is not
common, there are examples where people used a Cu(II)-IMAC-based ZipTip for the extraction
of phosphorylated peptides [258]. However, in this IMAC, instead of NTA, IDA (iminodiacetic
acid) was used as the chelating agent, which provides three coordination sites. Burns et al.
reported a crystal structure of the ternary complex between Cu+2, NTA and Bisimmidazole
ketone (a poly-His analog) [256]. Thus, there are examples of coordination complexes formed
between Cu and NTA, but no example is known in which Cu has been used for immobilization
on an NTA chip. Understanding the exact chemistry for Cu interaction with the NTA surface that
leads to an unstable surface with significant leaching requires further study. It is clear that the
SPR method developed will be limited to nickel binding and can be used as a preliminary screen
for metal binding to guide further studies on specific stability effects on PAI-1 with other metals.
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Figure 2. 32: Hexa-coordination geometry of Ni binding NTA and
Histidine

Figure-2.32: Coordination of Ni with NTA and two His molecules. NTA
being tetradentate provides four coordination sites
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CHAPTER-3
How does the interaction between Vitronectin and Plasminogen
Activator Inibitor-1 modulate their matrix associated functions?

3. 1. Introduction
Vitronectin is a glycoprotein (459 aa) found in both the circulation and the extracellular matrix
(ECM). In blood it circulates mainly as a monomer (0.2-0.4mg/ml, ~0.3-0.6uM), but in the
extracellular matrix it exists as a multimer [13-14, 259]. While the exact mechanism for its
conformational alteration and compartmentalization is unknown, it is well known that vitronectin
has specific and distinct functions in blood and extracellular matrix. The multifunctional nature
of this protein results from its ability to recognize various ligands including the thrombinantithrombin complex (T-AT) [44-45], heparin [46-48], PAI-1 [49-51], complement proteins
[52] as well as several cell surface receptors, including integrins and the urokinase plasminogen
activator receptor (uPAR) [53-59]. Vitronectin plays important regulatory roles in several
different physiological and pathological processes, e.g. - fibrinolysis, thrombosis, coagulation,
wound healing, cellular adhesion/migration [61-62, 66]. Regulation of cellular
adhesion/migration comes from its ability to act as a matrix protein that can bind to different cell
surface receptors like uPAR and certain subclasses of integrins (αvβ3 and αvβ5) [92].
PAI-1 is a member of the serpin (Serine protease inhibitor) family of proteins. Like VN,
PAI-1 is also found in both circulation and the extracellular matrix. The two main target serine
proteases that are inactivated by PAI-1 are urokinase plasminogen activator (uPA) and tissue
plasminogen activator (tPA) [80]. PAI-1 regulates the formation of plasmin and thus plays
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animportant role in the control of coagulation, fibrinolysis and thrombolysis [180, 260]. Such
protease-dependent effects of PAI-1 have remained in the limelight for a long time. Currently a
significant emphasis is also being given to its protease-independent effects. One of the
important protease-independent functions of PAI-1 is the regulation of cell surface receptor
interaction with ECM-associated VN. PAI-I is known to physically interfere with the interaction
of uPAR and integrin receptors with VN. It has been found that exogenously added PAI-1
blocked uPAR mediated binding of U937, endothelial and uPAR-transfected 293 cells to
multimeric „denatured‟ VN [53, 226]. On the other hand uPAR-mediated migration of U937 and
melanoma cells through multimeric „denatured‟ VN was blocked by PAI-1 [226, 228]. PAI-1 has
been also found to cause blocking of binding and migration of smooth muscle cells (SMC)
through multimeric „denatured‟ VN in a αvβ3 dependent manner [229]. There is evidence in
favor of PAI-1 being pro-angiogenic and pro-tumorigenic [191, 231]. On the other hand there is
also some evidence that indicates that PAI-1 may inhibit angiogenesis [232] and such inhibition
was found to be dependent on its ability to interact with VN. McMahon et al. reported a study
where they showed that PAI-1-mediated effect on tumor formation and angiogenesis is dosedependent [233]. While at low concentrations PAI-1 acted as pro-angiogenic, at high
concentrations it was anti-angiogenic [233]. A similar dose-dependent effect of PAI-1 on
angiogenesis was also observed in a study by Devy et al [261]. In this study they showed that the
increase in angiogenesis observed at physiological concentrations of PAI-1 was not dependent on
its ability to interact with VN [261]. Therefore a significant amount of controversy exists about
how PAI-1 regulates VN-mediated cell-matrix interactions.
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Though it appears that multimerization of VN happens in a biological setting, most of the
in vitro studies have been performed with „denatured‟ VN (formed by heat or chaotropic agents)
as an alternative to the matrix-associated multimeric form of vitronectin. „Denatured‟ multimeric
VN was found to possess the conformational sensitivity usually observed with matrix-associated,
multimeric VN [44, 77]. However, multimeric VN formed in a biologically relevant process may
have significant structural/functional differences compared to „denatured‟ VN. There are a
number of biomolecules that may initiate the process of transition to the multimeric
conformation of VN, e.g. – the thrombin-antithrombin-III (TAT) complex, the terminal
complement complex (C5b-C7) and PAI-1 [44, 205-206]. In our study we have relied on
purifying monomeric VN from blood and then investigating its conversion to a matrix-associated
form in the presence of PAI-1 as a co-factor. We have confirmed that PAI-1 induces
multimerization of VN in a concentration-dependent fashion, and we are also confident that PAI1 remains associated with this multimeric complex for several hours [203, 209-211]. With these
findings as a basis, we hypothesize: 1. that PAI-1 acts a biological partner for the transformation
of VN into the matrix-associated form, and 2. the multimeric complexes formed by the
interaction between these two proteins significantly influence their matrix associated functions.
Furthermore, we hypothesize that: 3. the multimeric complexes formed by this more biologically
feasible process modulate cellular binding/migration, and 4. such modulation is sensitive to the
pericellular microenviroment constituted of other matrix components, cell types and the set of
receptors expressed on the cell surface.

102

3. 2. Materials and methods
3.2. a. Proteins and antibodies
Recombinant wtPAI-1 and its mutant Q123K were expressed in the E. coli Rosetta2(DE3
media)pLysS strain, grown in TB and induced at 150C. Purification was carried out through a
three-step column chromatography that included cation-exchange (SP-Sepharose column),
immobilized metal ion affinity (Ni-IDA) and size-exclusion chromatography (Sephacryl S-100)
(Thompson et al., unpublished). The entire purification was carried out at 40C. Correctly folded
recombinant somatomedin-B (SMB) domain was expressed and purified as described in the work
by Thompson et al. (unpublished). Heparan sulfate proteoglycan (HSPG) was purchased from
SIGMA. Collagen-I & IV were purchased from BD Biosciences. Purified recombinant integrins
were purchased from Millipore Corp. Purified recombinant urokinase-plasminogen activator
inhibitor (uPAR) was purchased from R & D systems. Monoclonal antibodies against VN (1E9,
made in mouse) were obtained from Molecular Innovation. All the antibodies (monoclonal and
polyclonal) against integrins were purchased from Millipore corp. Monoclonal antibodies against
uPAR were purchased from R & D systems. Peroxidase conjugated anti mouse/rabbit IgG was
purchased from Vector Labs and Alexa-488 conjugated goat anti-mouse IgG was purchased from
Invitrogen.

3.2. b. Purification of monomeric vitronectin
Monomeric vitronectin was purified from human plasma using a procedure that is a
modified version of the protocol designed by Dahlback & Podack [32]. This method was
standardized in collaboration with Dr. Lawrence Thompson, a former postdoctoral associate of
our lab. 3litre plasma was subject to BaCl2 precipitation step and then (NH4)2SO4 was added to
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plasma at 50% saturation. After an overnight incubation, the precipitate was harvested by
centrifugation, resuspended in 1L of phosphate buffer containing DTNB (20 mM NaH2PO4, 0.1
mM EDTA, and 1 mM dinitrothiobenzoate (DTNB) pH 7.0) and centrifuged again.

The

supernatant was dialyzed twice against 22 L of the same buffer without DTNB at 40C. Protein
was then loaded onto a DEAE Sephacel column (5 x 21.5 cm), washed with the same phosphate
buffer, and the eluted with a linear 0-0.5M NaCl gradient with a total volume of 4.4 L.
Throughout the protein purification procedure, fractions to be pooled that contained vitronectin
were determined using a quantitative immunoaffinity column coupled with the 1E934
monoclonal antibody (see below). In two batches, pooled fractions from the DEAE column were
chromatographed on a blue Sepharose column (5 x 17.5 cm) using a linear 0.15-3.0 M NaCl
gradient with a total volume of 4.4 L. Fractions containing vitronectin from each blue-Sepharose
step were pooled separately and dialyzed against Tris buffer (20 mM Tris, pH 7.4, containing 20
mM NaCl and 0.1 mM EDTA) for chromatography on heparin-Sepharose. Dialyzed protein from
each batch of blue-Sepharose chromatography was loaded on to heparin-Sepharose column (2.5
x 15 cm). After loading, protein was eluted from the heparin-Sepharose column using a linear
gradient from 0.02 to 1.0 M NaCl with a total volume of 0.8 L. The protein pool from the
heparin column was concentrated by ultrafiltration to 8 mL, and then chromatographed in two
aliquots on a high-resolution Sephacryl S-200 gel filtration column (2.5 x 115 cm) equilibrated
in PBS, pH 7.4. 3ml fraction was collected from the Sephacryl S-200 gel filtration column at
flow rate of 0.5ml/min. Vitronectin containing fractions were pooled and stored at 4 0C under
saturating concentrations of (NH4)2SO4 (70%) prior to use.
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Vitronectin concentration was

determined at 280 nm using

280

= 1.0 mL mg-1 cm-1 [262] and a molecular weight = 62,000




g/mol [27].
In order to optimize the yield of vitronectin and to follow the purification steps using a
quantitative method, the total amount of protein recovered in each step was monitored using the
BCA assay, while the total amount of vitronectin was determined by immunoaffinity
chromatography using a mouse antihuman vitronectin monoclonal antibody (1E934) column.
Briefly, 2 mg of antibody 1E934 was covalently linked to 1 mL of NHS-activated Sepharose
following the standard protocol and used in HPLC.

Several standard amounts of purified

monomeric human vitronectin were loaded onto the column, washed for 5 min with PBS pH 7.4,
and then eluted with 100 mM NaH2PO4 pH 3.0. Elution of vitronectin was monitored at 220 nm.
A standard curve was generated by injecting known amount of vitronectin to the antibody
column. Area of the eluted peak was utilized for plotting the standard curve. This method gave a
linear range from 0 to 19 g of vitronectin. Quantification using the 1E934 antibody indicated
that 3 L of human plasma typically contained 0.2-0.3 mg/mL vitronectin, which was in good
agreement with previous measurements [3, 6, 31]. A typical final yield of vitronectin from 3 L
of human plasma using this modified purification method was ~9%-10% (approximately 60-70
mg).

3.2. c. Cell culture
The human fibrosarcoma cell line (HT1080) was purchased from American Tissue
Culture Collection (ATCC) and maintained in Eagle‟s Minimum Essential Medium (EMEM)
(purchased from ATCC) supplemented with 10% Fetal bovine serum (FBS, purchased from
ATCC) and 1% penicillin-streptomycin solution (ATCC). The EA.hy 926 cell line was a kind
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gift from Dr. John Biggerstaff‟s lab at University of Tennessee, Knoxville. This is an
immortalized hybridoma cell line created by the fusion between A459 cell (human lung
carcinoma) and human umbilical vascular endothelial cell (HUVEC) [263]. This cell line was
found to express factor-VIII related antigen (VIII-R:Ag), which is considered to be one of the
highly differentiated properties of the vascular endothelium. The fibrinolytic properties of this
cell line have also been found to be comparable with HUVE cell [264]. This cell line has been
successfully used in a number of studies as an effective alternative to HUVE cell [265-266].
Thus this cell line was used as an endothelial cell for this study. The EA.hy926 cell line was
maintained in Dulbecco‟s Modified Eagle Medium (DMEM) containing high amount of Dglucose (4500mg/L), 25mM HEPES, L-glutamine and no sodium-pyruvate (purchased from
GIBCO). This media was supplemented with 10% FBS (heat inactivated) (Atlanta Biologicals)
and 1% penicillin-streptomycin solution (ATCC). Heat inactivation of the FBS was carried out
by heating the thawed serum at 560C water-bath for 30 min. Both of these cell lines were
maintained at 370C in the cell-culture incubator containing 5% CO2.

3.2. d. In vitro matrix binding assay
All the in vitro protein binding assays were carried out in high-binding, half area, flat
bottom, transparent, 96-well plates from Costar. For studying the binding of monomeric VN and
its complex with PAI-1 to matrix components, plates were initially coated with either HSPG or
Col-IV. For HSPG coating, the matrix was dissolved in a binding buffer containing 50mM Tris,
100mM NaCl, 1mM CaCl2 and 1mM MgCl2 (pH- 7.4) at 5µg/ml concentration. Dissolved
matrix was allowed to coat the surface of the 96-well plate for 1.5hr at 370C. For collagen-IV,
the matrix was dissolved in 10mM acetic acid at 3.6 µg/ml concentration and allowed to coat the
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surface of the plate at room temperature for 1hr. Following coating, unbound matrix was washed
by the binding buffer at least three times. Coating with GAG molecules was carried out at 40C
overnight. Coating concentration was 25µg/ml for each GAG molecule, made in 1X PBS.
Blocking of matrix or GAG-coated plate was carried out by 0.2% gelatin solution (made in
binding buffer) for 1hr at 370C. Monomeric VN (or SMB domain) was mixed with wtPAI-1 and
its variants at indicated concentrations in binding buffer containing 0.1% Tween-20 and the
mixture was incubated at 370C for 1hr to allow complex formation. A preformed mixture of
these proteins was allowed to bind to the matrix coated (blocked) plate for 1hr at 370C. Unbound
protein was removed by washing (3X) with 0.1% Tween-20 containing buffer. Probing of VN or
SMB binding to the matrix-coated plate was carried out immunochemically. For all the steps that
involved antibody binding, 1X PBS containing 0.3%BSA was used as buffer. For probing VN,
either Bunny-11 (a polyclonal antibody, used at 1:5000 dilution) or 1E9 (a monoclonal antibody,
used at 1:2000) was used as primary antibody. For SMB, 1E9 (1:1000 dilution) was used.
Primary antibody was allowed to incubate for 1hr at 370C followed by 3X washing with antibody
binding buffer. Peroxidase conjugated anti-mouse/anti-rabbit IgG was used as secondary
antibody. Secondary antibody (1:2000 dilution) was added to plate and incubated for 1hr at 370C
followed by 3X washing with antibody binding buffer. Color was developed by adding 100µl of
50mM sodium-citrate (pH-5.5) solution containing 0.6mg/ml ABTS (SIGMA) and 1:1000
dilution of 30% H2O2 (Fisher) to each well of the plate and the absorbance data from each well
was collected in Synergy Labtek plate reader at 405nm wavelength. Figure-3.1 includes a
schematic presentation of all the basic steps of this matrix binding assay.
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Figure 3. 1: Basic scheme for matrix binding assay

Figure-3.1: This figure includes the schematic presentation of
the important steps for the matrix binding assay. When collagen
was included in the assay, it replaced proteoglycan for coating
the plate.
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3.2. e. In vitro receptor binding assay
For characterizing the binding of the VN/PAI-1 complex with cell surface receptors, two
different approaches were taken. In one approach, the receptor was directly coated on to the 96well plate, and in the second approach the receptor was maintained in solution phase during the
assay. For the direct coating of uPAR or integrin, the receptor was dissolved in binding buffer
containing 50mM Tris, 100mM NaCl, 1mM CaCl2 and 1mM MgCl2 (pH- 7.4) at 5µg/ml
concentration. Coating was allowed for 1hr at 370C followed by 3X washing with binding buffer.
Blocking and incubation of VN/PAI-1 complex were carried out in the same manner as described
in the previous section (matrix binding assay). VN binding was probed immunochemically (1E9
as primary antibody) as described in the previous section.
For binding assays with receptors in the solution phase, VN and PAI-1 were mixed
in 0.1% Tween-20 containing binding buffer, incubated for 1hr at 370C and then added to plate
with/out matrix coating followed by incubation for 1hr at 370C. When monomeric VN and its
complex with PAI-1 were directly added to the plate, blocking with gelatin was carried out after
VN/PAI-1 coating. When monomeric VN and its complex with PAI-1were added to the matrixcoated plate, blocking was carried out following matrix coating. Unbound proteins were removed
by 3X washing with binding buffer. Binding solutions of uPAR and integrin (20µg/ml and
10µg/ml respectively) were made in binding buffer containing 0.1%Tween-20 and the receptors
were allowed to bind to VN/PAI-1on the plate at 370C for 1-1.5hr as when indicated. For all the
steps that involved antibody binding, 1X PBS containing 0.3%BSA, 0.5mM CaCl2 and 0.5mM
MgCl2 was used as buffer. Unbound receptors were removed by 3X washing with this antibody
binding buffer. For integrin binding, a polyclonal antibody (made in rabbit) directed against the
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c-terminal domain of αv-subunit was used at 1:100 dilution. For uPAR binding a monoclonal
antibody (made in mouse) against uPAR was used at 1:100 dilution. Primary antibody binding
was carried out at 370C for 1hr followed by 3X washing with antibody binding buffer.
Peroxidase conjugated anti-mouse/anti-rabbit IgG was used as secondary antibody. This
antibody was used at 1:1000 dilution and incubation was carried out at 370C for 1hr followed by
3X washing with antibody binding buffer. Color was developed as described in the previous
section (matrix binding assay).
For all binding assays the average reading obtained from each treatment condition
(normalized with respect to background) was plotted along with the standard error. Statistical
significance was determined by two-tailed Student's t-tests. P-values <0.05 were considered
significant.

3.2. f. Cell binding assay
For cell binding assay, coating of matrix (HSPG or Col-IV), blocking of the coated
surface and incubation of preformed complex between VN and PAI-1 on to coated matrix were
carried out as described in the matrix binding assay. High-binding, solid side, transparent flat
bottom, 96-well plates from Costar were used for this assay. Cells were incubated overnight in
the absence/presence of growth factors, under serum free condition. VEGF (Vascular endothelial
growth factor) and bFGF (basic fibroblast growth factor) were used at 10ng/ml concentration and
PMA (phorbol 12-myristate13-acetate) was used at 100ng/ml concentration. Cells were detached
from the surface by 1% trypsin/EDTA solution and complete media (with serum) was used for
neutralizing the trypsin. Cells were resuspended in serum-free media at required concentration.
When Col-IV was used for coating the plate, 100µl of cell suspension containing 105cells/ml was
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added to each well followed by incubation at 370C for 30min. When HSPG was used for coating
the plate, 100µl of cell suspension containing 5*105cells/ml was added to each well followed by
incubation at 370C for 1.5hr. Unbound cells were removed and labeling of bound cells was
carried out by adding 100µl serum-free media containing 1µg/ml calcein to each well followed
by incubation at 370C for 30min. Incubation of the cells during binding assay was always carried
out in the cell-culture incubator. Free label and the unbound cells were removed by washing 2X
with serum free media. Fluorescent cells bound to the surface were observed under the Zeis
microscope using excitation and emission optics suitable for fluorescin. Photographs of the
randomly selected multiple fields (15 to 18) were taken from each well. Each treatment condition
was repeated in triplicates. The average number of cells bound/0.13mm2 (area of each field) was
plotted (along with the standard error) with respect to each treatment condition. Statistical
significance was determined by two-tailed Student's t-tests. P-values <0.05 were considered
significant.

3.2. g. Cell migration assay
Migration experiments were carried out using FluoroBlok cell culture inserts of 8µm pore
size, purchased from BD Bioscience. These inserts are made of polyethylene terephthalate (PET)
membrane containing a dye that blocks transmission of the light between the range of 490700nm. If a suitable fluorescent dye is chosen, selective observation of the top or the bottom of
the insert can be achieved. Thus, use of this insert allows efficient counting of the migrated cells
that are bound at the bottom of the insert. Migration experiments on these inserts also require the
use of companion 24-well cell-culture plate obtained from BD Bioscience. Coating of the insert
with matrix components was carried out as described in the previous sections. Premixing of VN
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and PAI-1 was carried out the in the binding buffer (same as mentioned in the matrix binding
section) that contained 0.3%BSA instead of 0.1% Tween-20. Mixing was carried out for 1hr at
370C followed by incubation onto the inserts for 1hr at 370C as described before. Cells were
treated and prepared as described in the cell binding assay section. When Col-IV was used for
coating the plate, 150µl of cell suspension containing 106cells/ml was added to each insert and
when HSPG was used for coating the plate, 150µl of cell suspension containing 2*105cells/ml
was added to each insert. 500µl serum-free media was added to the bottom of the each insert.
Migration was carried out overnight in the cell culture incubator. Labeling of the cells was
carried out by adding 500µl serum-free media containing 1µg/ml calcein to the bottom of each
insert followed by incubation at 370C for 30min. Media containing free calcein was replaced by
500µl serum-free media and the calcein-labeled migrated cells were observed under the
microscope (Zeiss). Photographs of the randomly selected multiple fields (15 to 18) from the
bottom of each insert were taken. Each treatment condition was repeated in triplicates. Average
number of cells migrated/0.13mm2 (area of each field) was plotted (along with standard error)
with respect to each treatment condition. Statistical significance was determined by two-tailed
Student's t-tests. P-values <0.05 were considered significant. Figure-3.2 represents the basic
scheme for the migration experiments.

3.2. h. Flow cytometry
Cells were incubated overnight in the absence/presence of growth factors, under serum
free condition. VEGF (Vascular endothelial growth factor) and bFGF (basic fibroblast growth
factor) were used at 10ng/ml concentration, and PMA (phorbol 12-myristate13-acetate) was used
at 100ng/ml concentration. Cells were detached from the surface by 1% trypsin/EDTA solution,
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Figure 3. 2: Basic scheme of migration experiments

Figure-3.2: During the migration experiment, cells are added on to the top
chamber of the fluoroblok membrane insert. To the bottom chamber, fresh
media is added. The presence of migrated cells is observed on the bottom of
the insert under the microscope. Photographs of multiple fields were taken
and the number of cells migrated per 0.13mm2 area is plotted.
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and complete media (with serum) was used for neutralizing the trypsin. Cells were resuspended
in serum-free media, and 100µl of cell suspension containing at least 106 cells for each treatment
condition were added to the wells of a 96-well round bottom plate. Staining of the cell surface
receptors was carried out in this plate. For each treatment condition, samples were taken in
duplicates. Cells were incubated with primary antibody against uPAR at 1:40 dilution and αvβ3,
αvβ5, α5β1 & α2β1 at 1:100 dilutions. Dilutions were carried out in FACS buffer, and incubation
with primary antibody was carried out for 1hr on ice. Unbound antibodies were removed by
washing 2X with FACS buffer followed by incubation with Alexa-488 conjugated goat antimouse IgG (1:200 dilution) for 1hr on ice. Unbound antibodies were removed by washing 2X
with FACS buffer. Stained cells were fixed by 1% paraformaldehyde for 20min at room
temperature. Cells were washed 2X with FACS buffer and content of each well was transferred
into FACS tube containing 1ml of FACS buffer. Receptor expression was observed in FACSCalibur instrument and the data was analyzed by Flow-Jo.

3. 3. Results
3.3. a. Multimeric Complexes Formed by the Interaction of PAI-1 and VN
Exhibit Increased Association with Matrix Components.
In most of the published work in which PAI-1 was checked for its effect on cellular
adhesion and migration, „denatured‟ multimeric VN was used to mimic its matrix associated
multimeric form and PAI-1 was added exogenously in order to affect interaction of VN with cell
surface receptors. There are many pathophysiological conditions where PAI-1 is found to be colocalized with VN in the matrix [49, 212, 225, 267] and so we believe a more realistic approach
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is to include PAI-1 as a part of the multimeric complex. Since we know that PAI-1 initiates
multimerization of VN and remains associated with the complex for a long period of time, we
have opted to test a preformed complex of VN and PAI-1 in all of our studies and compare its
effect with monomeric VN. Furthermore, instead of using VN directly as a binding substrate, we
have included other matrix components in our in vitro experiments; these include Col-IV, Col-I
and HSPG (heparan sulfate proteoglycan) to probe the specific role of PAI-1/VN complex in a
more relevant context. Col-IV is an important basement membrane component that provides
tensile strength [268-269]. Col-IV interacts with VN, and it was found that the conformationally
altered, multimeric VN interacted better with collagen [104]. HSPG is also an integral basement
membrane component and is found in almost any mammalian tissue [270-271]. One of the many
proposed functions of basement membrane associated HSPG is to interact with other matrix
components, like laminin, fibronectin, and Col-IV [272-273]. In this study we test whether
HSPG can interact with both monomeric and multimeric forms of VN.
Figure-3.3 & 3.4 show the dose-dependent increase in VN binding to Col-IV or HSPG
respectively as PAI-1 concentrations are varied. We observed that the multimeric complex of VN
and PAI-1 had a higher propensity to associate with the mixture of Col-IV and HSPG (Figure3.5). This finding is consistent with our hypothesis, i.e. as more multimeric complexes are being
formed by the interaction of increasing concentration of PAI-1, an increase in VN binding is
observed with the individual components or mixture of matrix substituents.
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Fingure-3.3-3.5: 100nM VN was mixed with increasing concentrations of PAI-1. The
mixtures were allowed to bind to Col-IV (Figure-3.3) and HSPG (Figure-3.4)
respectively and then probed for VN binding immunochemically. For Figure-3.5, the
plate was coated with Col-IV, followed by coating with HSPG. 20nM VN was mixed
with increasing concentrations of PAI-1 and the complexes were allowed to bind to the
matrix. VN binding was probed immunochemically.

Figure 3. 3: Association of VN/PAI-1 complex with Col-IV- dose
dependency

116

Figure 3. 4: Association of VN/PAI-1 complex with HSPG- dose
dependency

Figure 3. 5: Association of VN/PAI-1 complex with Col-IV- dose dependency
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3.3. b. Formation of a Complex with Full Length VN is Critical for Increased
Association with Matrix
It has generally been thought the interaction between VN and PAI-1 is mediated through
the SMB domain of VN. The crystal structure of recombinant SMB domain bound to 14-1-B
shows a single-turn 3-10 α-helix of SMB interacting with helix-F and part of the central β-sheet
of 14-1-B [22]. Recently we have found that the interaction between these two proteins actually
extends beyond this observed surface. By rapid reaction kinetics experiments done to test the
binding of VN and strategically labeled (fluorescent) PAI-1, under conditions where only 1:1
binding was allowed, it was observed that the interaction between these two proteins is biphasic.
Binding between PAI-1 and the isolated SMB, in contrast, was monophasic [168]. This data
showed that interaction with full length VN is more complex and involves multiple interactions.
We hypothesize that such multiple interactions between PAI-1 and full length VN are critical for
the assembly of multimeric complexes and thus for increased association of VN with matrix
components. In order test this idea, matrix-binding experiments have been carried out with
complexes formed with PAI-1 and fully functional isolated SMB domain. Figures-3.6 & 3.7
show binding data where SMB was mixed with two different concentrations of PAI-1, and the
binding of the complex was compared to SMB alone on HSPG and Col-IV respectively. As
expected, no significant increase in binding of SMB was observed upon mixing with PAI-1. The
complex formed between PAI-1 and full length VN was used as positive control.
Since it is the multimeric complex of VN that is commonly found to be localized in the
extracellular matrix and PAI-1 is the biological partner that causes such conformational
transitions that lead to relocalization of VN, disruption of the interaction between these proteins
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Figure 3. 6: Association of SMB/PAI-1 complex with HSPG

Figure 3. 7: Association of SMB/PAI-1 complex with Col-IV

Figure-3.6 & 3.7: 50nM VN and 100nM SMB were mixed with two different
concentrations of PAI-1 corresponding to 1:1 and 1:2 stoichiometry. The
VN/PAI-1 complex and SMB/PAI-1 complexes were added to HSPG
(Figure-3.6) and Col-IV (Figure-3.7). Binding of VN and SMB to the matrix
was probed immunochemically.
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can be a useful therapeutic strategy. Recently we have found two peptides (an octapeptide and a
pentapeptide, mimicking the RCL of PAI-1) that can completely disrupt the interaction between
VN and PAI-1 and inhibit the formation of oligomeric complexes. (A detailed description of
these two peptides and the experiments will be included under the Chapter-3.) In order to check
the potential of these peptides to disrupt matrix association, we have performed these matrix
binding experiments on the complex formed between VN and PAI-1 in the presence/absence of
the octapeptide. Figures-3.8 & 3.9 show the results of these binding experiments to HSPG or
Col-IV respectively. As expected, the presence of the octapeptide completely disrupted the
increased association of VN with matrix components.
Mutating glutamate-123 residue of PAI-1 by replacement with arginine (Q123K) has
been found to severely weaken the affinity for the primary site interaction with VN [197]. A
sedimentation velocity study done with monomeric VN and Q123K-PAI-1, mixed at equimolar
concentrations, showed that this mutant essentially lacked the ability to form multimeric
complexes (discussed in chapter-3). In order to check the effect of this mutant on influencing the
association of VN with matrix components, similar matrix binding experiments were done.
Figure-3.8 & 3.9 contain data that show that Q123K mutant of PAI-1 cannot promote increased
association of VN with Col-IV and HSPG.

3.3. c. Increased Association of VN Is Not Glycosaminoglycan (GAG)
Mediated.
Glycosaminoglycans (GAGs) are long unbranched polysaccharides comprised of
repeating disaccharide units. The disaccharide units are usually made of one hexose or
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Figure 3. 8: Effect of octapetide and Q123K-PAI-1 on VN/PAI-1
complex binding to HSPG

Figure 3. 9: Effect of octapetide and Q123K-PAI-1 on VN/PAI-1 complex
binding to Vol-IV

Figure-3.8.a & 3.9: 50nM VN was mixed with a 100nM concentration of the Q123K
mutant of PAI-1 or 100nM wtPAI-1 in the absence or presence of 2mM
octapeptide. Mixtures were added to HSPG (Figure-3.8) and Col-IV (Figure-3.9)
respectively. Binding of VN and SMB was quantified immunochemically using 1E9.
monoclonal antibody (1:2000 dilution).
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hexuronic acid residue and one hexosamine (6-C sugar made containing nitrogen). Heparin, the
natural anticoagulant found in our body is a common example of GAG. There are many other
types of GAGs, including heparin sulfate, chondroitin sulfate, dermatan sulfate etc. HSPG, the
matrix component that we have used in our study is a proteoglycan that contains heparan sulfate
as the GAG molecule. Col-IV is also heavily glycosylated [274]. The anticoagulant property of
heparin comes from its ability to increase the rate of antithrombin-III mediated inactivation of
thrombin [70]. VN is known to act as a scavenger of heparin and thus reduces the rate of
antithrombin-III-mediated inactivation of thrombin [5, 74]. Studies have shown that multimeric
VN exhibits increased binding affinity for heparin [48, 275]. Our lab showed that this apparent
increased binding of multimeric VN to heparin is attributed to avidity (e.g. multi-valent effects)
rather than differences in affinity. Thus, it was observed that the affinity of monomeric VN was
similar to that of a single unit of the multimer [276]. Nevertheless, the overall effective binding
to heparin was higher with „denatured‟ multimeric VN. In order to test whether the increased
association of the PAI-1/VN complex with the matrix is GAG mediated, we have performed
binding studies with different types of GAG molecules. Figure-3.10 compares monomeric VN
and VN/PAI-1 for their ability to interact with different types of GAG molecules. Though
monomeric VN was found to bind to all the different GAG molecules used, the multimeric
complex formed between VN and PAI-1 did not show any increased association. This finding
indicates that increased association of the complex to matrices and/or tissues is not GAG
mediated.
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Figure 3. 10: Association of VN/PAI-1 complex with different GAG

Figure-3.10: A plate designed for GAG binding was coated with
different GAGs as indicated. For each GAG molecule coating
concentration was 25µg/ml. Coating was carried out overnight at 40C.
VN was incubated with 100nM wt-PAI-1 and the mixtures were added
to plate coated with GAGs. Binding of VN was quantified
immunochemically using 1E9 monoclonal antibody.
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3.3. d. The Multimeric Complex Formed Between VN/PAI-1 Associate More
with Cell Surface Receptors.
VN interacts with several surface receptors, e.g. - uPAR αvβ3 and αvβ5. In vitro studies
indicate that binding of uPAR to „denatured‟ multimeric VN is inhibited by the addition of PAI1[226-227]. Other studies indicate that binding of αvβ3 to „denatured‟ multimeric VN is
inhibited by PAI-1 added exogenously [229, 277]. Unfortunately, no one except for our lab has
chosen to compare the interaction of receptors and VN with that of the multimeric complex
formed by the interaction of VN and PAI-1. Previously our lab has shown that the multimeric
complexes formed by the interaction between VN and PAI-1 associate more with αvβ3 and
GPIIaIIIb (a platelet integrin) compared to monomeric VN [209]. We further pursued this
strategy to add to our existing knowledge on: 1. the biological relevance of multimeric
complexes formed between VN and PAI-1; 2. the effect of PAI-1 on the interaction between VN
and cell surface receptors while associated with VN within the multimeric complexes.
Figure-3.11 shows the dose-dependent increase in VN binding to suPAR (soluble uPAR
with no GPI link) with increasing concentrations of PAI-1. This is an experiment that explicitly
checked binding of VN to a uPAR-coated plate. The side panel shows the basic schematic of the
binding assay. In this study we did not see any interference with VN binding to suPAR by PAI-1.
In fact, the multimeric complexes formed between VN and PAI-1 exhibit increased binding
compared to native monomeric VN. Figure-3.12 & 3.13 show binding experiments to test
association of uPAR with the VN/PAI-1 complex associated with matrix components. In these
experiments monomeric VN and the complex between PAI-1 and VN were incubated with ColIV and HSPG, and uPAR was added to the plate following VN binding. The binding of uPAR
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Figure 3. 11: Association of VN/PAI-1 complex with uPAR- dose dependency

Figure-3.11: 20nM VN was mixed with varying concentrations of
PAI-1 and incubated at 370C for 1hr. Mixtures were added to a
uPAR coated plate. Binding of VN to uPAR was quantified
immunochemically using the 1E9 monoclonal antibody against VN.
The right panel shows the basic scheme of this experiment. The
symbol for uPAR is defined. For all the other symbols, refer to
Figure-3.1.
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Figure 3. 12: uPAR binding to VN/PAI-1 complex associated with
HSPG

Figure 3. 13: uPAR binding to VN/PAI-1 complex
associated with Col-IV

Figure-3.12 & 3.13: 100nM VN was mixed with 200nM wtPAI-1 and the
mixtures were then added to HSPG (Figure-3.12) and Col-IV (Figure-3.13)
coated plate. Soluble uPAR was added and binding of uPAR to the
VN/PAI-1 complex was probed immunochemically using an antibody
directed against uPAR. The right panel shows the basic scheme of this
experiment. For all the symbols refer to Figure-3.1 and 3.11.
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was probed by an antibody that recognizes a non-VN binding epitope on uPAR. While uPAR
binding could not be detected to native VN under the given conditions, a significant increase in
binding was observed to the VN/PAI-1 complex associated with Col-IV or HSPG. A previous
study showed that the affinity of uPAR binding to native VN was lower than with „denatured‟
multimeric VN [278]. It may be that a significantly higher concentration of native VN is needed
to demonstrate binding of uPAR. Nevertheless, a significant increase in binding of uPAR to the
VN/PAI-1 complex compared to monomeric VN indicates that the presence of PAI-1 is not
inhibitory to uPAR binding. uPAR binding to native VN and the VN/PAI-1 complex directly
coated on to a 96-well plate was also checked (data not shown). Once again no binding could be
observed to native VN under these conditions, but binding was much higher with the VN/PAI-1
complex. Though a significant difference in binding was observed with the VN/PAI-1 complex,
the difference was more prominent when the VN/PAI-1 complex was associated with matrix
components.
Figure-3.14 shows tests of binding of the VN/PAI-1 complex to αvβ3, αvβ5 and α5β1.
We observe that multimeric complexes formed between VN and PAI-1 show increased
association with both αvβ3 and αvβ5 compared to monomeric VN. Once again, no inhibition of
VN binding to these integrins was observed in the presence of PAI-1. In this figure, we also see
that monomeric VN binds to α5β1, and this binding increase in the presence of the VN/PAI-1
complex. α5β1 is primarily known as a fibronectin receptor [279-280] that recognizes an RGD
sequence on fibronectin [280]. α5β1 shares some functions with αvβ3. Like αvβ3, expression of
α5β1 is minimal in quiescent endothelial cells, but activated endothelial cells show significant
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Figure 3. 14: Association of VN/PAI-1 complex with αvβ3, αvβ5 and α5β1

Figure-3.14: 50nM VN was mixed with 100nM PAI-1 and added to αvβ3, αvβ5 or
α5β1 coated plates. 50nM VN alone or in complex with 100nM PAI-1 were added
to integrin coated plates. Binding of VN was quantified immunochemically using
the 1E9 monoclonal antibody against VN. The right panel shows the basic scheme
of this experiment. The symbol for integrin is defined. For all the other symbols,
refer to Figure-3.1.
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increase in the expression of α5β1. Similarly, expression of α5β1 on endothelial cells can be
upregulated by bFGF or TNF-α [281]. Figure-3.15 & 3.16 show results that further confirm the
specific interaction of VN and α5β1. Figure-3.15 compares the binding of monomeric VN alone
or in complex with PAI-1 (equimolar mixture). Monomeric VN shows a concentrationdependent increase in binding to α5β1, whereas at each concentration, the presence of an
equimolar amount of PAI-1 resulted in a further increase in binding. Figure-3.16 shows the dose
dependent increase in VN binding with increasing concentrations of PAI-1. Figure-3.17 probes
for αvβ5 binding to native VN and the VN/PAI-1 complex coated on a 96-well plate. Probing of
αvβ5 binding was carried out using an antibody that recognizes the C-terminal domain of αv
integrin. A schematic presentation of the binding strategy is shown in the side panel. Though no
detectable binding of αvβ5 could be observed with monomeric VN, a significant increase was
observed with the VN/PAI-1 complex. The absence of binding to monomeric VN could be due to
a weak affinity. Seiffert et al. showed that „denatured‟ multimeric VN has much higher affinity
for αvβ3 [277]. A similar issue may play a role here with αvβ5. This study shows that the
presence of PAI-1 in the multimeric complex does not inhibit αvβ5 binding to VN. Strikingly,
when the binding of αvβ5 to VN/PAI-1 associated with matrix components was checked, no
binding was detected to either native VN or VN/PAI-1 under similar experimental conditions. It
appears that in the environment where αvβ5 is associated with multimeric VN in the context of
other matrix components, the C-terminal domain of αvβ5 is not accessible to the antibody.
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Figure 3. 15: Comparison of VN/PAI-1 complex and
monomeric VN binding to α5β1

Figure 3. 16: association of VN/PAI-1 with α5β1- dose
dependency

Figure-3.15: A series of VN concentrations was mixed with wtPAI-1 in an
equimolar concentration, and the binding of the VN/PAI-1 complex to an α5β1
coated plate is compared to that of a VN alone. Figure-3.16: 10nM VN was mixed
with varying concentrations of PAI-1 and added to α5β1 coated plate. The binding
of VN was probed immunochemically.
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Figure 3. 17: αvβ5 binding to VN and VN/PAI-1 complex

Figure-3.17: 100nM VN alone or mixed with 200nM PAI-1 were added to a
plate. αvβ5 was added to VN or VN/PAI-1 coated plate and the binding of the
integrin was probed by an antibody against the C-terminus of the αv subunit
(1:100 dilution). The right panel shows the basic scheme of this experiment.
For all the symbols refer to Figure-3.1 & 3.14.
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3.3. e. Effect of the VN/PAI-1 Complex on Cellular Adhesion and Migration:
Testing the Role of the Surrounding Environment.
Previous studies showed that PAI-1 promoted migration of U937 cells and melanoma
cells through VN in a uPAR-dependent manner [226, 228]. On the other hand, PAI-1 was found
to inhibit migration of SMC, WISH and Hep2 cells lines on VN in a αvβ3 mediated fashion
[229-230]. The particular effect of the interaction between PAI-1 and VN on cellular
migration/adhesion may thus be influenced by cell type and variability in cell surface receptors.
In order to explore the effect of specific cell types, we have included two different cell lines in
our study. They are HT1080 (fibrosarcoma) and EA.hy 926 (endothelial cell), cells relevant in
different aspects of angiogenesis, as discussed above [191, 231-233]. Angiogenesis is the process
of new blood vessel formation. In this process, activated endothelial cells migrate from the
existing blood vessel to the tumor site and initiate new blood vessel formation. Formation of new
blood vessels is key for the development and progression of the tumor [282-283]. VN is thought
to play an important role in the regulation of angiogenesis. The absence of VN was found to
decrease angiogenesis in mice [66]. There are a number of inhibitors of angiogenesis, designed
to disrupt the interaction of αvβ3 and αvβ5 with VN, currently being studied in clinical trial [99,
284-285]. Thus, the use of these two cell lines is relevant in the context of angiogenesis.
It is known that cytokines and growth factors can regulate the expression of receptors on
the cell surface. Waltz et al. found that stimulation of the monocytic cell line U937 with TGFβ1
and Vitamin-D3 (Cholecalciferol) caused expression of uPAR on the cell surface. In other
studies, the use of bFGF increases expression of αvβ3 in HDMEC (human dermal microvascular
endothelial cell) [286]. Phorbol 12-myristate 13-acetate (PMA), which is known to be a
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tumorigenic substance, was also found to cause an increase in αvβ3 expression in HDMEC
[287]. Angiogenesis is initiated by the activation of endothelial cells. Often times this activation
results from the change in receptor expression on the cell surface mediated by the effect of
different growth factors. Brooks et al. reported that bFGF and TNF-α (tumor necrosis factor-α)
can induce angiogenesis by increasing the expression of αvβ3 on the vascular endothelial [288].
Such angiogenesis could be blocked by a specific antibody against αvβ3. On the other hand,
Friedlander et al. showed that angiogenesis induced by VEGF and TGF-β (transforming growth
factor-β) was blocked by an antibody against αvβ5 [96]. Thus, angiogenesis induced by these
two growth factors was proposed to be αvβ5-mediated. In our study we have used bFGF and
VEGF as possible modulators of the receptor expression on the cell surface of the two cell lines.
We have also used PMA for influencing receptor expression. Our rationale was to determine the
specific regulation of receptors on our chosen cell types due to stimulation with bFGF, VEGF
and PMA. Among the many growth factors available, it was logical to choose those that are
known to cause changes in other systems. However, it should be noted that there were no
previous studies to establish the effects of these particular cytokines and chemicals on these cell
lines. Figure-3.18 contains the basic scheme of all the cell based experiments. Briefly, each cell
line (1080 and 926) was separately treated with different stimulants (bFGF, VEGF and PMA)
under serum free conditions. As control, each cell line was also left under serum free condition
with no treatment. Each cell line subject to separate treatment condition was utilized for cell
binding and migration assay. For all binding and migration experiments matrix conditions were
generated by using either Col-IV or HSPG as the base matrix component. VN alone and its
complex with PAI-1 were then allowed to bind to Col-IV or HSPG to complete two different sets
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Figure 3. 18: Basic scheme for the cell binding and migration experiments

Figure-3.18: 926 cells and HT1080 cells were treated with growth factors and PMA
separately. As a control, untreated cells were also used. Specific matrix conditions were
generated by adding VN or the VN/PAI-1 complex to either plates coated with HSPG
or Col-IV. Cells treated with different conditions were subject to both binding and
migration study in the presence of specific matrix condition.

134

of matrix preparation. Both 1080 and 926 cell lines that have already been treated with different
conditions were then subject to cell binding assay and cell migration assay separately under two
different sets of matrix conditions. While EA.hy926 cells were checked for adhesion to the
VN/PAI-1 complex associated with HSPG, no differential effect in cell binding was observed
between the VN/PAI-1 complex and monomeric VN. This was true under all conditions. Figure3.19 -3.22 show binding of unstimulated, bFGF-, VEGF- and PMA-stimulated EA.hy926 cells to
VN/PAI-1 complex associated with HSPG, respectively. For almost all the conditions tested the
presence of the VN/PAI-1 complex neither inhibited nor promoted cellular binding compared to
VN alone (P>0.05). However, VN alone increased cell binding relative to HSPG (P<0.05).
Another striking observation was that when PAI-1 was associated with HSPG, a significant
increase in binding compared to HSPG (P<0.05)) could be observed, as found with VN alone or
with the VN/PAI-1 complex. When HT1080 cell line was used for studying the effect of
different stimulation conditions on cell binding to VN/PAI-1 complex associated with HSPG
very similar results were obtained as with EA.hy926 cell line. Presence of VN/PAI-1 complex
showed no significant difference in terms of number of cell bound compared to VN alone
(P>0.05). When VN alone was mixed with HSPG significant increase in binding was observed
compared to that of HSPG alone.
926 Cell binding to VN or the VN/PAI-1 complex associated with Col-IV was dominated
by the presence of Col-IV. Considerable amount of cell binding was observed to Col-IV within
30 minutes of incubation and there was no additional influence of the presence of VN or the
VN/PAI-1 complex under all the conditions tested (P>0.05). Figure-3.23 - 3.26 show the result

135

Figure-3.19- 3.22: A 50nM concentration of VN was incubated with
100nM wt-PAI-1, and the mixtures were added to plates coated with
HSPG. Unstimulated (Figure-3.19), bFGF stimulated (Figure-3.20),
VEGF stimulated (Figure-3.21) and PMA stimulated (Figure-3.22) 926
cells were added to wells and bound cells were labeled with calcein. The
number of cells bound per 0.13mm2 area is plotted. *P<0.05

Figure 3. 19: Unstimulated 926 cell binding to VN/PAI-1 complex
associated with HSPG
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Figure 3. 20: bFGF stimulated 926 cell binding to VN/PAI-1 complex
associated with HSPG

Figure 3. 21:VEGF stimulated 926 cell binding to VN/PAI-1 complex
associated with HSPG
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Figure 3. 22: PMA stimulated 926 cell binding to VN/PAI-1 complex
associated with HSPG
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Figure-3.23 -3.26: A 50nM concentration of VN was incubated with
100nM wt-PAI-1, and the mixtures were added to plates coated with
Col-IV. Unstimulated (Figure-3.23), bFGF stimulated (Figure-3.24),
VEGF stimulated (Figure-3.25) and PMA stimulated (Figure-3.26) 926
cells were added to wells and bound cells were labeled with calcein. The
number of cells bound per 0.13mm2 area is plotted.

Figure 3. 23: Unstimulated 926 cell binding to VN/PAI-1 complex
associated with Col-IV
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Figure 3. 24: bFGF stimulated 926 cell binding to VN/PAI-1 complex
associated with Col-IV

Figure 3. 25: VEGF stimulated 926 cell binding to VN/PAI-1 complex
associated with Col-IV
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Figure 3. 26: PMA stimulated 926 cell binding to VN/PAI-1 complex
associated with Col-IV
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of unstimulated, bFGF-, VEGF- and PMA-stimulated EA.hy926 binding to VN/PAI-1
associated with Col-IV. Similar results were obtained with HT1080 cells (data not shown).
Figure-3.27 & 3.28 show the migration of VEGF-stimulated 1080 cells and PMAstimulated 926 cells on VN or the VN/PAI-1 complex associated with Col-IV, respectively. Both
of these results show that, with VN bound to Col-IV, migration was increased several fold. With
wtPAI-1, there was essentially no effect on migration. The effect of the multimeric complex is
the opposite. With VEGF stimulated 1080 cells, a statistically significant (P<0.05) increase in
migration compared to VN alone could be observed, whereas with PMA stimulated 926 cells
presence of the VN/PAI-1 complex on Col-IV caused statistically significant decrease (P<0.05)
in migration. Tables-3.1 & 3.2 summarize the effects of the VN/PAI-1 complexes relative to VN
alone on the migration of 1080 and 926 cells under all the tested conditions, respectively. In
general, the effect of VN associated with the matrix components was pro-migratory. PAI-1 by
itself had no effect on migration, which indicates that other binding partners like VN were
required to produce protease-independent effects on migration. The effect of the multimeric
complex formed by the interaction between VN and PAI-1 was subject to the specific
microenvironment in which it was found. While only a few stimulating conditions showed
difference in migration between monomeric VN and the VN/PAI-1 complex, most of the
stimulating conditions tested showed that PAI-1 associated with VN in the multimeric complex
can have no effect on migration. Conditions under which migration with VN/PAI-1 complex was
found to be different from VN alone with statistical significance (P<0.05) have been highlighted
in Tables-3.1 & 3.2.
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Figure 3. 27: VEGF stimulated 1080 cell migration through
VN/PAI-1 complex on Col-IV

Figure 3. 28: PMA stimulated 926 cell migration through VN/PAI-1
complex on Col-IV
Figure-3.27- 3.28: A 100nM concentration of VN was incubated
with 200nM wt-PAI-1, and the mixtures were added to inserts
coated with Col-IV. VEGF stimulated (Figure-3.27) 1080cells and
PMA (Figure-3.28) stimulated 926 cells were added to inserts and
migration was continued overnight. Cells were labeled with calcein
and the number of cells migrated per 0.13mm2 area is plotted.
*P<0.05
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Table- 3. 1: Summary of 1080 cell migration experiments

Table- 3. 2: Summary of 926 cell migration experiments
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3.3. f. Flow Cytometry Study: Receptor Expression on Cell Surface
Cell-matrix interactions are mediated between different matrix components and cell
surface receptors, such as uPAR and integrins. We have tested the effect of the VN/PAI-1
complex under a number of possible conditions, and the results obtained from such analyses
were exciting and to some extent unexpected. At this point it was important to examine the
receptor expression profile of 1080 and 926 cells under all the conditions tested. There are a total
of ~24 different kinds of integrin heterodimers [93] expressed on human cells. So it was
necessary to carefully select receptors for studying at flow cytometry. Many studies indicate the
importance of uPAR on the cell surface for the regulation of PAI-1-mediated effects on cellular
adhesion and migration via VN [226-227]. For these reasons, checking uPAR expression was an
obvious requirement. Among all the different integrins, the ones that are primarily involved in
VN recognition are αvβ3 and αvβ5. We have observed the role of αvβ3 in regulating the PAI-1
mediated effect on adhesion and migration through VN [229-230]. We are also aware that bFGF
and VEGF are the known modulators of the expression of αvβ3 and αvβ5 on endothelial cells,
respectively. Therefore, we decided to evaluate the expression of these two integrins. We
observed in our cell binding assays that there was no considerable effect of VN or the VN/PAI-1
complex while Col-IV was the substratum. It is possible that the expression of specific collagen
receptors dominates over the expression of VN receptors. There are four known Collagen
receptors (α1β1, α2β1, α10β1 and α11β1) [93]. Out of these, α2β1 has been found to be present
in endothelial cells and is known to recognize different kinds of collagens, including Col-IV
[289-290], so we decided to check the expression of α2β1. We also checked the expression of
α5β1 because we found that VN interacts with this receptor, and we observed that this interaction
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was even more prominent with the VN/PAI-1 complex. Moreover bFGF was found to cause
increase in expression of α5β1 on endothelial cell surface [281].
Figure-3.29 & 3.30 show the basal level (unstimulated condition) expression of all the
five receptors on 926 and 1080 cells respectively. As observed except for uPAR, all of the other
four receptors were expressed in both the cell lines. Expression of α2β1 was the highest among
all the five receptors on 1080 lines, followed by α5β1, αvβ5, αvβ3 and uPAR in the order of their
expression level. For 926 cells α5β1 expression was the highest under basal conditions, followed
by α2β1, αvβ3, αvβ5 and uPAR in the order of their expression level. Figure-3.31-3.35 and
Figure-3.36-3.40 show the expression profiles of each chosen receptor (uPAR, αvβ3, αvβ5,
α5β1 and α2β1) in the absence or presence of growth factor stimulation on 926 and 1080 cells
respectively. Each panel shows the signal from unstained cells (histogram in gray color). The
signal from unstained cell is due to auto-fluorescence. Expression of each receptor under
different treatment conditions can be compared relative to this background signal. No uPAR
expression was observed on these two cell lines, even under the influence of growth factor
stimulation. Expression of αvβ3 did not change under the influence of growth factors on both of
the cell lines. Expression of αvβ5 slightly increased in both cell lines with the application of
bFGF and VEGF. While PMA caused a greater increase in expression of αvβ5 on 1080, this
increase was not observed with 926 cells. Under any given stimulation condition, expression of
α2β1 was much higher compared to that of αvβ3 and αvβ5 on both cell lines. Growth factor
stimulation had no effect on the expression of α2β1. Expression of α5β1 was also much higher
compared to that of αvβ3 and αvβ5 on both cell lines under any stimulation condition. While
bFGF and VEGF had no effect on its expression, application of PMA caused a moderate
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Figure 3. 29: Basal receptor expression- 926 cells

Figure 3. 30: Basal receptor expression- 1080 cells

Figure-3.29- 3.30: Results of the flow cytometry study to compare the basal
expression level of uPAR (red), αvβ3 (blue), αvβ5 (green), α5β1 (brown ) and
α2β1 (turquoise) on unstimulated 926 cells (Figure-3.29) and 1080 (Figure-3.30)
cells. The histogram shown in the gray color indicates the unstained cells. The
line indicates the average percentage of the population showing signal over
background.
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Figure-3.31-3.35: A flow cytometry study to the check expression of uPAR
(Figure-3.31), αvβ3 (Figure-3.32), αvβ5 (Figure-3.33), α5β1 (Figure-3.34)
and α2β1 (Figure-3.35) on unstimulated (red), bFGF (blue), VEGF (green)
and PMA (turquoise) stimulated 926 cells. The histogram shown in gray
color indicates the unstained cells. The line indicates the average percentage
of the population showing signal over background.

Figure 3. 31: uPAR expression on 926 cells- growth factor
stimulation

148

Figure 3. 32: αvβ3 expression on 926 cells- growth
factor stimulation

Figure 3. 33: αvβ5 expression on 926 cells- growth
factor stimulation
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Figure 3. 34: α5β1 expression on 926 cells- growth
factor stimulation

Figure 3. 35: α2β1 expression on 926 cells- growth
factor stimulation
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Figure-3.36-3.40: A flow cytometry study to check expression of uPAR
(Figure-3.36), αvβ3 (Figure-3.37), αvβ5 (Figure-3.38), α5β1 (Figure-3.39)
and α2β1 (Figure-3.40) on unstimulated (red), bFGF (blue), VEGF (green)
and PMA (turquoise) stimulated 1080 cells. The histogram shown in gray
color indicates the unstained cells. The line indicates the average percentage
of the population showing signal over background.

Figure 3. 36: uPAR expression on 1080 cells- growth factor
stimulation
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Figure 3. 37: αvβ3 expression on 1080 cells- growth
factor stimulation

Figure 3. 38: αvβ5 expression on 1080 cells- growth
factor stimulation
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Figure 3. 39: α5β1 expression on 1080 cells- growth
factor stimulation

Figure 3. 40: α2β1 expression on 1080 cells- growth factor
stimulation
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decrease in the expression of α5β1 on 926 cells and a slight increase in expression on 1080 cells.
Overall it appears that none of the stimulants actually caused a dramatic change in the expression
pattern of any of the receptors tested.

3. 4. Discussion
3.4. a. ‘Denatured’ Multimeric VN vs. ‘Biological’ Multimeric VN
VN is an important biomolecule involved in various physiological processes. It is found
in both the circulation and the extracellular matrix. This molecule shows a preferred
conformation and functions specific to its localization. While it exists as a monomer in the
circulation, the preferred conformation in the extracellular matrix is multimeric [13-14, 259].
Volker et al. showed that while multimeric VN could readily bind with the monolayer of porcine
endothelial cells and the associated subcellular matrix, native monomeric plasma VN showed
little binding [259]. Extracellular matrix-associated VN plays an important role in the regulation
of cellular adhesion and migration. Though the mechanism of such compartmentalization is not
known, the general idea is that a conformational change is required for the transition of the
monomeric plasma form into its multimeric matrix associated form. There are studies that
indicate that a number of biological molecules may initiate the process of this conformational
transition, including thrombin-antithrombin-III (TAT) complex, terminal complement complex
(C5b-C7) and PAI-1 [44, 205-206]. Conformational changes initiated by the binding of these
molecules expose an epitope that is not found in monomeric plasma form of VN and is
recognizable by monoclonal antibodies like, 8E6. Conformational changes also expose the
binding sites for heparin. Among these biomolecules, PAI-1 has been considered to be primarily
responsible for the conformational transition of VN. Seiffert et al. showed that PAI-1 mixed with
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monomeric plasma VN causes a conformational transition and multimerization of the latter
[206]. This conformational alteration induced by PAI-1 was recognized by the conformational
sensitive antibody like 8E6.
Despite the fact that there are a number of biomolecules that can potentially cause the
conformational transition of VN, most of the studies related to the matrix-associated form of VN
have been limited to the use of a „denatured‟ form of VN, formed by various physical methods.
Treatment of the plasma form of monomeric VN with urea, guanidine chloride or heat result in
the conversion into the homomultimeric form also known as the „denatured‟ form of multimeric
VN. This „denatured‟ form of vitronectin was found to possess the conformational sensitivity
usually observed with matrix associated multimeric VN [44, 77]. The main assumption involved
in the use of these approaches is that the „denatured‟ form of multimeric VN is similar to the
naturally occurring matrix associated form of VN. While this approach has been found to be
valuable in the understanding the role of VN in regulating cell-matrix interactions, its
physiological relevance is questionable. In fact, Seiffert et al found out that platelet-associated
multimeric VN is structurally and conformationally distinct from „denatured‟ multimeric VN
[207]. Their study indicated that platelet-released multimeric VN was significantly smaller in
size compared to „denatured‟ multimeric VN, and the conformationally sensitive epitopes (for
mAb 153, 1244 and 8E6) were more pronouncedly expressed in „denatured‟ VN than platelet
released VN. Thorough examination and comparison between the multimeric form of
„denatured‟ VN and the multimeric form produced by biologically relevant processes is still
lacking. Thus, the primary motive of our study has been to understand the role of the matrixassociated form of VN in cellular adhesion and migration. These studies have used multimers
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produced under conditions that more likely replicate the physiological scenario. We consider that
PAI-1 is a potential biological factor that can cause the transition of monomeric VN into its
matrix-associated multimeric form, and we have used multimeric complexes formed by the
interaction of VN and PAI-1 for all our experiments.
In the last few years, our lab has produced data that show that PAI-1 mixed with
monomeric VN induces multimerization [209-211]. Also, we have established that PAI-1
remains associated with these multimeric complexes for several hours under in vitro
conditions.[209-210]. For these reasons, we refer to these multimeric complexes formed between
VN and PAI-1 as „biological‟ multimeric complexes. In this present study we have mixed PAI-1
and VN so that the „biological‟ multimeric complex is formed, and then have used these
complexes to check their ability to associate with matrix components like HSPG and Col-IV. A
previous sedimentation velocity study showed that VN mixed with various concentrations of
PAI-1 yielded multimeric complexes in a dose-dependent fashion [210]. Following the same
principle, VN was mixed with differing concentrations of PAI-1 to test the hypothesis that the
„biological‟ multimeric complexes formed between VN and PAI-1 will associate more readily
with matrix components. The extent of association with the matrix components should be
proportional to the amount of multimeric complexes present. Consistently, it was observed that
increasing concentrations of PAI-1 increased the amount of VN associated with both HSPG and
Col-IV in a dose-dependent fashion. This observation supports our hypothesis and suggests that
these „biological‟ multimeric complexes formed by the interaction between VN and PAI-1 have
practical relevance for determining the localization and function of VN in tissues. Another
observation is that these „biological‟ multimeric complexes did not show an enhanced propensity
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to associate with different GAGs, especially heparin. „Denatured‟ multimeric VN has previously
been presumed to bind heparin better than monomeric VN [48]. However, the „biological‟
multimeric complexes formed by the interaction between VN and PAI-1 did not show this
tendency, indicating that the assumption regarding „denatured‟ VN being an adequate mimic of
multimeric vitronectin in the ECM has flaws and should be re-examined.
We have also determined that the successful multimerization requires an interaction
between PAI-1 and full length VN. Limiting the interactions to PAI-1 binding to the primary
binding site within the SMB domain is not sufficient to cause increased association with the
matrix components. The isolated SMB domain mixed with PAI-1 did not exhibit increased
association with HSPG or Col-IV, compared to SMB alone. Thus interaction between PAI-1 and
full length VN with the more extensive binding interfaces that we have characterized before
[168] is required to ensure the successful transition into the multimeric form. If the interaction
between these two proteins is inhibited, the conformational transition from the monomeric form
to the multimeric form is impaired. We have recently found that an octapeptide that mimics the
reactive center loop of PAI-1, while mixed with this protein, almost completely disrupts the
interaction between VN and PAI-1, using a sedimentation velocity analysis that showed that
almost no higher order multimeric complexes were produced in the presence of this octapeptide
(discussed in detail in chapter-2). When VN and PAI-1 were mixed in the presence of this
octapeptide and association of VN to matrix components was probed, no increase in VN binding
could be observed compared to VN alone. Once again, this result supports our hypothesis that
the interaction between VN and PAI-1 that leads to the transformation into the higher order
multimeric complexes is required for showing increased association with the matrix components.
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This octapeptide is supposed to insert within the groove formed between the strand β3A and β5A
of PAI-1 and thus block the SMB domain mediated interaction of VN with PAI-1. Once this
interaction is blocked formation of higher order multimeric complexes is also inhibited and no
increased association of VN with the matrix components is observed. Similar results were
obtained when VN was mixed with a mutant of PAI-1 (Q123K) that has very low affinity for VN
binding. The sedimentation velocity study shows that this mutant (discussed in detail in chapter2) while mixed with VN forms very low amount of multimeric complexes compared to wtPAI-1.
Once again we can see that blocking the interaction between VN and PAI-1 interfere with the
amount of multimeric complexes formed, and that, in turn, is affecting how much increased
association of VN could be expected towards matrix components.

3.4. b. Does PAI-1 Always Negatively Interfere with the Interaction Between
VN and Cell Surface Receptors?
The most widely accepted role for PAI-1 regarding the interaction between VN and its
common cell surface receptors is as a general inhibitor that disrupts the interactions of
vitronectin with molecules such as uPAR or integrins. According to previous studies, the
interaction between uPAR and „denatured‟ multimeric VN was inhibited by exogenously added
PAI-1 [226-227]. The uPAR-binding site on the SMB domain appears to overlap with the PAI-1binding site, so that PAI-1 and uPAR compete for binding to VN [103]. Similar results were
observed with VN binding to αvβ3; binding of „denatured‟ multimeric VN to αvβ3 was blocked
by the addition of PAI-1 [229, 277]. Though the RGD domain responsible for integrin
recognition does not appear to be directly blocked by PAI-1 binding [22] in the crystal structure
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between the SMB domain and the 14-1-B form of PAI-1, steric interference resulting from the
proximity of the PAI-1-binding and integrin-binding sites has been thought to be the cause of the
inhibitory effect of PAI-1 on the VN-integrin interaction. The interaction of PAI-1 with VN has
been proposed to be a molecular switch [186, 227, 229]. According to Smith and his group, PAI1 binding to monomeric VN causes a conformational change and an opening up of the cryptic
cell adhesion site (for integrin binding) on VN, but that site remains inaccessible as long as PAI1 is bound. This model assumed that, once PAI-1 is released, the cell adhesion site becomes
available on VN and integrin binding can occur [277]. Release of PAI-1 from VN can be
initiated by the interaction of the cell surface bound urokinase also. Binding of protease by the
serpin causes significant decrease in affinity of PAI-1 for VN and may lead to release of PAI-1
from matrix associated VN [186, 232]. Seiffert et al. performed some studies where they used
PAI-1 to cause multimerization of VN, but waited for 16hrs until PAI-1 was released from these
multimeric complexes. These multimeric complexes of VN showed increased binding to αvβ3,
but such binding could be blocked by exogenously added PAI-1[277]. In this current study we
have taken a more realistic approach by using „biological‟ multimeric VN that remains
associated with PAI-1. Use of this „biological‟ multimeric complex of VN formed by the
interaction with PAI-1 allowed us to check what physiological roles they play and also revisit the
role of PAI-1 in regulating the interaction between VN and its receptors, while present as a part
of the „biological‟ multimeric complexes.
Testing for receptor-ligand binding with the receptor immobilized on the plate is a
common method that we have employed to test for the ability of the multimeric complexes to
recognize immobilized uPAR. Monomeric VN was mixed with varying concentrations of PAI-1,
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and the resulting multimeric complexes tested for binding to uPAR. With increasing
concentrations of PAI-1, binding of VN to uPAR increased in a dose-dependent fashion. Thus, in
these measurements, the presence of PAI-1 within the complexes did not inhibit the interaction
between VN and uPAR, although the time scale of the experiment (only a few hours) ensures
that PAI-1 remains in the multimeric complexes during the experiment. In an alternative
approach, we directly probed the binding of uPAR to the „biological‟ multimeric complex bound
to the plate directly or associated with other matrix components, such as HSPG or Col-IV. For
directly probing uPAR binding, an antibody was chosen that recognized an epitope that does not
interfere with the interaction between uPAR and VN. This approach again showed that uPAR
binding to the „biological‟ multimeric complex of VN was not blocked by the presence of PAI-1.
Presence of PAI-1 in the matrix (both Col-IV and HSPG), following addition of VN/PAI-1
complex was confirmed in separate study by using an antibody against PAI-1 (data not shown).
Little uPAR binding could be detected with monomeric VN associated with matrix components
or directly with the plate; however, this finding is not altogether surprising and can presumably
be explained by the proposed difference in binding affinity between monomeric VN and
multimeric VN for uPAR [278]. Clearly, uPAR binding was observed for the „biological‟
multimeric complexes formed between VN and PAI-1, but it is not clear how the interaction
between uPAR and VN occurs in the presence of PAI-1, as the two binding sites are known to
overlap. It is possible that another uPAR binding site, which lies at the C-terminal heparin
binding domain, as proposed by Waltz et al. [226], becomes more exposed following the
conformational transition.
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We have also tested the ability of these „biological‟ multimeric complexes to recognize
different integrin receptors. Previously we have shown that these complexes associate more
readily than VN alone with αvβ3 and αIIbβ3 integrins [209]. In this current study, we observed
that PAI-1 present in the multimeric complexes also did not block VN binding to integrins αvβ5.
Furthermore, we found that monomeric VN could interact with α5β1, a known fibronectin
receptor. Though the interaction was weaker compared to that of with αvβ3 and αvβ5, these
„biological‟ multimeric complexes showed an increased association with α5β1 compared to
monomeric VN. In an alternative approach, we also probed αvβ5 binding to monomeric VN and
„biological‟ multimeric VN directly bound to the plate. Though not much binding was observed
with monomeric VN, binding increased several fold with multimeric VN. Lack of binding to
monomeric VN once again is thought to be due to an affinity issue, with monomeric VN
exhibiting a lower affinity than the „biological‟ complexes. Surprisingly, no binding of αvβ5 to
either monomeric or multimeric VN could be detected while the proteins were present with other
matrix components like HSPG and Col-IV. There is a possibility that the epitope for the Cterminally directed antibody against the αv subunit is not easily accessible by the antibody under
this situation. Another possibility is that the specific activation state of αvβ5 that we are dealing
with under the current experimental conditions is not suitable for tight binding to the matrix
associated monomeric or multimeric VN. In other words the binding site for αvβ5 binding on
monomeric VN or „biological‟ multimeric VN has very low affinity while they are associated
with the matrix components like Col-IV and HSPG.
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3.4. c. PAI-1 Effects on Cellular Adhesion and Migration: Significance of the
Pericellular Environment.
The effect of PAI-1 and its interaction with VN on the regulation of cellular adhesion and
migration is an interesting subject. There is still no a consensus on the role of these two proteins
and their interaction in the regulation of cell-matrix interactions. The literature is full of opposing
claims made by different groups. Some studies say that PAI-1 inhibits cell binding to VN but
promotes migration, while others say that PAI-1 inhibits migration through VN [226-227, 229230]. Though the effect of PAI-1 on migration has been found to be variable, as far as its effect
on cell binding is concerned, most of the studies indicate that PAI-1 acts as an antiadhesive
molecule when cell binding occurs through VN. The majority of these studies were aimed at
understanding the role of exogenously added PAI-1 in regulating cellular adhesion and migration
mediated by „denatured‟ multimeric VN. Our approach has been different from these studies in
two ways; first, it is more reflective of natural environment because PAI-1 is present and bound
to vitronectin, and second, it is thorough in looking at a wide variety of biological settings with
different cell types and tissue components. We have compared the role of monomeric VN and
„biological‟ multimeric VN on cellular adhesion and migration in the context of other matrix
components such as HSPG and Col-IV. Also, we have placed emphasis on modulating the
pericellular microenvironments in which adhesion and migration are happening, as we believe
the specific role the multimeric complex formed between VN and PAI-1 may have on cellular
adhesion and migration is sensitive to the surrounding environment. The specific
microenvironment in which the adhesion or migration takes place is comprised of different
matrix components, different cell types and different receptors expressed on their surface. The
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choice of cancer fibroblast (HT1080) and endothelial (EA.hy926) cells for our work has
provided the context of a cellular environment for angiogenesis. We have also used PMA and
different growth factors, including bFGF and VEGF, in order to modulate receptor expression on
the cell surface. The choice of growth factors was based on previous studies that showed changes
in receptor expression on the surface of HDMEC (endothelial cells) [96, 288].
The results of our adhesion studies do not support the majority of studies in the literature.
The presence of „biological‟ multimeric complexes on either HSPG or Col-IV neither inhibited
nor promoted cellular attachment relative to VN alone. With HSPG, VN caused some increase in
binding of the „biological‟ complexes, while the presence of Col-IV did not lead to differential
effects for VN or its multimeric form on cellular adhesion or migration. This result was similar
with both cell lines, and the presence of growth factors also did not cause a difference in
adhesion. When isolated PAI-1 was associated with Col-IV, it had no effect on adhesion or
migration, but PAI-1 associated with HSPG appeared to increase cell binding to some extent and
this increase in binding was the same for the multimeric complexes. VN was found to promote
migration under all conditions, whereas isolated PAI-1 bound to the matrix components had no
effect on migration. The effect of the „biological‟ multimeric complex on migration was variable.
While under most conditions it neither promoted nor inhibited migration relative to VN alone,
under a few conditions it exhibited both promigratory and antimigratory effect. For example with
Col-IV as the matrix component, VEGF stimulated 1080 cells showed a statistically significant
increase (P<0.05) in migration, whereas PMA stimulated 926 cells showed a statistically
significant decrease (P<0.05) in migration compared to VN alone.
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There are examples from other studies where VN was found to promote migration of
different cell lines, such as SMCs (smooth muscle cell line) and keratinocytes [291-292]. There
are also other studies in which PAI-1 had no effect on cellular attachment but caused a decrease
in cellular migration. Stefansson et al. showed that PAI-1 did not have any effect on cellular
attachment of SMCs while „denatured‟ multimeric VN was associated with matrigel, an artificial
ECM mimic. However, under similar conditions, PAI-1 blocked migration of SMCs via
„denatured‟ multimeric VN associated with matrigel [229]. Stefansson et al. suggested that the
lack of an effect of PAI-1 on cellular attachment was due to the presence of receptors that
recognized matrix components other than VN. Following a similar line of rationale, we
performed a flow cytometry study to test for the expression of a number of receptors (uPAR,
αvβ3, αvβ5, α5β1, α2β1) on the surface in the two cell lines upon growth factor treatment. Under
any condition, irrespective of growth factor stimulation and among all the receptors tested, α2β1,
the collagen receptor, showed very high expression in both the cell lines. Because of this
abundance of the collagen receptors, it is possible that no differential effect of monomeric or
multimeric VN could be observed using Col-IV as the matrix substratum. Another striking
observation from flow cytometry was that uPAR was not found to be expressed in either of the
cell lines under any of the conditions tested. Since uPAR is a cell surface receptor that
recognizes only VN among all the matrix components, the absence of this receptor may account
for the relative insensitivity of the cells to the presence of monomeric or multimeric VN in the
matrix. The effect of uPAR could be exclusively tested using cells like U937, which show high
levels of uPAR expression on the surface [293].
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Though some increase in cell binding could be observed with monomeric VN while
associated with HSPG, the presence of the „biological‟ multimeric complex with HSPG did not
promote additional cell binding. We know from our matrix binding assay that such „biological‟
multimeric complexes of VN associate more with matrix components like HSPG. While the
presence of more VN was expected to provide more binding sites for cell surface receptor
interaction, no increase in cell binding was observed. It may appear that the multimeric form of
VN is providing multiple contact points for a single cell. Integrin clustering at focal adhesions at
the leading edge of cells is a common phenomenon that provides added strength of binding
[294]. So the presence of the multimeric VN might be associated with the strength of binding by
providing multiple connection points for integrins expressed at the focal adhesion surface of the
cell. This would result in the increase in the strength of the cell binding rather than the total
number of binding. Alternatively, it may be that the binding of one cell masks multimeric
complexes so that they are inaccessible for further cellular attachment. Regardless, the presence
of PAI-1 in the multimeric complexes did not inhibit cellular attachment, and this appears
opposite to with the prevailing opinion in the literature from studies with a different experimental
design.
While the results for cellular adhesion followed a general pattern with respect to the
effect of „biological‟ multimeric complexes of VN, the results regarding migration were more
variable. Once again, that signifies a more complicated process. As expected, the increase in the
cell migration due to the presence of monomeric VN in the substratum was several-fold higher
relative to the ECM components alone. However, the change in migration due to the presence of
the „biological‟ multimeric complex of VN was significant only in some cases, but not dramatic
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compared to the levels observed with monomeric VN. A flow cytometry study told us that none
of the growth factors had any notable effect on the expression pattern of any of the receptors
tested. Any changes observed were moderate. Perhaps other integrin receptors are more
significantly affected under the given conditions. What we have observed demonstrates that PAI1, while associated with the matrix as a part of the „biological‟ multimeric complex of VN, will
not necessarily promote or inhibit migration. The specific effect of PAI-1 on the regulation of
cellular adhesion and/or migration, while acting as a biological partner for the conformational
and oligomeric transition of VN, is strongly influenced by the pericellular environment.
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CHAPTER-4
Evaluating the Role of Vitronectin in the Pathogenesis of Candida
albicans Infection

4. 1. Introduction
Vitronectin (VN) is a glycoprotein found in both the circulation and extracellular matrix
[13-14, 259] that has important functional roles in controlling hemostasis and different
pathological conditions. The multifunctional nature of this protein results from its ability to
recognize different ligands, e.g. the thrombin-antithrombin complex (T-AT) [44-45], heparin
[46-48], PAI-1 [49-51], complement proteins [52] and cell surface receptors like integrins and
the urokinase plasminogen activator receptor (uPAR) [53-59]. The circulating pool of VN has a
role in regulating coagulation, fibrinolysis, wound healing, and thrombosis [61-62, 66]. On the
other hand, extracellular matrix associated VN has an important role in controlling cell-matrix
interactions and cell signaling [13]. Regulation of the cell-matrix interactions results from its
ability to act as a matrix protein that can bind to different cell surface receptors like uPAR and
certain subclasses of integrins (αvβ3 and αvβ5) [92] that govern cellular adhesion and migration.
In last few years, researchers have begun to understand the importance of VN in
pathogenic infections. A number of studies have been published indicating the significance of
VN in the regulation of host-pathogen interactions. For example, Duensing et al. for the first time
showed that VN was required for the internalization of Neisseria gonorrhoeae by CHO cells
[295]. Later, Dehio et al showed that the internalization of Neisseria gonorrhoeae into epithelial
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cells (HeLa cells) was mediated by VN, and the process also required binding of VN to integrin
αvβ5 (primarily) and αvβ3 [296]. Li et al. proposed that the infection of Staphylococcus
epidermidis, the most common infection to be found in patients undergoing shunt implantations,
is mediated by the vitronectin [297]. They showed that VN adsorbed on the surface of the shunt
provides sites for bacterial adhesion and colonization [297]. Bergmann et al. established the
importance of VN as a host cell component in the uptake of Streptococcus pneumoniae [298],
demonstrating that VN bound on the cell surface mediated adherence and invasion of the bacteria
in to the epithelial and endothelial cells [298]. They also showed in that study that the
internalization of the pathogen inside the host cells occurs in an αvβ3-dependent manner.
Involvement of VN in fungal pathogenesis has also become evident in the last few years.
Fungal infection (such as Candida albicans, Cryptococcus neoformans, Pneumocystis carinii) in
the lung is known to cause increase in the secretion of inflammatory mediators such as tumor
necrosis-α (TNF-α) [299-301]. For many of these fungal infections, release of TNF-α happens
following the binding of the macrophage through the β-glucan present on the fungal cell wall
[301-302]. It has also been demonstrated that VN increases macrophage recognition by P.
Carinii and C. albicans [303-304]. Olson et al. showed that VN could bind to the β-glucan
present on the cell wall of Pneumocystis carinii and this interaction in turn helped fungal binding
to the macrophages and the subsequent release of TNF-α [305]. Spreghini et al. reported the
presence of VN receptors on the surface of C. albicans that were antigenically and functionally
related to the mammalian αvβ3 and αvβ5 receptors [108]. The application of the antibodies that
block the function of αvβ3 and αvβ5 interfered with the interaction of C. albicans with VN;
when VN was added exogenously, the interaction of the pathogen with the endothelial cells was
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blocked [108]. Santoni et al. used immunochemical analysis to show that αvβ3- and αvβ5-like
receptors were present on the surface of the germ tube of C. albicans [306]. Binding of these
germ tubes to VN and to endothelial cells (EAhy.926 cells) could be significantly blocked by the
addition of RGD based peptides and function blocking antibody against αvβ3 and αvβ5 [306].
Based on the potential involvement of VN in fungal pathogenesis and the presence of
integrin αvβ3, αvβ5 like receptors on the cell surface of C. albicans, our lab began a
collaboration with Dr. Jeffrey Becker to use a genetic approach to further explore the role of VN
in the progression of C. albicans pathogenesis. A systemic infection with C. albicans (strain:
SC5314) was carried out in control mice (C57BL/6) and VN knock-out mice generated in the
background of C57BL/6. This knock-out line was generated by David Ginsburg and his group
and was found to be normal in terms of development, fertility and survival [307]. Infection with
C. albicans resulted in a marked difference in terms of survival between the wild type and the
knock-out mice. Figure-4.1 shows the results on the survival of these two strains upon injection
with an inoculum of 1x105 and 5x104 cells of the SC5314 strain of C. albicans. This figure
clearly shows a significant difference in survival between the strains upon C .albicans infection
and also indicates that the VN knock-out mice are more tolerant to the C. albicans infection.
Increased survival of the VN knock-out mice could be due to a variety of reasons.
Perhaps the absence of VN did not allow the pathogen to interact with the host cells, and as a
result it took a longer time for the infection to progress. It is also possible that the increased
death rate of the wild type mice was due to the adverse immune response resulting from the
infection. The absence of VN in the knock-out mice might interfere with the adverse
manifestation of the immune reaction, leading to increased survival. The requirement of VN
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Figure 4. 1: Composite survival curve- Candida infection

Figure-4.1: Composite survival curve of C. albicans infection on wild type and VN
knock-out mice from two different experiments. In one experiment, the inoculum
containing 105 cells was injected to each mouse, and the other experiment had 5x104
cells injected to each mouse. These data show a significant difference in survival
between VN knock-out and wild type mice. VN knock-out mice were found to be more
tolerant to C. albicans infection. These data are attributed to Sara Kauffman,
Christine Schar, Cynthia Peterson and Jeff Becker.
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for recognition of macrophages and subsequent release of TNF-α has been shown with C.
albicans and other types of fungi [303-304, 308]. The purpose of this current study is to
understand the increased survival in the the absence of VN. We are currently focusing on
comparing neutrophil invasion, cytokine expression and colonization of C. albicans in different
tissues, including lung, kidney, blood and spleen.

4. 2. Materials and method
4.2. a. Infection of mice with C. albicans
For all the C .albicans infection experiments, only male mice were used. Vitronectin
knock-out mice (generated at the background of C57BL/6) were initially provided by David
Ginsburg (Univ. of Michigan, Ann Arbor). They were maintained and bred in our animal facility
at University of Tennessee, Knoxville. Wild type C57BL/6 mice were purchased from Harlan
Sprague Dawley, Indianapolis, IN. For infection studies, C57BL/6 mice were purchased so that
their age matched the knock-out mice. The age of the mice ranged between 7-8 weeks during
infection. Infection was carried out with the virulent strain of C. albicans. , SC5314. The night
before the infection, SC5314 was cultured in 50ml YEPD media with constant shaking at 300C.
After overnight culture, cells were harvested and washed twice with 1XPBS, and a final
suspension of 106cells/ml was made in 1XPBS (phosphate buffer saline) in a sterile environment.
100µl of this cell suspension was injected using a 0.5 cc insulin syringe (purchased from BD
Bioscience) through the dorsal tail vein of each mouse (105cells/mouse). The Falcon tube in
which the original cell suspension was stored was shaken from time to time in order to maintain
the uniformity of the cell suspension. In each group (wild type and knock-out) there were at least
24 mice were included for the infection study.
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4.2. b. Collection of tissue for the analysis of fungal burden, cytokine
expression and myeloperoxidase assay.
Following infection, mice from each group (wild type and knock-out) were sacrificed on
day 6, 8, 11 and 14. An equal number of mice were sacrificed (five) at each time point, except
for day-14. On day-14 there were always more knock-out mice present than wild type due to
their increased survival. In another set of infections, tissues were collected at day 5, 9 and 14.
Various tissues were collected, including lung, kidney, spleen and blood. Collection of blood
was carried out following a terminal procedure. Briefly, mice were anaesthetized, and blood was
collected through retro-orbital bleeding into BD Microtainer tubes that are designed to enhance
coagulation. Tubes containing blood were stored in ice. From the collected blood, 50µl was
mixed with 450µl DI (deionized) water and stored for the fungal burden assay. Following
collection of blood, mice were killed by vertebral dislocation, and kidney, lung and spleen were
harvested. Kidney and spleen from each mouse were stored in sterile tubes for fungal burden and
cytokine analysis. For each mouse and for each type of tissue, a separate tube was used. Each
tube contained 1ml of sterile 1XPBS mixed with protease cocktail inhibitor (purchased from
Roche). Lung from each mouse was divided approximately into two portions. One portion was
collected in a tube containing 0.5ml of 1XPBS mixed with protease cocktail inhibitor and the
other portion was wiped on clean tissue to remove excess blood and then collected into a tube for
myeloperoxidase assay. Tubes containing tissues were left at -800C for further analysis.
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4.2. c. Fungal burden and cytokine expression analysis
For the fungal burden analysis of blood, the mixture of 50µl blood and 450µl DI water
that was made during tissue collection was directly mixed with 3ml of noble-agar (liquefied at
550C), and the mixture was plated on to YEPD plates and incubated for 48hours at 300C. The
number of colony forming units present on each plate was counted. The rest of the blood that
was stored in the BD Microtainer tube was centrifuged at 40C for 10min at 15000rpm, and the
separated serum was collected from the top and stored at -800C fro cytokine analysis.
For fungal burden analysis on kidney and spleen tubes were thawed and weight of the tissue
in each tube was measured. The specific weight of the tissue from each tube was obtained as
follows:
(Weight of tissue in each tube) =
(Weight of the whole tube with tissue & buffer) – (Weight of the tube with buffer only)
In order to obtain the „weight of the tube with buffer only‟, five empty tubes were filled with 1ml
1XPBS mixed with protease cocktail inhibitor and weighed to calculated the average weight.
Tissues were then sliced into small pieces using a razor blade, and the sliced tissues were
homogenized by a polytron homogenizer for 30-45 seconds. 10µl of homogenized kidney from
each sample was transferred to tubes containing 0.5ml DI water for the fungal burden assay. For
the spleen, 50ul of the homogenized tissues was used for fungal burden assay. The content of
each tube collected for the fungal burden assay was mixed with 3ml noble agar (liquefied at
550C), and the mixture was directly plated on to a YEPD plate followed by incubation for 48
hours at 300C. After 48hours, the number of colony forming units (CFU) from each plate was
counted, and the fungal burden in terms of number of CFU/gm of tissue was plotted for each
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group of mice at each time point. The rest of the homogenized tissues were centrifuged at
12000rpm for 15min, and the supernatants were stored at -800C for cytokine analysis.
For cytokine analysis the homogenized tissue (frozen) samples were sent to Dr. Chad
Steele‟s lab at University of Alabama, Birmingham and the analysis, was done following a
multiplex procedure using a 23-plex kit purchased from Biorad. This kit allows analysis of 23
different cytokines at the same. The basic scheme of the method is depicted in Figure-4.2.
Briefly the tissue extract is incubated with antibody-coupled beads. For each different cytokine, a
specific antibody is used. The mixture is then centrifuged to pull down the bead-coupled
antibody attached to the specific cytokine. Biotinylated detection antibody is then added to the
mixture to test for binding to the cytokine that is attached to the bead-coupled antibody.
Following incubation, PE (phycoerythrin) conjugated streptavidin is added and read in a Bioplex suspension array system.

4.2. c. Myeloperoxidase assay
The following reagents were made for myeloperoxidase assay.
MPO buffer
50mM potassium-phosphate, pH-6.5. Stored at room temperature.
HTAB buffer:
0.5% hexadecyltrimethylammonium bromide (HTAB) (w/v) made in MPO buffer. Stored at
room temperature.
O-dianisidine HCl solution
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Figure 4. 2: Basic scheme for multiplex analysis

Figure-4.2: Basic scheme of multiplex analysis for checking cytokine
expression. Antibody coupled to the bead is used to isolate a specific
cytokine. Another specific antibody conjugated with biotin is then
allowed to bind to the cytokine. Streptavidin conjugated PE is then
added to bind to the biotinylated Ab and read at Bioplex system.
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16.7 mg O-dianisidine-HCL was dissolved in 90ml DI water and 10ml MPO buffer. The
container was wrapped with an aluminium foil and stored in dark at 40C.
Lung tissue for myeloperoxidase assay was stored in sterile tubes at -800C. Tissue was thawed
and the weight of the tissue was measured similarly to what has been described before.
(Weight of tissue in each tube) =
(Weight of the whole tube with tissue) – (Weight of the empty tube)
Five empty tubes were taken and each of these tubes was weighed and the calculated average
weight was used as „weight of the empty tube‟. 1ml of HTAB buffer was added to each tube, and
the tissue from each tube was sliced using a razor blade. The sliced tissue was homogenized
using a polytron homogenizer for ~ 30-45 seconds. 30µl of the homogenized tissue was
transferred to a tube containing 500µl of DI water, and this mixture was used to check the fungal
burden in lung following the same method as described for kidney and spleen above. The rest of
the homogenized tissue was centrifuged at 12000rpm for 30min at 40C. The supernatant was
collected, distributed in smaller aliquots and stored at -800C for the future analysis of
myeloperoxidase activity.
For performing the assay for myeloperoxidase activity, the aliquots of lung tissue
samples were thawed. A portion of the thawed aliquot was diluted 8-fold and used for measuring
the total protein concentration in that sample using the Bio-Rad DC protein assay. This assay
was done in 96-well plates, and the absorbance of the reacted samples was measured in a plate
reader following the protocol from the manufacturer. A standard curve was generated using the
protein-standards provided with the kit. This standard curve was used for calculating the total
protein concentration in the lung tissue extract. For each ELISA plate, a separate standard curve
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was generated. Each sample was measured in triplicate. In order to calculate the crude
myeloperoxidase activity in the lung, 5µl of the lung homogenate from each sample added to the
wells of a 96-well plate. The same aliquot that was used for total protein concentration
measurement was used for measuring myeloperoxidase activity. O-dianisidine HCl solution was
warmed at 370C and mixed with 0.3% hydrogen-peroxide (1:600 dilution, final concentration
0.0005% hydrogen peroxide.). 200µl of the mixture was added to each well containing 5µl of the
lung homogenate, and the plate was read at 450nm using the Synergy Labtek plate reader
following a kinetic assay condition (total run time: 10min, each cycle: 30sec with 3sec shaking
before each cycle). Each sample was measured in triplicate. The absorbance at 10min (when the
myeloperoxidase reaction has ended) for each sample was normalized with respect to the total
protein concentration for that sample and the average normalized myeloperoxidase activity for
each time point was plotted for each group of mice (wild type and knock-out).

4. 3. Results and discussion
4.3. a. Fungal Burden Analysis Shows no Difference between Wild-type and
Knock-out Mice
Systemic infection of mice with C . albicans results in the distribution of the pathogen in
a wide variety of tissues, including kidney, heart, spleen, thymus, brain and liver [309]. Out of
these tissues, the kidney has been found to be the site for most extensive fungal colonization
[309-310]. Thus, the kidney was our first choice for comparing the fungal burden between C
.albicans infected male wild type and VN knock-out mice. Figure-4.3 shows the number of
colony forming units (CFU) present per gram of kidney tissue at different post infection time
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Figure 4. 3: Fungal burden analysis on kidney upon Candida infection

Figure-4.3: Colony forming units (CFU) of C. albicans present per gram of
kidney. Male wild type and VN-knock-out mice were infected with inoculum
containing 105 viable C. albicans cells. Mice were sacrificed at day 5, 8, 11 & 14,
and both kidneys were collected. At each time point, a minimum of 5 mice were
sacrificed from each group. Fungal burden analysis was performed on each of
those mice, and the average CFU/gm kidney tissue is plotted for each time point
and for each group of mice.
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points for both groups of mice. Statistically there is no difference (P<0.05) in terms of fungal
burden between the wild type and the knock-out mice in the kidney. We have also performed
fungal burden analysis on spleen, lung and blood. Little to no colony forming units could be
observed for blood, spleen and lung on the YEPD plate, even after 48hours of incubation. The
absence of colony forming unit within the lung is in line with what Rozell et al. found in their
study of C. albicans infection in mice [309]. Lung collected from the mice at day two postinfection did not show any presence of C. albicans; even at day fourteen post-infection we did
not observe presence of C. albicans in lung. Though we did not observe any colony forming unit
from spleen extract at any of our selected time points, Rozell et al. observed the presence of C.
albicans in spleen at two day post-infection [309]. It appears that by day five, which is our first
time point, significant clearance of the pathogen has been achieved in spleen. Rozell et al. found
that though C. albicans was present in the heart tissue at day one post-infection and caused
severe damage to the cardiac myocytes, from day two post-infection and afterwards very little
C. albicans was found in the heart due to clearance of the pathogen by neutrophilic granulocytes
[309]. A similar mechanism is likely in the spleen also.
The fungal burden assay performed on the above mentioned tissues did not show any
difference in terms of colonization, irrespective of the presence and absence of VN. Kidney,
being the primary site for C. albicans colonization upon systemic infection, was found to be
equally loaded with the pathogen in both wild type and VN knock-out mice at each time point.
Overall, the number of colony forming units increased with time as expected. Fungal burden is
not always correlated with death though. Warenda et al. showed that Candida strains that were
mutant for septin (a family of cytoskeletal proteins that is important for the proper
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morphogenesis of C. albicans) could colonize nicely within kidney but could not propagate the
invasion [311]. Silver staining of the kidney of the mice infected with septin-mutant strains of
Candida showed localized growth of the pathogen mainly in the uretar space but did not show
any sign of invasion [311]. This resulted in no difference in fungal burden but the mutant strains
were less virulent. It will be interesting to see if such localized colonization is happening with
VN knock-out mice.
Adhesion of the fungus to the host is considered important for the colonization and
virulence of fungal pathogens like C. albicans [312]. Since VN has been found to be involved in
recognizing receptors on the fungal cell surface and integrin αvβ3 and αvβ5 like receptors were
found to be present on the surface of C. albicans [305-306], our initial idea was that absence of
VN is interfering with the colonization of C. albicans in mouse tissue and causing increased
tolerance to the infection in knock-out mice, but these findings with fungal burden analysis
performed at different tissues suggest that absence of VN may not directly interfere with the
colonization of the pathogen..

4.3. b. Myeloperoxidase Activity in the Infected Lung
When neutrophils invade the site of inflammation, a number of lysozomal enzymes are
secreted [313-314]. One of these enzymes is myeloperoxidase (MPO), which has been found to
have antimicrobial and cytotoxic properties [315-316]. Bradley et al. reported that neutrophils
involved in phagocytosis release active MPO in the surrounding extracellular matrix at the site of
bacterial infection [313]. MPO also acts intracellularly during lysozomal degradation of the
phagocytosed pathogen [317]. The primary function of MPO is to generate reactive oxygen from
hydrogen-peroxide. Reactive oxygen then acts on chloride and generates highly oxidative
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hypochlorous acid (HOCl), which further acts on the bacterial system and causes killing of the
bacteria [318-319]. Zhang et al. reported that MPO at the site of inflammation generates reactive
intermediates that can cause lipid peroxidation. Lipid peroxidation results in cellular dysfunction
due to disruption of the membrane integrity [320]. In this study, Zhang et al. showed that MPO
can generate reactive intermediates like tyrosyl radicals and nitrogen dioxide ,which in turn may
cause lipid peroxidation [320]. Since MPO is primarily secreted by the activated neutrophils,
measurement of MPO activity has been utilized as an indicator of neutrophil invasion at the site
of infection or inflammation. For example, Mullane et al. reported the use of MPO activity as a
measurement for neutrophil invasion at the site of ischemic myocardium [321].
Neutrophils are the effector cells in innate immunity that play a major role in the early
stages of the C. albicans infection [309, 322]. MPO produced by activated neutrophils
contributes to the host defense mechanism against fungal infection [323]. Aratani et al. reported
that pulmonary or systemic infection with Candida. albicans or Aspergillus. fumigatus results in
a severe effect in the mice that are null mutants for MPO [324-325]. It has been also found that
patients with congenital MPO deficiency show an increased rate of infection with C. albicans
[326]. Due to the importance of neutrophil function in the defense against C. albicans infection
and the inherent relationship between neutrophil infiltration and MPO activity, we decided to
compare neutrophil invasion in the lung between wild type and knock-out mice following C.
albicans infection. Lung tissue was collected at day 5, 9 and 14, and half of the lung tissue from
each mouse was used for measuring the MPO activity. Figure-4.4 shows the result of the
comparison of MPO activity between the two groups of mice at different time points. No
difference in MPO activity in the lung was observed between wild type and VN knock-out mice
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Figure 4. 4: Myeloperoxidase assay in lung upon Candida infection

Figure-4.4: Myeloperoxidase activity per mg of total protein in lung. Male wild type
and VN-knock-out mice were infected with inoculum containing 105 viable C. albicans
cells. Mice were sacrificed at day 5, 9 & 14, and half of the lung from each mouse was
collected. At each time point a minimum of 5 mice were sacrificed from each group.
Total amount of protein present in the lung sample collected from each mouse was
measured using the kit from Biorad. MPO activity was measured using H2O2 and Odianisidine-HCl and normalized with respect to the total amount protein in that
sample.
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at all the time points checked. Also, MPO activity did not increase with time. This is reminiscent
of what we observed with the fungal burden assay in which there was no measurable number of
colony-forming units in the lung for both groups of mice following C. albicans infection.
Since the neutrophil is the primary line of defense against C. albicans infection, the absence of
fungal burden correlates with no change in MPO activity over time. It appears that lung is not the
best tissue for evaluating the change in neutrophil invasion following systemic C. albicans
infection. Since kidney is normally found to have the highest fungal burden content, our next
study will include the MPO assay on kidney tissue.

4.3. c. Analysis of Cytokine Expression
Cytokines are important modulators of the immune system and play important roles in
response to pathogenic attack. Specific cytokines expressed by tissues dictate the fate of the host
response to the C. albicans infection [327]. For example, infection with C. albicans has been
found to induce expression of interleukin-6 (IL-6), interleukin-8 (IL-8) and monocyte
chemoattractant protein-1 (MCP-1) from endothelial cells, and thus affects the inflammatory
response and augments the host defense against the infection [328]. Expression of cytokines in
response to C. albicans causes activation of the candidacidal activity of effector immune cells,
including lymphocytes, neutrophil, macrophages, etc [329-330]. A number of different cytokines
can be expressed in response to different kinds of C. albicans infections, which include oral,
vaginal and systemic infections [330].
Ashman et al. have provided a comprehensive review on different types of cytokines that
are expressed in response to different kinds of C. albicans infections, including how these
cytokines influence the activation of different effector immune cells [330]. For example,
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expression of interferon-γ (IFN-γ) in response to C. albicans infection in mice causes activation
of polymorphonuclear leukocytes (PMNL) and macrophages and that promote killing of C.
albicans cells [330-333]. Application of recombinant IFN-γ has been found to play a protective
role in the acute disseminated C. albicans infection in mice by activating PMNL [334]. Injury by
C. albicans on endothelial cells plays a major role in assisting the microbe in its invasion into the
surrounding tissue from the circulation. It has been found that application of IFN-γ protects the
endothelial cells from the C. albicans induced damage by reducing the extent of phagocytosis of
the microbe by the endothelial cells [335-336].
T-helper-1 (Th1) and T-helper-2 (Th2) lymphocytes have an important role in
determining the fate of C. albicans following infection. While the type-1 immunity obtained
from Th1 provides protection to both mucocutaneous and disseminated C. albicans infection,
type-2 immunity (from Th2 cells) is unprotective and results in the greater susceptibility of the
host towards disseminated infection by suppressing the type-1 immunity [337]. There are
specific types of cytokines that are involved in mediating type-1 and type-2 immunity. Th1 cells
release cytokines like IFN-γ, IL-2, IL-12, lymphotoxin-1 (LT-1), which induces type-1 immunity
by activating the phagocytic activity of immune cells. Th2 cells, on the other hand, release
cytokines including IL-4, IL-5, IL-9, IL-10, IL-13, which act by deactivating the phagocytic
activity of the immune cells [337-339]. The ability of the fungus to undergo the yeast to hyphae
transformation provides a specific advantage to C. albicans over other fungi in terms of
activating the type-2 immune response, which is ineffective and in turn suppresses the type-1
response [339]. C. albicans in its hyphal phase inhibits IL-12 production (important for type-1
immunity) and increases the production of IL-4 (important for type-2 response) [340-341].
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TNF-α is another cytokine that plays an important role in responding to the C. albicans
infection. This cytokine exhibits harmful effects as a mediator of the inflammatory response in
sepsis that happens during endotoxemia or gram negative bacterial infection [342-343].
However, with C. albicans infection, TNF-α has been found to play a protective role, as
inhibition of this cytokine by antibody or pharmacological inhibitors has deleterious effects on
the outcome of the C. albicans infection [344-345]. By performing a systemic C. albicans
infection in TNF-α knock-out mice, Netea et al. reported that TNF-α mediated an increased host
resistance against this infection that results from the activation of neutrophil and phagocytosis of
the microbes [346]. Another cytokine that may have important role in C. albicans infection is
granulocyte-colony stimulating factor (G-CSF). G-CSF has been found to cause an increase in
amount and an enhancement of the microbicidal property of PMNL under in vitro conditions
[347-348]. Kullberg et al. reported that application of recombinant G-CSF during systemic
infection increases the host resistance by enhancing the activation and recruitment of PMNL in
the infected organs [349].
Considering the potential involvement of this large set of cytokines in mediating the host
response to C. albicans infection, we aimed to check the expression of different cytokines in
response to the C. albicans infection in wild type and VN knock-out mice. The availability of the
multi-plex system allows us to check the expression of an array of cytokines within specific
tissues. Table-4.1 shows the summary of the results of 23 different cytokine expression assays in
the kidney and spleen tissues of C. albicans infected wild type and VN knock-out mice. Most of
the tested cytokines do not show any marked difference between the two groups of mice. For
example IFN-γ, which plays such an important role in providing type-1 immunity, was found to
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show no difference in expression between the two different groups of mice in both tissues tested
(see Figure-4.5 & 4.6). Also, many of the cytokines tested that are involved in type-1 and type-2
immunity (e.g. – IL-2, IL-10) showed no change in expression between both groups of mice.
There are some cytokines that showed changes in the expression between two groups of
mice, but explanation of those changes may require input from other experiments. For example,
G-CSF which is known to have protective role in C. albicans infection, showed no change in
expression between the two groups of mice and stayed at same level until day-11 of infection.
On day-14, both groups of mice showed significant decreases in expression of G-CSF compared
to day-11 in both of the tissues tested. These decreases in expression at day-14 may not be
attributed to the clearance of the microbes from the organ, since on day-14 the kidney maintained
considerable fungal burden. Some other cytokines showed differences between two groups of
mice, but only at certain time points after infection. For example, MIP-1α showed increase in
expression with wild type mice but only at day-11 and with kidney tissue. No other time point
showed any difference in kidney. Expression of TNF-α showed perhaps the most consistent
results among all the cytokines. In the kidney, the expression of TNF-α was significantly higher
at day-8 for both groups of mice. After day-8, the expression stayed same for the knock-out
mice, but for wild type mice the expression was significantly lower (see Figure-4.7).
Considering the important protective role TNF-α has against C. albicans infection, the decrease
in expression of this cytokine may partially explain the increased mortality of wild type mice. In
spleen, the expression of this cytokine was highest on day-6 for both groups of mice, but then
decreased at the subsequent time points (see Figure-4.8). The significant decrease in the
expression of TNF-α at the later time points correlates nicely with the clearance of the microbes
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from the tissue, as fungal burden in the spleen did not exist at these time points. Though fungal
burden in the spleen was absent even at day-6 post infection, the relatively higher expression of
TNF-α at this time point is presumably due to an initial spike that occurred in response to the
primary phase of infection. Cytokine expression analysis at earlier time point may be more
informative in this regard.
The overall results obtained from the cytokine expression analyses on kidney and spleen
were not sufficient to explain the apparent difference in mortality between wild type and VNknock-out mice. While certain results from this analysis are interesting, a much better
understanding of the situation is anticipated from cytokine expression analysis performed on
other tissues, such as blood serum, lung etc. Another important area that requires attention is
sepsis. Spellberg et al. reported that the major cause of death in mice suffering from
disseminated candidiasis is progressive sepsis [350]. They reported the presence of certain
symptoms, including hypotension, tachycardia, hypothermia, metabolic acidosis, acidemia,
hypoglycemia that clearly established the role of sepsis in the infection mediated death. In our
next study, we will monitor some of these hemodynamic parameters to characterize progression
of sepsis in both groups of mice upon C. albicans infection.
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Table 4. 1: Summary of cytokine expression analysis in kidney and spleen

CYTOKINE

Comparison of cytokine expression between wild
type and VN knock-out mice
KIDNEY

SPLEEN

IL-1a

No noticeable difference

No noticeable difference

IL-1b

No noticeable difference

No noticeable difference

IL-2

No noticeable difference

No detectable signal was
obtained

IL-4

No noticeable difference

No detectable signal was
obtained

IL-5

No noticeable difference

No detectable signal was
obtained

IL-6

No noticeable difference

No detectable signal was
obtained

IL-9

No noticeable difference

No noticeable difference

No noticeable difference

No noticeable difference

IL-12(p40)

Expression was significantly
higher in wild type mice only
at day-14

Expression was significantly
higher in wild type mice only
at day-14

IL-12(p70)

No noticeable difference

No detectable signal was
obtained

IL-13

No noticeable difference

No noticeable difference

IL-10
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CYTOKINE

Comparison of cytokine expression between wild
type and VN knock-out mice
KIDNEY

SPLEEN

IL-17

No noticeable difference
between the groups. A general
trend of increase in expression
observed with both group of
mice

No detectable signal was
obtained

Eotaxin

No noticeable difference

No detectable signal was
obtained

G-CSF

No noticeable difference
No noticeable difference
between the groups. At day-14 between the groups. At day-14
expression went down for
expression went down for
both group of mice
both group of mice

GM-CSF

No noticeable difference
between the groups. At day-14
expression went down for
both group of mice

No noticeable difference

IFN-γ

No noticeable difference

No noticeable difference

KC

No noticeable difference
except for day-8 when VNknock-out show higher
expression. Expression for
wild type mice stay
unchanged, where as for
knock-out mice it seems to
reach peak at day-8 followed
by a decrease

No noticeable difference
except for day-8 when VNknock-out mice show higher
expression. Expression for
wild type mice stay
unchanged, where as for
knock-out mice it seems to
reach peak at day-8 followed
by a decrease

MCP-1 (M-CAF)

No noticeable difference

No noticeable difference

MIP-1a

No noticeable difference
except for day-11 when wild
type mice show higher
expression.

No noticeable difference
except for day-11 when wild
type mice show higher
expression.
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CYTOKINE

MIP-1b

RANTES

TNF-α

Comparison of cytokine expression between wild
type and VN knock-out mice
KIDNEY

SPLEEN

No noticeable difference

No noticeable difference

No noticeable difference
between the groups.
Expression is highest at day-6
and then decrease
Expression reaches a peak for
both groups of mice at day-8.
While expression for knockout mice stay same after that,
for wild type mice it came
down and remained lower
than knock-out mice
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No noticeable difference

No noticeable difference
between the groups.
Expression is highest at day-6
but then goes down for both
group of mice

Figure 4. 5: Expression of IFN-γ in kidney upon Candida infection

Figure 4. 6: Expression of IFN-γ in spleen upon Candida infection
Figure-4.5 & 4.6: IFN-γ expression analysis in the kidney (Figure-4.5) and
spleen (Figure-4.6) following C. albicans infection. Male wild type and VNknock-out mice were infected with inoculum containing 105 viable C. albicans
cells. Mice were sacrificed at day 5, 8, 11 & 14, and both kidneys and spleen
were collected. At each time point a minimum of 5 mice were sacrificed from
each group. Expression of IFN-γ was analyzed using the 23-plex kit from
Biorad.
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Figure 4. 7: Expression of TNF-α in kidney upon Candida infection

Figure 4. 8: Expression of TNF-α in spleen upon Candida infection

Figure-4.7 & 4.8: TNF-α expression analysis in the kidney (Figure-4.7) and
spleen (Figure-4.8) following C. albicans infection. Male wild type and VNknock-out mice were infected with inoculum containing 105 viable C.
albicans cells. Mice were sacrificed at day 5, 8, 11 & 14, and both kidneys
and spleen were collected. At each time point a minimum of 5 mice were
sacrificed from each group of mice. Expression of TNF-α was analyzed
using the 23-plex kit from Biorad.
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CHAPTER-5
Summary and Future Studies
Vitronectin (VN) and Plasminogen Activator Inhibitro-1 (PAI-1) are two blood proteins
that are well known for their involvement in a wide variety of biological processes. Both of these
proteins are found in the extracellular matrix (ECM) also. Though in the circulation VN exist as
monomer, it exists as a multimer in the ECM. VN can recognize a number of different ligands
like the thrombin-antithrombin complex (T-AT) [44-45], heparin [46-48], PAI-1 [49-51],
complement proteins [52] and several cell surface receptors, including integrins and the
urokinase plasminogen activator receptor (uPAR) [53-59]. The ability to recognize such a wide
variety of ligands makes this protein required in several physiological processes, including
thrombus formation, coagulation, fibrinolysis, pericellular proteolysis, wound healing, inhibition
of the membrane attack complex, and cellular adhesion/migration [8, 60-66, 81-82, 91-92]. On
the other hand, PAI-1 is a member of the serine protease inhibitor family of proteins whose
physiological functions can be broadly classified into two main categories- protease dependent
and protease independent activities. Under protease dependent functions, PAI-1 is primarily
involved in the regulation of plasmin formation from inactive plasminogen by inhibiting tissueplasminogen activator-1 (tPA) and urokinase-plasminogen activator-1(uPA) [79-80]. PAI-1mediated regulation of plasmin formation plays regulatory roles in several patho-physiological
processes like coagulation, fibrinolysis, thrombolysis and renal diseases such as nephritic
syndrome and hemolytic uremic syndrome [109, 112, 170-172, 175, 177].
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In the last two decades, protease-independent functions of PAI-1 have drawn attention
and been heavily investigated. In this context, PAI-1 function is not directly related to its ability
to inhibit proteases like uPA or tPA. For example, binding of PAI-1 to receptor-bound uPA on
the cell surface causes internalization of the ternary complex of PAI-1/uPA/uPAR via receptormediated endocytosis process [180-182]. PAI-1 has been also found to be involved in the
internalization of the tPA/PAI-1 complex [188]. Thus, such protease-independent activities of
PAI-1 play important roles in the turnover of its target proteases.
Many of the protease-independent functions of PAI-1 are mediated by its interaction with
VN. One of the areas where this interaction has generated a much interest is in cellular adhesion
and migration. A major part of this dissertation work has been devoted to the understanding of
the interaction between these two proteins and how such interaction regulates their extracellularmatrix associated functions. PAI-1 has been found to interfere with the interaction of matrix
associated VN with cell surface receptors (like uPAR and integrin) and thus regulate cell-matrix
interactions. Though considerable effort has been made in this area, a significant amount of
controversy still exists regarding how the interaction between PAI-1 and VN regulates cellular
adhesion and migration. Some studies suggest that PAI-1 inhibits cell binding to VN but
promotes migration, while others indicate that PAI-1 inhibits migration that would be mediated
by VN [226-227, 229-230]. Our main goal in this current research has been to attempt to mimic
the natural biological environment under which these proteins interact. Most of the studies in the
literature have been aimed at understanding the role of exogenously added PAI-1 in regulating
cellular adhesion and migration mediated by „denatured‟ multimeric VN. In our studies, we have
used multimeric VN formed by a process that is relevant to actual biological settings. We have
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used PAI-1 as a biological factor for the transition of monomeric VN into its multimeric
counterpart, and then have evaluated the association of this „biological‟ multimeric VN with the
extracellular matrix. The ECM is made of a number of components. As a protein that binds a
broad array of ligands, VN interacts with other matrix components like Col-IV [104] and thus
associates with the ECM. While associated with the matrix, it interacts with cell surface
receptors. We evaluated the relevance of this „biological‟ multimeric form of VN by checking its
ability to interact with matrix components such as Col-IV and HSPG. Our results show that
multimeric complexes of VN formed in the presence of PAI-1 associate more with the matrix.
We also report for the first time that VN can interact with HSPG.
PAI-1has been considered to promote the matrix partitioning of VN because these two
proteins are co-localized in extracellular matrix [21, 192-193]. The observed increased
association of this „biological‟ multimeric form of VN with matrix components is significant,
providing strong evidence for the role of PAI-1 in regulating compartmentalization of VN from
the circulation to the matrix. We have also evaluated the interaction of this complex with a
variety of cell surface receptors including uPAR and different integrins. Our study indicates that
the „biological‟ multimeric complex of VN interacts more with the receptors tested compared to
monomeric VN. The fact that this multimeric form of VN, while still bound with PAI-1, interacts
with uPAR and integrins is in contrast to current thinking. Here we are able to show that PAI-1,
while associated with VN within the multimeric complex, does not block receptor interaction
with VN. This is an important finding since PAI-1 and VN are found to be co-localized under
many physiological conditions. This result indicates that their effects on cell-matrix interaction
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while part of the same multimeric complexes may be significantly different from what is
observed when one of the proteins is added in isolation exogenously.
We have taken a thorough approach in evaluating components in the pericellular
environment for understanding the role of the interaction between these two proteins on the
regulation of cell-matrix interaction. The effect of the „biological‟ multimeric complex of VN
formed in the presence of PAI-1 on cellular adhesion and migration was checked in the context
of different matrix components, different cell types and different growth factor conditions that
may modulate the receptor expression pattern on the cell surface. Our results indicate that the
effect that the VN/PAI-1 complex has on cell-matrix interactions is largely dictated by the
specific cell type and the pericellular conditions. Though most of the studies have indicated that
PAI-1 blocks cellular interactions with VN, our findings indicate that PAI-1 within the
„biological‟ multimeric complex of VN has no effect on cellular adhesion. However, the effect
on cellular migration has been found to be variable.
VN as a constituent of the ECM is involved in the modulation of cell-matrix interactions
in various important patho-physiological processes like angiogenesis [66]. Targeting the
interaction between VN and cell surface receptors for VN is a subject of therapeutic interest.
Thiolutin is an example of a drug that was used for preventing tumor cell induced angiogenesis
by blocking the interaction of VN and αvβ3on the surface of HUVEC [351]. There are a number
of inhibitors of angiogenesis (targeted to prevent cancer), designed to act as antagonists of αvβ3
and αvβ5, the two most common receptors for VN, that have been subject to clinical trials [99,
284-285]. One example is cilengitide, a RGD based inhibitor of αvβ3. Though it showed
tremendous promise in the initial phases, most of the trials with this drug failed at the clinical
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level. Out of different types of cancers tried at the phase-II level, it showed promise only with
patients of glioblastoma multiforme (GMB); currently it is being tested in phase-III clinical trials
[284, 352]. This example tells us the importance of understanding the underlying biology for
designing effective therapeutic strategies. In our study the main goal has been to understand the
biological role that VN and PAI-1 have in a nearly natural cell-matrix environment.
Another important aspect of this study involving the interaction between VN and PAI-1
is the finding of the unique function of reactive center mimicking peptides. These peptides were
found to almost completely disrupt the interaction between VN and PAI-1 and they blocked the
formation of higher order multimeric complexes. It was found that increased association of VN
to Col-IV and HSPG that is normally induced by binding to PAI-1 was completely inhibited in
the presence of these peptides. This finding of a new function for these peptides represents
tremendous potential, considering how important the role the interaction between VN and PAI-1
is in several biological processes. For example, the interaction between VN and PAI-1 has been
implicated in the development of renal fibrotic disease. Expression of PAI-1 becomes very high
in renal fibrotic condition and is thought to be one of the major causes for the loss of matrix turn
over. VN significantly contributes to the progression of this disease by localizing PAI-1 in the
fibrotic matrix [223-225]. Disrupting the interaction between PAI-1 and VN thus is desirable,
and compounds such as the peptide mimetics that accomplish this may have clinical benefit.
Another important goal of this dissertation work was to understand the role of VN in
Candida pathogenesis. This was pursued in continuation of a very interesting finding from our
lab where VN knock-out mice were found to be more tolerant against Candida infection
compared to wild type C57BL/6 mice. In this dissertation work, our goal was to investigate how
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the absence of the vitronectin gene acts to increased survival. We have studied at different
aspects of infection pathogenesis, and we have performed assays to compare cytokine expression
levels in different tissues. We have also evaluated neutrophil invasion in the lung, and we have
performed fungal burden analysis on different tissues. Though we have not obtained conclusive
evidence that would clearly explain the role of VN in Candida infection, our approach has
demonstrated that there are not obvious differences in expected inflammatory markers.
Addressing the specific role that VN may have in Candida pathogenesis will thus require a
thorough investigation of all possible aspects involved with fungal infection. In this dissertation
work we have been able to pursue some of them.
A significant portion of this dissertation work was involved in developing methods for
understanding the structure and dynamics PAI-1. We have for the first time reported the use of
an electron paramagnetic resonance (EPR) based method for understanding the structural change
in PAI-1 that happens naturally or due to ligand binding. We have been able to strategically
place the nitroxide spin level on PAI-1 (at the P9 position) and have shown that this spin label
can be successfully used for monitoring the conformational transition that happens during the
latency transition. This spin labeled PAI-1 can be further utilized for understanding the
conformational transitions that may happen in the reactive center loop upon metal binding. A
spin label may also be placed in other positions for specifically probing ligand binding to PAI-1.
We have also developed a surface plasmon resonance (SPR) based method for analyzing
metal binding to PAI-1. Using this method useful affinity information has been generated for
PAI-1 (and its mutants) binding to nickel. Though this method could not be extended for metals
other than nickel, it will serve the important purpose for screening different mutants of PAI-1 for
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metal binding in order to identify the metal-binding site in the protein. Our lab is currently in the
process of generating many different mutants of PAI-1 for locating the metal binding sites. This
SPR based method will provide a quick of way screening these mutants for metal binding.

Future Experiments
On functional aspects of VN/PAI-1 complex
o Specific role of uPAR will be tested on the effect of VN/PAI-1 complex in
cellular adhesion and migration. U937 cells will be cultured, and uPAR
expression will be induced by TGF-β and Vitamin-D3. Expression of uPAR will
be confirmed by flow cytometry. uPAR expressing U937 cells will be used for
studying cell adhesion and migration under the conditions where VN/PAI-1
complex is associated with Col-IV and HSPG.
o Effect of the VN/PAI-1 complex on cellular adhesion and migration will be
tested under 3-dimensional matrix conditions.
o Role of the VN/PAI-1 complex in angiogenesis will be tested by using the
standard endothelial tube formation assay system from BD bioscience.
On structural aspects of the VN/PAI-1 complex
o Effect of the octapeptide and pentapeptide on formation of complexes will be
tested using latent-PAI-1 with VN in sedimentation velocity experiments.
o Dose dependent effects of the octapeptide will be tested on the inhibition of the
multimerization reaction between VN and wtPAI-1.
o Effect of the triple mutant of PAI-1 (R115E, R118E, Q123K), which is defective
in binding to VN, will be tested for its effect on forming multimeric complex
199

with VN. This mutant should be capable of taking part in the PAI-1/PAI-1
interaction as observed in the SANS model.
On EPR studies
o P9 labeled mutant will be utilized for monitoring the insertion dynamics of the
reactive center loop upon metal binding
o Spin label will be incorporated at different positions of the reactive center loop
and will be monitored for changes that occur during the insertion of the loop
during the latency transition and also during ligand binding.
o Spin lapel will be also put at V328. This residue sits at the base of the reactive
center loop. It does not get inserted during the latency transition, but may show
significant movement during the process. Spin label at this residue can tell us
about structural events at the base of the loop during insertion. It will be also
used for studying the effect of ligand binding on loop insertion.
On the role of VN in Candida pathogenesis
o Neutrophil invasion in kidney will be checked by performing myeloperoxidase
assay on both wild type and knock-out mice.
o Cytokine expression analysis will be carried out on blood and lung.
o Symptoms for sepsis (e.g. - hypotension, tachycardia, hypothermia, metabolic
acidosis, acidemia, and hypoglycemia) will be checked in both wild type and
knock-out mice upon Candida infection.
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o Role of VN will be further checked by performing survival study under condition
where Candida and VN were co-injected in knock-out mice. This will test if the
presence of VN is needed during the onset infection.
o The potential involvement of integrin like receptors on the surface of Candida.
albicans in the colonization of the microbes inside the body will be tested by
injecting Candida along with cyclic-RGD peptide to wild type C57BL/6 mice.
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Cell types and their culture conditions

Cell Type

Culture Condition

HT1080
(fibrosarcoma)

MEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock)

EA.hy926
(immortalized endothelial
cell)

DMEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
1X HAT (from 500X stock)

HEK293
(human embryonic
kidney fibroblast)

DMEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
20mM HEPES

NIH3T3
(mouse embryonic kidney
fibroblast)

DMEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
20mM HEPES

U937
(monocyte)

RPMI-1640 + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
20mM HEPES
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Comments
Adherent type of culture grows in
monolayer. This cell line grows pretty
fast but doesn‟t like too much of
overgrowth. Sensitive to cell-cell
contact. Once they come off the surface
they do not re-adhere.
Purchased from ATCC.
Hybrid of A549 (lung carcinoma celli
line) and HUVEC. Contains more than
46 chromosomes. Expresses factor-VIII
related antigen that is characteristic
feature of endothelial cell. Media is
purchased from GIBCO which already
contains HEPES but no Na-pyruvate.
Use FBS-premium from Atlanta
Biologicals and heat denature the FBS
before use (560C for 30 min)
Obtained from Dr. John Biggerstaff‟s
lab.
Adherent type of culture grows in
monolayer. This cell line grows fairly
well and okay with overgrowth. As
long as the media is regularly changed
they can tolerate cell-cell contact better
than 1080 cells.
Purchased from ATCC.
Adherent type of culture grows in
monolayer. Cell growth is nice. Growth
needs to be maintained within 70%.
Greater confluency will change the
property of the cell.
Obtained from Dr. Wang‟s lab.
Suspension type of culture. Maximum
growth allowed 2*106/ml. Subculture
can be started with a concentration of
105/ml
Purchased from ATCC.

Cell Type

Culture Condition

HUVEC
(primary endothelial cell)

MEF
(mouse embryonic
fibroblast)

DMEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
20mM HEPES

PEA13

DMEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
20mM HEPES

HEK293-β3

HEK293-β5

DMEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
20mM HEPES
DMEM + 10%FBS + 1X
penicillin-streptomycin
solution (from 100X stock) +
20mM HEPES
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Comments
Primary cell line. Grows for only few
passages (5-6 passages). Growth rate is
not very fast.
Purchased from CAMBREX Biosc.
Adherent type of culture grows in
monolayer. This cell line grows fairly
well. Shows high level of LRP
expression.
Obtained from Dr. Dudley Strickland‟s
lab.
Adherent type of culture grows in
monolayer. This cell line grows fairly
well. LRP is not expressed.
Obtained from Dr. Dudley Strickland‟s
lab.
This is integrin β3 transfected HEK293
cells. Grows like HEK293 cells.
Obtained from Dr. Jeff Smith‟s lab.
This is integrin β5 transfected HEK293
cells. Grows like HEK293 cells.
Obtained from Dr. Jeff Smith‟s lab.
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